{"23643abfb6f70046ee76ef5fadc17e8828eb4da4": [["by coronaviruses can therefore typically be transmitted through several different routes, including the aerosol and fecal-to-oral routes, with fomites often playing an important role in the infection cycle (5) .", [["oral", "ANATOMY", 125, 129], ["infection", "DISEASE", 190, 199], ["coronaviruses", "ORGANISM", 3, 16], ["oral", "ORGANISM_SUBDIVISION", 125, 129], ["coronaviruses", "PROBLEM", 3, 16], ["the aerosol", "TREATMENT", 100, 111], ["fomites", "PROBLEM", 143, 150], ["fecal", "ANATOMY", 116, 121], ["infection", "OBSERVATION", 190, 199]]], ["Notably, coronaviruses possess a distinctive morphological feature, consisting of a ring of spike proteins on the outer surface of the virus, giving the appearance of a halo or corona.", [["outer surface", "ANATOMY", 114, 127], ["coronaviruses", "ORGANISM", 9, 22], ["outer surface", "CELLULAR_COMPONENT", 114, 127], ["spike proteins", "PROTEIN", 92, 106], ["coronaviruses", "PROBLEM", 9, 22], ["a distinctive morphological feature", "PROBLEM", 31, 66], ["a ring of spike proteins", "PROBLEM", 82, 106], ["the virus", "PROBLEM", 131, 140], ["a halo or corona", "PROBLEM", 167, 183], ["coronaviruses", "OBSERVATION", 9, 22], ["spike", "OBSERVATION_MODIFIER", 92, 97], ["outer surface", "OBSERVATION_MODIFIER", 114, 127], ["virus", "OBSERVATION", 135, 140], ["halo", "OBSERVATION", 169, 173], ["corona", "ANATOMY_MODIFIER", 177, 183]]], ["In addition to inspiring the name of the coronavirus genus, the spike proteins are also essential for infection of host cells.", [["cells", "ANATOMY", 120, 125], ["infection", "DISEASE", 102, 111], ["coronavirus genus", "ORGANISM", 41, 58], ["host cells", "CELL", 115, 125], ["spike proteins", "PROTEIN", 64, 78], ["host cells", "CELL_TYPE", 115, 125], ["coronavirus", "SPECIES", 41, 52], ["the coronavirus genus", "PROBLEM", 37, 58], ["the spike proteins", "TEST", 60, 78], ["infection of host cells", "PROBLEM", 102, 125], ["coronavirus genus", "ANATOMY", 41, 58], ["host cells", "OBSERVATION", 115, 125]]], ["The SARS-CoV-2 spike protein recognizes and binds to human cellular receptor angiotensin-converting enzyme 2 (ACE2) and subsequently mediates fusion of the viral and host cell membranes, allowing the virus to gain entry (6, 7) .", [["cellular", "ANATOMY", 59, 67], ["cell membranes", "ANATOMY", 171, 185], ["angiotensin", "CHEMICAL", 77, 88], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 4, 14], ["human", "ORGANISM", 53, 58], ["cellular", "CELL", 59, 67], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 77, 108], ["ACE2", "GENE_OR_GENE_PRODUCT", 110, 114], ["cell membranes", "CELLULAR_COMPONENT", 171, 185], ["SARS-CoV-2 spike protein", "PROTEIN", 4, 28], ["human cellular receptor angiotensin-converting enzyme 2", "PROTEIN", 53, 108], ["ACE2", "PROTEIN", 110, 114], ["human", "SPECIES", 53, 58], ["SARS-CoV", "SPECIES", 4, 12], ["human", "SPECIES", 53, 58], ["The SARS", "TEST", 0, 8], ["CoV", "TEST", 9, 12], ["2 spike protein recognizes", "PROBLEM", 13, 39], ["human cellular receptor angiotensin", "TEST", 53, 88], ["converting enzyme", "TEST", 89, 106], ["the viral and host cell membranes", "PROBLEM", 152, 185], ["viral", "OBSERVATION", 156, 161], ["host cell membranes", "OBSERVATION", 166, 185]]], ["The ACE2 receptor is found on epithelial cells of the lungs and small intestines (8) .", [["epithelial cells", "ANATOMY", 30, 46], ["lungs", "ANATOMY", 54, 59], ["small intestines", "ANATOMY", 64, 80], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 4, 17], ["epithelial cells", "CELL", 30, 46], ["lungs", "ORGAN", 54, 59], ["small intestines", "ORGAN", 64, 80], ["ACE2 receptor", "PROTEIN", 4, 17], ["epithelial cells", "CELL_TYPE", 30, 46], ["The ACE2 receptor", "TEST", 0, 17], ["epithelial cells", "OBSERVATION", 30, 46], ["lungs", "ANATOMY", 54, 59], ["small intestines", "ANATOMY", 64, 80]]]], "PMC7363337": [["Synthesis specifications can be expressed in various ways: as input-output examples[19, 20], temporal logic specifications for reactive programs[44], logical specifications[1, 4], etc. Many targets for program synthesis exist, ranging from transition systems[31, 44], logical expressions[1], imperative programs[51], distributed transition systems/programs[38, 43, 45], filling holes in programs[51], or repairs of programs[49].IntroductionA classical stream of program synthesis research is one that emerged from a problem proposed by Church[13] in 1960 for Boolean circuits.", [["Synthesis specifications", "TREATMENT", 0, 24], ["program synthesis", "TREATMENT", 202, 219], ["filling holes in programs", "TREATMENT", 370, 395], ["Boolean circuits", "TREATMENT", 559, 575], ["reactive", "OBSERVATION_MODIFIER", 127, 135]]], ["Seminal results by B\u00fcchi and Landweber[9] and Rabin[48] led to a mature understanding of the problem, including connections to infinite games played on finite graphs and automata over infinite trees (see[18, 32]).", [["Seminal", "ANATOMY", 0, 7], ["Seminal", "ORGANISM_SUBSTANCE", 0, 7], ["Landweber", "TEST", 29, 38]]], ["Tractable synthesis for temporal logics like LTL, CTL, and their fragments was investigated and several applications for synthesizing hardware circuits emerged[6, 7].IntroductionIn recent years, the field has taken a different turn, tackling synthesis of programs that work over infinite domains such as strings[19, 20], integers[1, 51], and heaps[47].", [["LTL", "DNA", 45, 48], ["CTL", "CELL_TYPE", 50, 53], ["Tractable synthesis", "TREATMENT", 0, 19], ["temporal logics like LTL, CTL, and their fragments", "PROBLEM", 24, 74], ["synthesizing hardware circuits", "TREATMENT", 121, 151], ["tackling synthesis of programs", "TREATMENT", 233, 263], ["CTL", "OBSERVATION", 50, 53]]], ["Typical solutions derived in this line of research involve (a) bounding the class of programs to a finite set (perhaps iteratively increasing the class) and (b) searching the space of programs using techniques like symmetry-reduced enumeration, SAT solvers, or even random walks[1, 4], typically guided by counterexamples (CEGIS)[28, 34, 51].", [["Typical solutions", "TREATMENT", 0, 17], ["reduced enumeration", "PROBLEM", 224, 243], ["SAT solvers", "TEST", 245, 256], ["reduced", "OBSERVATION_MODIFIER", 224, 231], ["enumeration", "OBSERVATION", 232, 243]]], ["7 for some exceptions in certain heavily restricted cases).IntroductionIn this paper we present, to the best of our knowledge, the first decidability results for program synthesis over a natural class of programs with iteration/recursion, having arbitrary sizes, and which work on infinite data domains.", [["sizes", "OBSERVATION_MODIFIER", 256, 261]]], ["The theory of uninterpreted functions and relations is well studied\u2014classically, in 1929, by G\u00f6del, where completeness results were shown[5] and, more recently, its decidable quantifier-free fragment has been exploited in SMT solvers in combination with other theories[8].", [["free fragment", "PROBLEM", 186, 199], ["SMT solvers", "TREATMENT", 222, 233], ["free fragment", "OBSERVATION", 186, 199]]], ["In recent work[39], a subclass of uninterpreted programs, called coherent programs, was identified and shown to have a decidable verification problem.", [["a decidable verification problem", "PROBLEM", 117, 149]]], ["Note that in this verification problem there are no user-given loop invariants; the verification algorithm finds inductive invariants and proves them automatically in order to prove program correctness.IntroductionIn this paper, we consider the synthesis problem for coherent uninterpreted programs.", [["loop invariants", "PROBLEM", 63, 78], ["the verification algorithm", "TEST", 80, 106], ["the synthesis problem", "TREATMENT", 241, 262]]]], "PMC7461321": [["A Brief Review of the Efficacy of PE via CVTEvidence supporting PE via CVT has grown significantly in the past decade.", [["PE", "CHEMICAL", 64, 66], ["CVT", "DISEASE", 71, 74], ["PE", "MULTI-TISSUE_STRUCTURE", 64, 66], ["PE", "PROBLEM", 34, 36], ["PE", "PROBLEM", 64, 66], ["CVT", "PROBLEM", 71, 74], ["PE", "OBSERVATION", 34, 36], ["PE", "OBSERVATION", 64, 66]]], ["Building on positive results from pilot studies (N = 27, Franklin et al., 2017; N = 12, Tuerk et al., 2010) and an open trial (N = 89, Gros, Yoder, et al., 2011) that demonstrated the feasibility and initial effectiveness of CVT PE, two large randomized controlled trials (RCTs) have examined the efficacy of this modality relative to in\u2010person PE.", [["CVT", "DISEASE", 225, 228], ["pilot studies", "TEST", 34, 47], ["N", "TEST", 80, 81], ["an open trial", "TEST", 112, 125], ["CVT PE", "PROBLEM", 225, 231], ["two large randomized controlled trials (RCTs", "TREATMENT", 233, 277], ["this modality", "TREATMENT", 309, 322], ["in\u2010person PE", "PROBLEM", 335, 347], ["PE", "OBSERVATION", 229, 231], ["large", "OBSERVATION_MODIFIER", 237, 242], ["PE", "OBSERVATION", 345, 347]]], ["Consistent with preliminary findings (Yuen et al., 2015), the final results of a noninferiority trial (N = 132) showed that 8\u201312 weeks of telehealth PE was noninferior to in\u2010person PE with regard to PTSD symptom reduction, with treatment gains maintained through 6 months posttreatment (Acierno et al., 2017).", [["PE", "CHEMICAL", 149, 151], ["PTSD", "DISEASE", 199, 203], ["a noninferiority trial", "TEST", 79, 101], ["telehealth PE", "PROBLEM", 138, 151], ["PE", "PROBLEM", 181, 183], ["PTSD symptom reduction", "PROBLEM", 199, 221], ["treatment gains", "TREATMENT", 228, 243], ["PE", "OBSERVATION", 149, 151], ["PE", "OBSERVATION", 181, 183]]], ["A second RCT (N = 175) examined PE delivered in three ways: home\u2010based CVT; clinic\u2010based CVT; and home\u2010based, in\u2010person PE (Morland et al., 2019).", [["PE", "CHEMICAL", 32, 34], ["CVT", "DISEASE", 71, 74], ["CVT", "DISEASE", 89, 92], ["A second RCT", "TEST", 0, 12], ["PE", "PROBLEM", 32, 34], ["home\u2010based CVT", "PROBLEM", 60, 74], ["CVT", "PROBLEM", 89, 92], ["PE", "OBSERVATION", 32, 34], ["PE", "OBSERVATION", 120, 122]]], ["The results showed no significant differences between study conditions\u2014all were associated with significant reductions in PTSD symptoms.", [["PTSD", "DISEASE", 122, 126], ["study conditions\u2014all", "TEST", 54, 74], ["significant reductions in PTSD symptoms", "PROBLEM", 96, 135], ["no", "UNCERTAINTY", 19, 21], ["significant", "OBSERVATION_MODIFIER", 22, 33], ["significant", "OBSERVATION_MODIFIER", 96, 107], ["reductions", "OBSERVATION_MODIFIER", 108, 118]]], ["However, the two CVT conditions were associated with significantly higher drop\u2010out rates than the in\u2010person, at\u2010home condition.", [["CVT", "DISEASE", 17, 20], ["the two CVT conditions", "PROBLEM", 9, 31], ["significantly higher drop\u2010out rates", "PROBLEM", 53, 88]]], ["This pattern of increased dropout from CVT relative to in\u2010person PE was also observed in one previous study (Gros, Allan, et al., 2018) but not in another study (Hernandez\u2010Tejada et al., 2014).", [["CVT", "DISEASE", 39, 42], ["increased dropout", "PROBLEM", 16, 33], ["CVT", "PROBLEM", 39, 42], ["in\u2010person PE", "PROBLEM", 55, 67], ["increased", "OBSERVATION_MODIFIER", 16, 25], ["dropout", "OBSERVATION_MODIFIER", 26, 33], ["PE", "OBSERVATION", 65, 67]]], ["Moreover, Hernandez\u2010Tejada et al. (2014) found that among participants who dropped out of treatment, those assigned to CVT completed more PE sessions, on average, than those assigned to in\u2010person PE.A Brief Review of the Efficacy of PE via CVTOne of the clinical considerations of providers adopting CVT is the concern that this modality will adversely impact the therapeutic relationship.", [["CVT", "DISEASE", 119, 122], ["CVT", "DISEASE", 300, 303], ["participants", "SPECIES", 58, 70], ["treatment", "TREATMENT", 90, 99], ["CVT", "PROBLEM", 119, 122], ["PE", "PROBLEM", 196, 198], ["PE", "PROBLEM", 233, 235], ["CVT", "PROBLEM", 300, 303], ["PE", "OBSERVATION", 138, 140], ["PE", "OBSERVATION", 196, 198], ["PE", "OBSERVATION", 233, 235]]], ["However, research has demonstrated strong, stable therapeutic alliances during PE via CVT, with patient and provider ratings of satisfaction and therapeutic alliance comparable to those found for in\u2010person care (Gros, Lancaster, et al., 2018; Hernandez\u2010Tejada et al., 2014).", [["PE", "DISEASE", 79, 81], ["CVT", "DISEASE", 86, 89], ["patient", "ORGANISM", 96, 103], ["patient", "SPECIES", 96, 103], ["PE", "PROBLEM", 79, 81], ["CVT", "PROBLEM", 86, 89], ["strong", "OBSERVATION_MODIFIER", 35, 41], ["stable", "OBSERVATION_MODIFIER", 43, 49], ["PE", "OBSERVATION", 79, 81]]], ["Data on patient preference indicate that many patients prefer PE delivered via CVT to in\u2010person therapy, and among individuals who prefer CVT, home\u2010based CVT has been shown to be preferable to clinic\u2010based telehealth (Morland et al., 2019).A Brief Review of the Efficacy of PE via CVTWhen providing PE through a CVT platform, providers can include mobile applications (i.e., \u201capps\u201d), such as PE Coach, to facilitate treatment.", [["PE", "CHEMICAL", 62, 64], ["CVT", "DISEASE", 79, 82], ["CVT", "DISEASE", 138, 141], ["CVT", "DISEASE", 154, 157], ["CVT", "DISEASE", 312, 315], ["patient", "ORGANISM", 8, 15], ["patients", "ORGANISM", 46, 54], ["patient", "SPECIES", 8, 15], ["patients", "SPECIES", 46, 54], ["PE", "PROBLEM", 62, 64], ["CVT", "PROBLEM", 79, 82], ["therapy", "TREATMENT", 96, 103], ["CVT", "PROBLEM", 138, 141], ["CVT", "PROBLEM", 154, 157], ["PE", "PROBLEM", 274, 276], ["PE", "PROBLEM", 299, 301], ["mobile applications", "TREATMENT", 348, 367], ["treatment", "TREATMENT", 416, 425], ["PE", "OBSERVATION", 62, 64], ["PE", "OBSERVATION", 274, 276], ["PE", "OBSERVATION", 299, 301], ["PE", "OBSERVATION", 392, 394]]], ["The PE Coach app (Reger et al., 2013) is a patient\u2010facing mobile app designed to support providers and patients engaged in PE.", [["PE", "DISEASE", 123, 125], ["patient", "ORGANISM", 43, 50], ["patients", "ORGANISM", 103, 111], ["patient", "SPECIES", 43, 50], ["patients", "SPECIES", 103, 111], ["PE", "PROBLEM", 123, 125], ["PE", "OBSERVATION", 4, 6], ["PE", "OBSERVATION", 123, 125]]], ["The app includes psychoeducational material and functionality to allow patients to record their trauma narrative, complete and track in vivo and imaginal exposure homework, practice breathing retraining, monitor PTSD symptoms, and schedule upcoming sessions.", [["trauma", "DISEASE", 96, 102], ["PTSD", "DISEASE", 212, 216], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["psychoeducational material", "TREATMENT", 17, 43], ["practice breathing retraining", "TREATMENT", 173, 202], ["PTSD symptoms", "PROBLEM", 212, 225]]], ["Preliminary data suggest good uptake of PE Coach and positive perceptions of the app among Veterans Affairs (VA) providers.", [["Preliminary data", "TEST", 0, 16], ["PE", "PROBLEM", 40, 42], ["good", "OBSERVATION_MODIFIER", 25, 29], ["PE", "OBSERVATION", 40, 42]]], ["In addition, PE Coach automates a number of PE therapy tasks and facilitates patient\u2013provider sharing of therapy data, which could make it particularly useful to incorporate into PE delivered via CVT.", [["CVT", "DISEASE", 196, 199], ["PE therapy tasks", "TREATMENT", 44, 60], ["therapy data", "TREATMENT", 105, 117], ["PE", "PROBLEM", 179, 181], ["CVT", "PROBLEM", 196, 199], ["PE", "OBSERVATION", 13, 15], ["PE", "OBSERVATION", 44, 46], ["PE", "OBSERVATION", 179, 181]]], ["For example, assessing PTSD symptoms during the course of therapy, which allows patients and providers to easily monitor treatment response over time, can otherwise be more challenging with CVT, as providers would not have the ability to pass the patient a paper\u2010and\u2010pencil form to fill out.", [["PTSD", "DISEASE", 23, 27], ["CVT", "DISEASE", 190, 193], ["patients", "ORGANISM", 80, 88], ["patient", "ORGANISM", 247, 254], ["patients", "SPECIES", 80, 88], ["patient", "SPECIES", 247, 254], ["PTSD symptoms", "PROBLEM", 23, 36], ["therapy", "TREATMENT", 58, 65], ["CVT", "PROBLEM", 190, 193]]], ["Additionally, the app allows patients to obtain all the therapy materials they need without the provider having to send them, and sessions can be recorded and saved as password\u2010protected documents on a personal device.Safety Practices when Providing PE Through CVTProviders may be concerned about managing safety during CVT because the patient is in a location unfamiliar to the provider, and providers do not have access to in\u2010person clinical staff to assist in the event of an emergency (e.g., providing immediate consultation, walking a patient to the emergency room); therefore, it is important to have preestablished safety procedures (Luxton et al., 2014).", [["CVT", "DISEASE", 320, 323], ["patients", "ORGANISM", 29, 37], ["patient", "ORGANISM", 336, 343], ["patient", "ORGANISM", 540, 547], ["patients", "SPECIES", 29, 37], ["patient", "SPECIES", 336, 343], ["patient", "SPECIES", 540, 547], ["all the therapy materials", "TREATMENT", 48, 73], ["a personal device", "TREATMENT", 200, 217], ["CVT", "PROBLEM", 320, 323]]], ["Before beginning every appointment, providers should determine the patient's physical location (i.e., the address) and ensure the patient is in a safe environment.", [["patient", "ORGANISM", 67, 74], ["patient", "ORGANISM", 130, 137], ["patient", "SPECIES", 67, 74], ["patient", "SPECIES", 130, 137]]], ["Providers should also identify a back\u2010up means of communication, such as the telephone, for emergencies or CVT\u2010related technical difficulties.", [["CVT", "DISEASE", 107, 110], ["CVT", "PROBLEM", 107, 110]]], ["Providers of PE may consider having the patient identify an emergency support person (ESP) if clinically indicated.", [["patient", "ORGANISM", 40, 47], ["patient", "SPECIES", 40, 47], ["person", "SPECIES", 78, 84], ["PE", "PROBLEM", 13, 15], ["PE", "OBSERVATION", 13, 15]]], ["It is ideal if the ESP resides at the same residence as the patient, but patients can identify other individuals if necessary.", [["patient", "ORGANISM", 60, 67], ["patients", "ORGANISM", 73, 81], ["patient", "SPECIES", 60, 67], ["patients", "SPECIES", 73, 81]]], ["Providers will need to obtain a release of information early in treatment, often before the first PE session so that they can speak to the ESP during a clinical crisis, if needed (Luxton et al., 2014).", [["treatment", "TREATMENT", 64, 73]]], ["Providers should document these details in each CVT clinical note (see The Supplementary Materials for example documentation for screening and therapy sessions), which will allow for a quick in\u2010person response to clinical or medical emergencies, should they arise.", [["CVT", "DISEASE", 48, 51], ["screening", "TEST", 129, 138], ["therapy sessions", "TREATMENT", 143, 159]]], ["For additional safety, it may be important to request that weapons, including guns or knives, be removed from the space where the patient will engage in the session.", [["patient", "ORGANISM", 130, 137], ["patient", "SPECIES", 130, 137]]], ["Given that some individuals may be reticent to be separated from a weapon, providers may need to discuss this at the outset and discuss other harm\u2010reduction strategies as needed (e.g., safe weapon storage, giving the weapon to an adult family member during the session for safekeeping).Safety Practices when Providing PE Through CVTProviders can safely conduct PE via CVT for patients at low, moderate, or high risk for suicide, with the appropriate safety planning in place.", [["CVT", "DISEASE", 368, 371], ["patients", "ORGANISM", 376, 384], ["patients", "SPECIES", 376, 384], ["other harm\u2010reduction strategies", "TREATMENT", 136, 167], ["Safety Practices", "TREATMENT", 286, 302], ["CVTProviders", "TREATMENT", 329, 341], ["PE", "PROBLEM", 361, 363], ["CVT", "PROBLEM", 368, 371], ["suicide", "PROBLEM", 420, 427], ["PE", "OBSERVATION", 361, 363]]], ["Gros, Veronee, et al. (2011) presented a case study demonstrating how CVT actually enhanced patient safety during PE when a patient experienced suicidal intent; CVT facilitated immediate engagement of the patient's support system (i.e., family, treatment team, local authorities), allowing for effective, real\u2010time crisis management.", [["CVT", "DISEASE", 70, 73], ["CVT", "DISEASE", 161, 164], ["patient", "ORGANISM", 92, 99], ["patient", "ORGANISM", 124, 131], ["patient", "ORGANISM", 205, 212], ["patient", "SPECIES", 92, 99], ["patient", "SPECIES", 124, 131], ["patient", "SPECIES", 205, 212], ["a case study", "TEST", 39, 51], ["CVT", "PROBLEM", 70, 73], ["PE", "PROBLEM", 114, 116], ["suicidal intent", "PROBLEM", 144, 159], ["CVT", "PROBLEM", 161, 164], ["real\u2010time crisis management", "TREATMENT", 305, 332], ["PE", "OBSERVATION", 114, 116]]], ["Providers can conduct a safety plan via CVT and provide patients with a copy through secure messaging, screen sharing, file sharing, mailing a hardcopy (Luxton et al., 2014).", [["CVT", "DISEASE", 40, 43], ["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["CVT", "PROBLEM", 40, 43]]], ["If the patient is in imminent danger to themselves or others, the provider should contact local emergency services (i.e., 911) or, if the patient is a veteran and outside the provider's region, E911, which can be reached by calling the Emergency Relay Center (267\u2010908\u20106605) and providing the patient's address.", [["patient", "ORGANISM", 7, 14], ["patient", "ORGANISM", 138, 145], ["patient", "ORGANISM", 292, 299], ["patient", "SPECIES", 7, 14], ["patient", "SPECIES", 138, 145], ["patient", "SPECIES", 292, 299]]], ["The operator will connect the provider to the patient's local emergency dispatch and facilitate emergency response.", [["patient", "ORGANISM", 46, 53], ["patient", "SPECIES", 46, 53]]], ["Should the provider lose contact during a session and risk is present, the provider should document attempts to contact the patient, as well as a follow\u2010up plan (e.g., interventions to manage distress in future sessions), in the patient's treatment record.Safety Practices when Providing PE Through CVTOther safety concerns might include mobility and physical health limitations.", [["patient", "ORGANISM", 124, 131], ["patient", "ORGANISM", 229, 236], ["patient", "SPECIES", 124, 131], ["patient", "SPECIES", 229, 236], ["interventions", "TREATMENT", 168, 181], ["distress", "PROBLEM", 192, 200], ["Safety Practices", "TREATMENT", 256, 272], ["PE", "OBSERVATION", 288, 290]]], ["Notably, if a provider is meeting an individual for the first time over CVT, they may be unable to observe mobility devices, such as a wheelchair or walker, or prostheses that could potentially impact the feasibility of certain in vivo exposures.", [["CVT", "DISEASE", 72, 75], ["CVT", "PROBLEM", 72, 75], ["mobility devices", "TREATMENT", 107, 123], ["walker", "TREATMENT", 149, 155], ["prostheses", "TREATMENT", 160, 170]]], ["Providers should assess relevant medical history and identify any physical conditions at the start of therapy so the therapy can be applied safely.Establishing Boundaries and Guidelines for the Delivery of PE via TelehealthThe informed consent process should include a discussion about boundaries for CVT, particularly during the pandemic, when there are more unique considerations, such as more family sheltering in place.", [["CVT", "DISEASE", 301, 304], ["any physical conditions", "PROBLEM", 62, 85], ["therapy", "TREATMENT", 102, 109], ["the therapy", "TREATMENT", 113, 124], ["PE", "PROBLEM", 206, 208], ["CVT", "PROBLEM", 301, 304], ["PE", "OBSERVATION", 206, 208]]], ["A preemptive discussion of rules and guidelines for PE via CVT is important for creating a virtual therapeutic environment comparable to office\u2010based settings that will promote physical and psychiatric safety, ensure adherence to the PE protocol, and reduce distractions during the session (see The Supplementary Materials for an example of guidelines that can be provided to patients prior to beginning therapy).The Importance of Privacy When Conducting PE via CVT During COVID\u201019Ensuring privacy can be more difficult during a pandemic, when multiple people may be sharing the same residence throughout the day.", [["PE", "DISEASE", 52, 54], ["CVT", "DISEASE", 59, 62], ["psychiatric", "DISEASE", 190, 201], ["CVT", "DISEASE", 462, 465], ["patients", "ORGANISM", 376, 384], ["people", "ORGANISM", 553, 559], ["patients", "SPECIES", 376, 384], ["people", "SPECIES", 553, 559], ["PE", "PROBLEM", 52, 54], ["CVT", "PROBLEM", 59, 62], ["the PE protocol", "TREATMENT", 230, 245], ["Privacy", "TREATMENT", 431, 438], ["Conducting PE", "PROBLEM", 444, 457], ["CVT", "PROBLEM", 462, 465], ["COVID\u2010", "TREATMENT", 473, 479], ["PE", "OBSERVATION", 234, 236], ["PE", "OBSERVATION", 455, 457]]], ["However, it is essential to encourage patients to maximize privacy during PE to the extent possible.", [["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["PE", "PROBLEM", 74, 76], ["PE", "OBSERVATION", 74, 76]]], ["Problem\u2010solving to identify a private and safe location that can be used for each 90\u2010min session and for daily listening to imaginal exposure audio recordings is essential.", [["imaginal exposure audio recordings", "TEST", 124, 158]]], ["Patients may need to discuss privacy logistics with housemates or find another private location outside the home, such as a parked car, private outdoor area, or garage, for sessions.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Providers may consider working with patients to practice conversations with family members or to include a family member in an initial appointment to help to create a productive therapeutic frame.", [["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44]]], ["Providers and patients may consider purchasing white noise machines for the home to help muffle noises in small shared spaces.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["white noise machines", "TREATMENT", 47, 67], ["muffle noises in small shared spaces", "PROBLEM", 89, 125], ["small", "OBSERVATION_MODIFIER", 106, 111]]], ["Providers may also need to be flexible with the location and timing of sessions, such as offering flexible appointment times after children have gone to bed or during times when children are participating in online classes.", [["children", "ORGANISM", 131, 139], ["children", "ORGANISM", 178, 186], ["children", "SPECIES", 131, 139], ["children", "SPECIES", 178, 186]]], ["Patients may also choose to use headphones during sessions as an additional means of privacy.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["headphones", "TREATMENT", 32, 42]]], ["Ensuring a quiet, private location for therapy is especially important for PE due to the focus required during imaginal exposures and the time needed for a full session.The Importance of Privacy When Conducting PE via CVT During COVID\u201019It is important to remind patients that privacy also extends to the storage of session recordings and PE homework assignments between sessions.", [["PE", "DISEASE", 75, 77], ["CVT", "DISEASE", 218, 221], ["patients", "ORGANISM", 263, 271], ["patients", "SPECIES", 263, 271], ["therapy", "TREATMENT", 39, 46], ["PE", "PROBLEM", 75, 77], ["Conducting PE", "PROBLEM", 200, 213], ["CVT", "PROBLEM", 218, 221], ["PE", "OBSERVATION", 211, 213], ["PE", "OBSERVATION", 339, 341]]], ["For patients using the PE Coach app, phones and the app can be password\u2010protected with a pin to increase security, especially if the phone is used by multiple family members.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["PE", "OBSERVATION", 23, 25]]], ["Therapists should discuss secure locations, such as a home safe or vehicle glove box, to keep recordings and paper homework assignments for patients who are not using their smartphones.", [["patients", "ORGANISM", 140, 148], ["patients", "SPECIES", 140, 148], ["vehicle glove box", "TREATMENT", 67, 84]]], ["Brainstorming ways to protect privacy should be discussed at the outset of therapy and adapted as pandemic\u2010related guidelines change.Logistical and Technical Issues for the Use of CVT During COVID\u201019Therapists should be prepared to navigate challenges that may arise with the use of technology, particularly during the COVID\u201019 pandemic, when technological servers\u2019 bandwidths may be overburdened.", [["CVT", "DISEASE", 180, 183], ["privacy", "TREATMENT", 30, 37], ["therapy", "TREATMENT", 75, 82], ["CVT", "PROBLEM", 180, 183], ["COVID\u201019Therapists", "TREATMENT", 191, 209]]], ["The PE Coach app can be a valuable adjunctive tool that allows providers and patients to track progress, record sessions, and complete homework worksheets (Reger et al., 2013).", [["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["PE", "OBSERVATION", 4, 6]]], ["There are, however, limitations to PE Coach.", [["PE", "OBSERVATION", 35, 37]]], ["If a patient is using an iOS phone for CVT sessions, they will need to put their phone on the \u201cdo not disturb\u201d setting, and the recording will only record the voice of the person with the device (e.g., closet to the device) and not the therapist's voice.", [["CVT", "DISEASE", 39, 42], ["patient", "ORGANISM", 5, 12], ["patient", "SPECIES", 5, 12], ["person", "SPECIES", 172, 178], ["CVT sessions", "TREATMENT", 39, 51], ["the device", "TREATMENT", 184, 194]]], ["One significant limitation of the PE Coach app is that patients who use Android phones for their CVT sessions cannot record sessions through PE Coach, so they will need to use another recording device, such as a handheld recorder.", [["CVT", "DISEASE", 97, 100], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["their CVT sessions", "TREATMENT", 91, 109], ["another recording device", "TREATMENT", 176, 200], ["a handheld recorder", "TEST", 210, 229], ["significant", "OBSERVATION_MODIFIER", 4, 15], ["limitation", "OBSERVATION_MODIFIER", 16, 26], ["PE", "OBSERVATION", 34, 36], ["PE", "OBSERVATION", 141, 143]]], ["Given that technology literacy varies across patients, having a pretreatment session with individuals who need additional help with technology could be beneficial.", [["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["a pretreatment session", "TREATMENT", 62, 84]]], ["If CVT technology fails, therapists should follow the established backup plan identified at the outset of treatment, which often involves switching to the telephone.", [["CVT", "DISEASE", 3, 6], ["treatment", "TREATMENT", 106, 115]]], ["Although the research on telephone therapy is limited, there is some preliminary evidence that it is acceptable to patients (Cuijpers et al., 2019), but no research has examined telephone\u2010based therapy in relation to PE.Logistical and Technical Issues for the Use of CVT During COVID\u201019The exchange of PE therapy materials requires more flexibility for CVT compared to in\u2010person therapy, but data can be exchanged between patients and providers via an electronic exchange, such as encrypted mail, screenshots of shared screens, or file sharing on video platforms; verbally, with the patient reading responses to the provider; or, if needed, by mail (see Table 1 for more information about various ways to exchange and send PE documents).", [["PE", "DISEASE", 217, 219], ["CVT", "DISEASE", 267, 270], ["PE", "CHEMICAL", 302, 304], ["CVT", "DISEASE", 353, 356], ["patients", "ORGANISM", 115, 123], ["PE", "SIMPLE_CHEMICAL", 302, 304], ["patients", "ORGANISM", 422, 430], ["patient", "ORGANISM", 583, 590], ["patients", "SPECIES", 115, 123], ["patients", "SPECIES", 422, 430], ["patient", "SPECIES", 583, 590], ["telephone therapy", "TREATMENT", 25, 42], ["telephone\u2010based therapy", "TREATMENT", 178, 201], ["PE", "PROBLEM", 217, 219], ["CVT", "PROBLEM", 267, 270], ["PE therapy materials", "TREATMENT", 302, 322], ["CVT", "PROBLEM", 353, 356], ["in\u2010person therapy", "TREATMENT", 369, 386], ["PE", "OBSERVATION", 217, 219], ["PE", "OBSERVATION", 302, 304], ["PE", "OBSERVATION", 723, 725]]], ["Please see Morland et al. (2020) for additional advice about sharing materials with patients.Logistical and Technical Issues for the Use of CVT During COVID\u201019To facilitate efforts to rapidly deploy telehealth during COVID\u201019, a number of free, public resources have been made available to providers interested in adopting this technology.", [["CVT", "DISEASE", 140, 143], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["CVT", "PROBLEM", 140, 143], ["this technology", "TREATMENT", 323, 338]]], ["The American Psychological Association (APA) has developed a free online continuing education program on telepsychology best practices (https://apa.content.online/catalog/product.xhtml?eid=15132&eid=1921) and a free technology checklist (https://www.apa.org/practice/programs/dmhi/research-information/telepsychological-services-checklist) for providers; see these materials for more helpful information.Utilizing Social Support during PE in the Midst of a PandemicPatients are often interested in including loved ones in their PTSD treatment and have been shown to respond to PE more effectively when there are family and peer supports included in their care (Batten et al., 2009; Hundt et al., 2015).", [["PTSD", "DISEASE", 528, 532], ["PE", "PROBLEM", 436, 438], ["their PTSD treatment", "TREATMENT", 522, 542], ["PE", "OBSERVATION", 436, 438], ["PE", "OBSERVATION", 577, 579]]], ["Utilizing family or peer support during PE may increase engagement, decrease dropout, and enhance clinical outcomes (Hernandez\u2010Tejada et al., 2017; Meis et al., 2019; Price et al., 2013, 2018).", [["PE", "CHEMICAL", 40, 42], ["PE", "OBSERVATION", 40, 42]]], ["For example, Meis et al. (2019) found that veterans with loved ones who encouraged them to approach anxiety\u2010provoking situations and sit with their distress rather than avoid it were twice as likely to complete trauma\u2010focused PTSD treatment (e.g., PE or cognitive processing therapy).", [["anxiety", "DISEASE", 100, 107], ["PTSD", "DISEASE", 226, 230], ["anxiety", "PROBLEM", 100, 107], ["their distress", "PROBLEM", 142, 156], ["trauma\u2010focused PTSD treatment", "TREATMENT", 211, 240], ["PE", "PROBLEM", 248, 250], ["cognitive processing therapy", "TREATMENT", 254, 282], ["PE", "OBSERVATION", 248, 250]]], ["If a patient consents, providers may consider meeting with the patient and their social support or supports via CVT after the first session of PE to summarize psychoeducation about PTSD, avoidance, and exposure therapy and provide information about how they can support the patient to engage in approach behaviors rather than collude with avoidance.", [["CVT", "DISEASE", 112, 115], ["PTSD", "DISEASE", 181, 185], ["patient", "ORGANISM", 5, 12], ["patient", "ORGANISM", 63, 70], ["patient", "ORGANISM", 274, 281], ["patient", "SPECIES", 5, 12], ["patient", "SPECIES", 63, 70], ["patient", "SPECIES", 274, 281], ["CVT", "TREATMENT", 112, 115], ["PE", "PROBLEM", 143, 145], ["PTSD", "PROBLEM", 181, 185], ["exposure therapy", "TREATMENT", 202, 218], ["PE", "OBSERVATION", 143, 145]]], ["Partner accommodation (i.e., partners\u2019 altering their own behaviors due to the patient's PTSD symptoms) is often well\u2010intended but can prevent opportunities for corrective learning (Fredman et al., 2014).", [["PTSD", "DISEASE", 89, 93], ["patient", "ORGANISM", 79, 86], ["patient", "SPECIES", 79, 86], ["the patient's PTSD symptoms", "PROBLEM", 75, 102]]], ["Additionally, patients may need to ask partners, family members, and friends to cover childcare, homeschooling, or household responsibilities during their PE appointments to minimize distractions so that they can fully engage in their sessions, especially during imaginal exposures.Utilizing Social Support during PE in the Midst of a PandemicProviders should leverage opportunities to use social support during in vivo exposure practice assignments while also being thoughtful about when they may serve as safety signals (e.g., permitting inappropriate avoidance of fear).", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["distractions", "PROBLEM", 183, 195], ["social support", "TREATMENT", 390, 404], ["PE", "OBSERVATION", 314, 316]]], ["It is appropriate and helpful to include loved ones in in vivo exposures when the exposures are designed to target themes such as intimacy, trust, fear of interpersonal rejection, or physical contact; these can include sharing vulnerable emotions or holding hands with a partner.", [["hands", "ORGANISM_SUBDIVISION", 258, 263], ["interpersonal rejection", "PROBLEM", 155, 178]]], ["Additionally, loved ones may be included in exposures lower on the fear hierarchy while the patient works toward independence; for example, the patient may first go to a grocery store with their partner before eventually going alone.", [["patient", "ORGANISM", 92, 99], ["patient", "ORGANISM", 144, 151], ["patient", "SPECIES", 92, 99], ["patient", "SPECIES", 144, 151]]], ["When including others in exposures, ensure that the patients\u2019 supports are facilitating the therapeutic process and not interfering.", [["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60]]], ["For instance, if an individual feels unable to engage in an in vivo exposure without a partner's presence, the therapeutic goal should be to eventually have the patient do the exposure alone.", [["patient", "ORGANISM", 161, 168], ["patient", "SPECIES", 161, 168]]], ["Although you may start with an exposure that includes the partner, as the patient's anxiety is reduced, the partner should stop participating in exposures.", [["anxiety", "DISEASE", 84, 91], ["patient", "ORGANISM", 74, 81], ["patient", "SPECIES", 74, 81], ["the patient's anxiety", "PROBLEM", 70, 91]]], ["Providers may review the guidelines for effective exposure practice with loved ones.", [["effective exposure practice", "TREATMENT", 40, 67]]], ["Having a well\u2010intentioned partner suggest that the patient engage in safety behaviors (i.e., behaviors a patient does to reduce their anxiety that are not actually related to reduced risk, such as carrying a pill bottle or sitting with their back to the door) would be counterproductive.", [["anxiety", "DISEASE", 134, 141], ["patient", "ORGANISM", 51, 58], ["patient", "ORGANISM", 105, 112], ["patient", "SPECIES", 51, 58], ["patient", "SPECIES", 105, 112], ["their anxiety", "PROBLEM", 128, 141], ["a pill bottle", "TREATMENT", 206, 219]]], ["In this case, the provider can discuss with the patient the importance of removing safety signals and behaviors to maximize learning and, if necessary, develop a plan to wean the safety signal gradually; for example, a loved one might be present but physically distant at a grocery store and later wait outside the grocery store during in vivo practice.Imaginal Exposure Considerations ::: Clinical Considerations for PE during COVID\u201019 and through CVTThe application of imaginal exposure is unlikely to be impacted by COVID\u201019.", [["PE", "DISEASE", 418, 420], ["patient", "ORGANISM", 48, 55], ["patient", "SPECIES", 48, 55], ["PE", "PROBLEM", 418, 420], ["COVID\u2010", "TREATMENT", 428, 434], ["imaginal exposure", "PROBLEM", 471, 488], ["PE", "OBSERVATION", 418, 420], ["unlikely to be", "UNCERTAINTY", 492, 506]]], ["However, there are some general clinical considerations worth noting with regard to implementing imaginal exposures using CVT.", [["CVT", "DISEASE", 122, 125], ["CVT", "PROBLEM", 122, 125]]], ["When providing PE through CVT, providers may need to be more attentive to individuals\u2019 underengagement or overengagement during imaginal exposure, as CVT offers less access to patient nonverbal cues relative to in\u2010person therapy.", [["CVT", "DISEASE", 26, 29], ["CVT", "DISEASE", 150, 153], ["patient", "ORGANISM", 176, 183], ["patient", "SPECIES", 176, 183], ["CVT", "PROBLEM", 26, 29], ["CVT", "PROBLEM", 150, 153], ["in\u2010person therapy", "TREATMENT", 211, 228], ["PE", "OBSERVATION", 15, 17]]], ["In the event that a session needs to transfer to telephone due to technological difficulties, issues around monitoring engagement are even more important, as providers cannot see nonverbal cues of engagement or distress.", [["technological difficulties", "PROBLEM", 66, 92], ["distress", "PROBLEM", 211, 219]]], ["If providers sense that an individual is underengaging with the trauma memory and the associated emotions, providers may use more verbal prompts (e.g., \u201cWhat are you feeling?) during the imaginal exposures to help elicit emotions, physiological arousal, and a more detailed memory to sufficiently activate the fear network and allow for corrective learning to occur.", [["trauma", "DISEASE", 64, 70], ["fear network", "MULTI-TISSUE_STRUCTURE", 310, 322], ["the trauma memory", "PROBLEM", 60, 77], ["physiological arousal", "PROBLEM", 231, 252]]], ["Additionally, if a provider thinks that the individual had been underengaged in the imaginal exposure, the provider may allow more silence following completion of imaginal exposures to allow the individual to sit with the emotional experience for a few minutes prior to processing it.", [["imaginal exposures", "TREATMENT", 163, 181]]], ["Overengagement during an imaginal exposure is often more obvious, and providers can utilize the standard techniques for managing overengagement provided in the latest PE manual (Foa et al., 2019).", [["Overengagement", "TREATMENT", 0, 14], ["the standard techniques", "TREATMENT", 92, 115], ["managing overengagement", "TREATMENT", 120, 143], ["PE", "OBSERVATION", 167, 169]]], ["Providers may choose to elicit subjective units of distress (SUDs) ratings more frequently during imaginal exposures via CVT to better monitor changes in engagement.", [["CVT", "DISEASE", 121, 124], ["distress (SUDs) ratings", "PROBLEM", 51, 74], ["CVT", "PROBLEM", 121, 124]]], ["Providers may want to check in with patients about their experience with imaginal exposures through CVT.", [["CVT", "DISEASE", 100, 103], ["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["imaginal exposures", "PROBLEM", 73, 91], ["CVT", "PROBLEM", 100, 103]]], ["This discussion provides valuable input about the patient's subjective experience and allows for the opportunity to problem\u2010solve ways to promote more effective imaginal exposures through CVT, such as closing a window so there are fewer distractions.Imaginal Exposure Considerations ::: Clinical Considerations for PE during COVID\u201019 and through CVTIn PE, it is important to eliminate safety behaviors during imaginal exposures.", [["CVT", "DISEASE", 188, 191], ["patient", "ORGANISM", 50, 57], ["patient", "SPECIES", 50, 57], ["CVT", "PROBLEM", 188, 191], ["closing a window", "TREATMENT", 201, 217], ["PE", "PROBLEM", 315, 317], ["CVTIn PE", "PROBLEM", 346, 354], ["fewer", "OBSERVATION_MODIFIER", 231, 236], ["distractions", "OBSERVATION", 237, 249], ["PE", "OBSERVATION", 315, 317], ["PE", "OBSERVATION", 352, 354]]], ["However, identifying subtle safety behaviors can be more difficult to detect when PE is delivered via CVT compared to in person.", [["PE", "CHEMICAL", 82, 84], ["CVT", "DISEASE", 102, 105], ["person", "SPECIES", 121, 127], ["subtle safety behaviors", "PROBLEM", 21, 44], ["PE", "PROBLEM", 82, 84], ["CVT", "PROBLEM", 102, 105], ["PE", "OBSERVATION", 82, 84]]], ["For example, with the camera focused on the patient's face, the provider may not be able to see what the patient is holding (e.g., a pet on their lap).", [["patient", "ORGANISM", 44, 51], ["patient", "ORGANISM", 105, 112], ["patient", "SPECIES", 44, 51], ["patient", "SPECIES", 105, 112]]], ["Discussing expectations upfront may prevent this, but providers may consider asking prior to each session if the patient has any safety signals, such as pets, in the room.", [["patient", "ORGANISM", 113, 120], ["patient", "SPECIES", 113, 120]]], ["Finally, distractions during imaginal exposures are more common in the home, especially during COVID\u201019, than during office\u2010based sessions, so providers should problem\u2010solve with patients about how to reduce distractions.Leveraging Exposures At\u2010Home ::: In Vivo Exposure Considerations ::: Clinical Considerations for PE during COVID\u201019 and through CVTMany useful in vivo exposures can be successfully conducted within an individual's home.", [["patients", "ORGANISM", 179, 187], ["patients", "SPECIES", 179, 187], ["distractions during imaginal exposures", "PROBLEM", 9, 47], ["PE", "PROBLEM", 318, 320], ["PE", "OBSERVATION", 318, 320]]], ["Although in vivo exposures will be tailored to each individual patient, we outline several common concerns and provide examples of possible in vivo exposures that can be done from home.Leveraging Exposures At\u2010Home ::: In Vivo Exposure Considerations ::: Clinical Considerations for PE during COVID\u201019 and through CVTFor individuals who have anxiety about social activities or groups of people, feel socially disconnected from others, or have difficulty trusting others, negative beliefs about their likability and worth, or fears of interpersonal rejection, patients can arrange in vivo exposures with other individuals to be conducted on electronic platforms (e.g., Zoom).", [["anxiety", "DISEASE", 341, 348], ["patient", "ORGANISM", 63, 70], ["people", "ORGANISM", 386, 392], ["patients", "ORGANISM", 558, 566], ["patient", "SPECIES", 63, 70], ["people", "SPECIES", 386, 392], ["patients", "SPECIES", 558, 566], ["PE", "PROBLEM", 282, 284], ["anxiety", "PROBLEM", 341, 348], ["interpersonal rejection", "PROBLEM", 533, 556], ["PE", "OBSERVATION", 282, 284], ["rejection", "OBSERVATION", 547, 556]]], ["If individuals do not have access to these to electronic platforms, they can schedule phone calls with individuals or groups of people through telephone conference functions.", [["people", "ORGANISM", 128, 134], ["people", "SPECIES", 128, 134]]], ["Individuals can gradually adjust the difficulty of the in vivo exposure by increasing the number or types of people present on the call or the types of information that they share with others (i.e., personal disclosures to facilitate emotional intimacy).", [["people", "ORGANISM", 109, 115], ["people", "SPECIES", 109, 115]]], ["Patients can also do in vivo exposures to target emotional intimacy or trust by disclosing personal information or engaging in lengthier conversations with supportive individuals in their homes.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Using technology and leveraging other members of the household can target multiple themes, such as trust and intimacy.Leveraging Exposures At\u2010Home ::: In Vivo Exposure Considerations ::: Clinical Considerations for PE during COVID\u201019 and through CVTIndividuals with PTSD tend to have exaggerated concerns about the safety of themselves, their home, and their loved ones, and they often engage in safety rituals or behaviors to reduce anxiety.", [["PTSD", "DISEASE", 266, 270], ["anxiety", "DISEASE", 434, 441], ["PE", "PROBLEM", 215, 217], ["PTSD", "PROBLEM", 266, 270], ["anxiety", "PROBLEM", 434, 441], ["PE", "OBSERVATION", 215, 217]]], ["There are numerous opportunities within the home to eliminate safety rituals and practice eliminating hypervigilant behaviors.", [["safety rituals", "TREATMENT", 62, 76], ["hypervigilant behaviors", "PROBLEM", 102, 125], ["numerous", "OBSERVATION_MODIFIER", 10, 18], ["opportunities", "OBSERVATION", 19, 32]]], ["For example, as relevant, individuals can reduce checking on locks, leave window curtains open during the day, eliminate looking out the windows to monitor neighborhood activity, turn on television or music so that they cannot hear every small noise, sit with their back to windows and doors, and reduce or stop engaging in perimeter checks when they hear noises outside.", [["perimeter checks", "TEST", 324, 340]]], ["Many individuals with PTSD have weapons strategically placed throughout the home, such as by their bed, to help them feel safer.", [["PTSD", "DISEASE", 22, 26], ["PTSD", "PROBLEM", 22, 26]]], ["For patients who carry weapons outside the home, weapons can be left at home while the patient engages in exposures or activities outside of the home.", [["patients", "ORGANISM", 4, 12], ["patient", "ORGANISM", 87, 94], ["patients", "SPECIES", 4, 12], ["patient", "SPECIES", 87, 94]]], ["There are ample opportunities to practice safety\u2010related in vivo exposures without leaving the home.Leveraging Exposures At\u2010Home ::: In Vivo Exposure Considerations ::: Clinical Considerations for PE during COVID\u201019 and through CVTIndividuals may also engage in in vivo exposures to safe but avoided trauma\u2010related material through media, such as television, news, movies, online videos, and photos found online.", [["PE", "PROBLEM", 197, 199], ["ample", "OBSERVATION_MODIFIER", 10, 15], ["PE", "OBSERVATION", 197, 199]]], ["For example, many veterans with PTSD avoid war\u2010related movies, shows, documentaries, or footage of military\u2010related stimuli, such as helicopters, military fatigues, or explosive noises.", [["PTSD", "DISEASE", 32, 36], ["fatigues", "DISEASE", 155, 163], ["PTSD", "PROBLEM", 32, 36], ["explosive noises", "PROBLEM", 168, 184]]], ["Individuals can engage in vivo exposures that target these stimuli by finding relevant material online or through television or movies.", [["these stimuli", "TEST", 53, 66]]], ["Individuals who avoid watching the news out of fear of trauma\u2010related triggers may practice gradually increasing exposure to news, such as starting by watching for 5 min and slowly increasing the time.Leveraging Exposures At\u2010Home ::: In Vivo Exposure Considerations ::: Clinical Considerations for PE during COVID\u201019 and through CVTIndividuals with PTSD often avoid small spaces or locations they fear they cannot escape if they are endangered.", [["PTSD", "DISEASE", 349, 353], ["trauma\u2010related triggers", "PROBLEM", 55, 78], ["PE", "PROBLEM", 298, 300], ["PTSD", "PROBLEM", 349, 353], ["small spaces", "PROBLEM", 366, 378], ["PE", "OBSERVATION", 298, 300]]], ["For example, it is common to assign an exposure to ride in an elevator to approach small spaces, but it may be difficult or unsafe to access elevators during the COVID\u201019 pandemic.", [["an elevator to approach small spaces", "TREATMENT", 59, 95], ["pandemic", "PROBLEM", 171, 179], ["small", "OBSERVATION_MODIFIER", 83, 88], ["spaces", "OBSERVATION", 89, 95]]], ["Individuals can participate in exposures to enclosed spaces in the home by lying on the floor and covering their face with a towel or spending prolonged periods of time in a smaller space, such as a pantry, laundry room, closet, or shower stall, if available.", [["a towel", "TREATMENT", 123, 130]]], ["The home also provides an opportunity to practice in vivo exposures to trauma\u2010related reminders that are tied to smells, tastes, and textures.", [["trauma\u2010related reminders", "TREATMENT", 71, 95]]], ["For example, individuals can use lotions that remind them of smells tied to a perpetrator or handle meat that has textures that remind them of elements of the traumatic experience (i.e., meats that feel similar to flesh).", [["meat", "ANATOMY", 100, 104], ["traumatic", "DISEASE", 159, 168], ["meat", "ORGANISM_SUBDIVISION", 100, 104], ["meats", "ORGANISM_SUBDIVISION", 187, 192], ["flesh", "ORGANISM_SUBDIVISION", 214, 219], ["lotions", "TREATMENT", 33, 40], ["traumatic", "OBSERVATION", 159, 168]]], ["Although participation in exposures outside the home is recommended, there are opportunities to arrange applicable home\u2010based exposures as well.Leveraging Exposures At\u2010Home ::: In Vivo Exposure Considerations ::: Clinical Considerations for PE during COVID\u201019 and through CVTIt is common to incorporate behavioral activation activities into weekly PE practice assignments given the comorbidity between PTSD and depression.", [["PTSD", "DISEASE", 402, 406], ["depression", "DISEASE", 411, 421], ["PE", "PROBLEM", 241, 243], ["weekly PE practice", "TREATMENT", 341, 359], ["the comorbidity", "PROBLEM", 378, 393], ["PTSD", "PROBLEM", 402, 406], ["depression", "PROBLEM", 411, 421], ["PE", "OBSERVATION", 241, 243]]], ["This is even more important during the COVID\u201019 pandemic when individuals may be at an increased risk of depression due to isolation and decreased opportunities for positive reinforcement from the environment.", [["depression", "DISEASE", 105, 115], ["individuals", "ORGANISM", 62, 73], ["depression", "PROBLEM", 105, 115], ["isolation", "TREATMENT", 123, 132], ["positive reinforcement", "TREATMENT", 165, 187], ["depression", "OBSERVATION", 105, 115]]], ["Although what is pleasurable will differ for each person, several behavioral activation activities could be scheduled from within the home.", [["person", "SPECIES", 50, 56]]], ["For example, people may engage in exercise in or around the home either alone or with family members or housemates.", [["people", "ORGANISM", 13, 19], ["people", "SPECIES", 13, 19]]], ["People may also try engaging in cooking, baking, art projects, music, craftsmanship, and mechanical activities (e.g., working on a car).", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6]]], ["For patients with children, this could mean playing games at home or in an accessible outdoor space.Engaging in Relatively Safe In Vivo Exposures Outside of the Home ::: In Vivo Exposure Considerations ::: Clinical Considerations for PE during COVID\u201019 and through CVTDue to safety\u2010related fears and mistrust of others, it may be tempting for individuals with PTSD to remain isolated at home without ever leaving the house during the COVID\u201019 pandemic.", [["PTSD", "DISEASE", 360, 364], ["patients", "ORGANISM", 4, 12], ["children", "ORGANISM", 18, 26], ["patients", "SPECIES", 4, 12], ["children", "SPECIES", 18, 26], ["PE", "PROBLEM", 234, 236], ["COVID\u2010", "TREATMENT", 244, 250], ["PTSD", "PROBLEM", 360, 364], ["pandemic", "PROBLEM", 443, 451], ["PE", "OBSERVATION", 234, 236]]], ["Although individuals need to practice prudent safety precautions as prescribed by their local public health officials during the pandemic, some in vivo exposures outside the home are possible, and certain activities out of the home may be required while adhering to COVID\u201019 safety guidelines.", [["practice prudent safety precautions", "TREATMENT", 29, 64]]], ["Examples of in vivo exposures that are not possible or advisable during the pandemic include visiting certain businesses, including movie theaters and crowded bars, and driving in heavy traffic.", [["not possible", "UNCERTAINTY", 39, 51]]], ["As businesses reopen, individuals can consider engaging in in vivo exposures in public places while maintaining physical distance guidelines (e.g., remaining 6 feet away from others at all times), wearing a mask to help prevent the risk of infection or transmission, and carrying hand sanitizer or disinfectant wipes to use in public.", [["hand", "ANATOMY", 280, 284], ["infection", "DISEASE", 240, 249], ["a mask", "TREATMENT", 205, 211], ["infection", "PROBLEM", 240, 249], ["infection", "OBSERVATION", 240, 249]]], ["For example, individuals may practice standing in lines, talking to cashiers while making eye contact, purposefully going down each aisle of a store without rushing, and practicing not scanning for exits.", [["eye", "ANATOMY", 90, 93], ["eye", "ORGAN", 90, 93], ["eye", "ANATOMY", 90, 93]]], ["However, some outdoor recreational areas have narrow pathways (e.g., hiking trails) that may make it difficult to maintain physical distancing at all times, so masks should be worn and caution should be taken.", [["masks", "TREATMENT", 160, 165], ["narrow", "OBSERVATION_MODIFIER", 46, 52]]], ["Individuals who avoid places with loud noises can park near loud locations like airports or military bases.", [["loud noises", "PROBLEM", 34, 45], ["bases", "ANATOMY_MODIFIER", 101, 106]]], ["For example, a patient could drive to a grocery store that is 30 min away or to a park to spend the day with their family.", [["patient", "ORGANISM", 15, 22], ["patient", "SPECIES", 15, 22]]], ["The types of in vivo exercises done outside the home must take into account both the current COVID\u201019 safety guidelines, patient risk factors (e.g., advanced age, autoimmune or respiratory disorders), and the patient's environment (e.g., access to safe outdoor spaces, access to safe means of transportation).In Vivo Exposures Specific to COVID\u201019 ::: In Vivo Exposure Considerations ::: Clinical Considerations for PE during COVID\u201019 and through CVTDue to the pandemic, individuals with PTSD may have COVID\u201019\u2013related fears that can be incorporated into the fear hierarchy as additional homework.", [["respiratory", "ANATOMY", 177, 188], ["autoimmune or respiratory disorders", "DISEASE", 163, 198], ["PTSD", "DISEASE", 488, 492], ["patient", "ORGANISM", 121, 128], ["patient", "ORGANISM", 209, 216], ["patient", "SPECIES", 121, 128], ["patient", "SPECIES", 209, 216], ["vivo exercises", "TREATMENT", 16, 30], ["patient risk factors", "PROBLEM", 121, 141], ["autoimmune or respiratory disorders", "PROBLEM", 163, 198], ["PE", "PROBLEM", 416, 418], ["PTSD", "PROBLEM", 488, 492], ["PE", "OBSERVATION", 416, 418]]], ["Individuals may be avoiding all COVID\u201019\u2013related news due to anxiety or, in contrast, compulsively checking COVID\u201019\u2013related news.", [["anxiety", "DISEASE", 61, 68], ["anxiety", "PROBLEM", 61, 68]]], ["Some individuals may experience distress related to the physical sensations associated with restricted breathing and not follow current recommendations to wear masks, which could increase their risk of contracting COVID\u201019.", [["COVID", "DISEASE", 214, 219], ["distress", "PROBLEM", 32, 40], ["the physical sensations", "PROBLEM", 52, 75], ["restricted breathing", "PROBLEM", 92, 112], ["masks", "TREATMENT", 160, 165]]], ["If so, providers can help patients desensitize themselves to wearing a mask by following the guidelines provided here: https://adaa.org/sites/default/files/Tips%20for%20Getting%20Comfortable%20in%20Your%20Mask%20and%20with%20PPE_UChicago%20Medicine%2C%20NYU%2C%20Emory%20.pdf", [["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["a mask", "TREATMENT", 69, 75]]]], "36fa2a2d2db68998a28dcb39a58386bf86a17010": [["IntroductionSmart contracts-computer protocols that regulate the exchange of assets in trustless environments-have become popular with the growth of interest in blockchain technologies.", [["IntroductionSmart contracts", "TREATMENT", 0, 27], ["computer protocols", "TREATMENT", 28, 46], ["blockchain technologies", "TREATMENT", 161, 184]]], ["Mainstream blockchain platforms like Ethereum, Libra, and Cardano, feature expressive high-level languages for programming smart contracts.", [["Mainstream blockchain platforms", "TEST", 0, 31], ["Libra", "ANATOMY", 47, 52]]], ["This flexibility has a drawback in that it may open the door to attacks that steal or tamper with the assets controlled by vulnerable contracts [4, 22] .IntroductionAn alternative approach, pursued first by Bitcoin and more recently also by Algorand, is to sacrifice the expressiveness of smart contracts to reduce the attack surface.", [["surface", "ANATOMY", 326, 333], ["surface", "CELLULAR_COMPONENT", 326, 333], ["the attack surface", "PROBLEM", 315, 333], ["steal", "OBSERVATION", 77, 82]]], ["For instance, Bitcoin has a minimal language for transaction redeem scripts, containing only a limited set of logic, arithmetic, and cryptographic operations.", [["Bitcoin", "CHEMICAL", 14, 21], ["cryptographic operations", "TREATMENT", 133, 157]]], ["Despite the limited expressiveness of these scripts, it is possible to encode a variety of smart contracts (like gambling games, escrow services, crowdfunding systems, etc.) by suitably chaining transactions [1] [2] [3] 5, 8, 10, 13, [18] [19] [20] [21] 23] .", [["[1] [2] [3] 5, 8, 10, 13, [18] [19] [20] [21] 23", "SIMPLE_CHEMICAL", 208, 256]]], ["The common trait of these works is that they render contracts as cryptographic protocols, where participants can exchange/sign messages, read the blockchain, and append transactions.", [["participants", "SPECIES", 96, 108]]], ["Verifying the correctness of these protocols is hard, since it requires to reason in a computational model, where participants can manipulate arbitrary bitstrings, only being constrained to use PPTIME algorithms.IntroductionDeparting from this approach, BitML [11] allows to write Bitcoin contracts in a high-level, process-algebraic language.", [["participants", "SPECIES", 114, 126]]], ["BitML features a compiler that translates contracts into sets of standard Bitcoin transactions, and a sound and complete verification technique of relevant trace properties [12] .", [["BitML", "PROTEIN", 0, 5]]], ["The computational soundness of the compiler guarantees that the execution of the compiled contract is coherent with the semantics of the source BitML specification, even in the presence of adversaries.", [["adversaries", "PROBLEM", 189, 200]]], ["Although BitML can express many of the Bitcoin contracts presented in the literature, it is not \"Bitcoin-complete\", i.e. there exist contracts that can be executed on Bitcoin, but are not expressible in BitML [6] .IntroductionFor instance, consider a zero-coupon bond [17] , where an investor A pays 1B upfront to a bank B, and receives back 2B after a maturity date (say, year 2030).", [["zero-coupon", "CHEMICAL", 251, 262], ["BitML", "PROTEIN", 9, 14], ["Bitcoin", "TREATMENT", 167, 174]]], ["First, as a precondition to the stipulation of the contract, we require both A and B to provide a deposit: A's deposit is 1B, while B's deposit is 2B.", [["B", "CELL", 83, 84]]], ["In BitML, we write this precondition as:Introductionwhere x 1 and x 2 are the identifiers of transactions containing the required amount of bitcoins (B) .", [["bitcoins", "PROTEIN", 140, 148], ["bitcoins (B)", "TREATMENT", 140, 152]]], ["Under this precondition, we can specify the zero-coupon bond contract ZCB as follows:IntroductionUpon stipulation, all the deposits required in the preconditions pass under the control of ZCB , and can no longer be spent by A and B. The contract splits these funds in two parts: 1B, that can be withdrawn by B at any moment, and 2B, that can be withdrawn by A after the maturity date.IntroductionAlthough ZCB correctly implements the functionality of zero-coupon bounds, it is quite impractical: for the whole period from the stipulation to the maturity date, 2B are frozen within the contract, and cannot be used by the bank in any way.", [["ZCB", "CHEMICAL", 188, 191], ["ZCB", "SIMPLE_CHEMICAL", 70, 73], ["ZCB", "SIMPLE_CHEMICAL", 188, 191], ["ZCB", "PROTEIN", 405, 408], ["stipulation", "TREATMENT", 102, 113], ["all the deposits", "PROBLEM", 115, 131], ["ZCB", "TREATMENT", 188, 191], ["deposits", "OBSERVATION", 123, 131]]], ["Although this is a desirable feature for the investor, since it guarantees that he will receive 2B even if the bank fails, it is quite undesirable for the bank.", [["2B", "TREATMENT", 96, 98]]], ["The risk that the bank fails is mitigated by external mechanisms, like insurances or government intervention.IntroductionIn this paper we propose an extension of BitML that overcomes this issue.", [["BitML", "SIMPLE_CHEMICAL", 162, 167], ["BitML", "PROTEIN", 162, 167], ["government intervention", "TREATMENT", 85, 108], ["IntroductionIn", "TREATMENT", 109, 123], ["an extension of BitML", "PROBLEM", 146, 167]]], ["The idea is to allow the contract participants to renegotiate it after stipulation, in a controlled way.", [["participants", "SPECIES", 34, 46], ["stipulation", "TREATMENT", 71, 82]]], ["Renegotiation makes it possible to inject in the contract new funds, that were not specified in the original precondition.", [["Renegotiation", "TREATMENT", 0, 13]]], ["We can use this feature to solve the issue with the ZCB contract.", [["the ZCB contract", "TREATMENT", 48, 64]]], ["The new precondition is A: 1B x 1 , i.e. we only require A's deposit.", [["A's deposit", "TREATMENT", 57, 68], ["new", "OBSERVATION_MODIFIER", 4, 7]]], ["In the second part of the , the participants renegotiate the contract: if they both agree, 0B pass under the control of the contract .", [["participants", "SPECIES", 32, 44]]], ["The crucial difference with ZCB is that the deposit variable d is instantiated at renegotiation time, unlike x, which must be fixed at stipulation time.IntroductionThe revised contract ZCB2 solves the problem of ZCB , in that it no longer freezes 2B for the whole duration of the bond: the bank could choose to renegotiate the contract, paying 2B, just before the maturity date.", [["ZCB", "SIMPLE_CHEMICAL", 28, 31], ["ZCB", "SIMPLE_CHEMICAL", 212, 215], ["ZCB", "PROTEIN", 28, 31], ["The revised contract ZCB2", "TREATMENT", 164, 189], ["ZCB", "TREATMENT", 212, 215], ["crucial", "OBSERVATION_MODIFIER", 4, 11], ["difference", "OBSERVATION_MODIFIER", 12, 22]]], ["The remaining f B are transferred to the renegotiated contract 1 , or, if the renegotiation is not completed by 2021, to the investor.IntroductionWe remark that the pattern D + t : D , where D requires some authorizations but D does not, is rather common in BitML, as it ensures that the contract can proceed even if the authorizations are not provided.", [["f B", "GENE_OR_GENE_PRODUCT", 14, 17], ["D", "SIMPLE_CHEMICAL", 181, 182]]], ["By suitably exploiting this pattern, it is possible to guarantee that a BitML contract enjoys liveness, by just assuming that at least one participant is honest.IntroductionThe contracts n , for n \u2208 1..9, allow the insurer to receive the annual premium until 2030: if the bank does not renegotiate the contract for the following year (paying the corresponding premium), then the investor can redeem the face amount of f B. Finally, the contract 10 can be triggered if the bank deposits the 2B: when this happens, the face amount is given back to the insurer, and the investor can redeem 2B after the maturity date.IntroductionCompared to ZCB2 , the contract ZCB3 offers more protection to the investor.", [["ZCB3", "CHEMICAL", 658, 662], ["ZCB2", "GENE_OR_GENE_PRODUCT", 638, 642], ["ZCB3", "GENE_OR_GENE_PRODUCT", 658, 662], ["ZCB2", "DNA", 638, 642], ["ZCB2", "TREATMENT", 638, 642]]], ["To see why, we must evaluate A's payoff for all the possible behaviours of the other participants.", [["participants", "SPECIES", 85, 97], ["A's payoff", "TREATMENT", 29, 39]]], ["If B and I are both honest, then A will redeem 2B, as in the ideal contract ZCB .", [["B", "GENE_OR_GENE_PRODUCT", 3, 4], ["ZCB", "CANCER", 76, 79]]], ["Instead, if either B or I do not accept to renegotiate some n , then A can redeem f B as a partial compensation (unlike in ZCB2 , where A just loses 1B).", [["f B", "GENE_OR_GENE_PRODUCT", 82, 85], ["ZCB2", "PROTEIN", 123, 127], ["a partial compensation", "PROBLEM", 89, 111]]], ["In the real world, A could use this compensation to cover the legal fee to sue the bank in court; also, I could e.g. increase the premium for future interactions with B. By further refining the contract, we could model these real-world mechanisms as oracles, which sanction dishonest participants according to the evidence collected in the blockchain and in messages broadcast by participants.", [["participants", "SPECIES", 284, 296], ["participants", "SPECIES", 380, 392], ["this compensation", "TREATMENT", 31, 48]]], ["The sanction could consist e.g. in blacklisting A, so to prevent her from buying other bonds from B.Contributions.We summarise our main contributions as follows:Contributions.-We extend BitML with the renegotiation primitive * :Contributions., suitably adapting the language syntax and semantics.", [["BitML", "CANCER", 186, 191], ["BitML", "PROTEIN", 186, 191]]], ["The new primitive increases the expressiveness of BitML: besides allowing participants to provide new deposits and secrets at run-time, it also allows for unbounded recursion.Contributions.-We extend the BitML compiler to the new primitive, making it possible to execute renegotiations on Bitcoin.", [["BitML", "PROTEIN", 50, 55], ["participants", "SPECIES", 74, 86], ["new deposits", "PROBLEM", 98, 110], ["unbounded recursion", "PROBLEM", 155, 174], ["Bitcoin", "TREATMENT", 289, 296], ["new", "OBSERVATION_MODIFIER", 4, 7], ["primitive", "OBSERVATION_MODIFIER", 8, 17], ["increases", "OBSERVATION_MODIFIER", 18, 27]]], ["We accordingly extend the computational soundness result in [11] , guaranteeing that the BitML semantics is coherent with the actual Bitcoin executions, also in the presence of adversaries. -We exploit renegotiation to design a new gambling game where two players repeatedly flip coins, and whoever wins twice in a row takes the pot (a form of unbounded recursion).", [["coherent", "OBSERVATION_MODIFIER", 108, 116]]], ["We prove the game to be fair. -We introduce alternative renegotiation primitives, which allow participants to choose some parameters (e.g. the amounts to be deposited) at renegotiation time, and to change the set of participants involved in the renegotiated contract.", [["participants", "SPECIES", 94, 106], ["participants", "SPECIES", 216, 228], ["alternative renegotiation primitives", "TREATMENT", 44, 80]]], ["We show that both primitives can be executed on Bitcoin as is.Contributions.We also introduce a primitive that, at the price of minor Bitcoin extensions, supports non-consensual renegotiations, which are automatically triggered by the contract without requiring the participants' agreement.Contributions.Because of space constraints, we relegate part of the technicalities to [9] .BitML with Renegotiation and RecursionWe start by formalising contract preconditions.", [["participants", "SPECIES", 266, 278], ["space constraints", "PROBLEM", 315, 332], ["Renegotiation", "TREATMENT", 392, 405], ["RecursionWe", "TREATMENT", 410, 421], ["space constraints", "OBSERVATION", 315, 332]]], ["We use A, B, . . . to range over participants.", [["participants", "SPECIES", 33, 45]]], ["We use \u03c7, \u03c7 , . . . to range over deposit names and variables, and v, v to range over non-negative values.Definition 1 (Contract precondition).Contract preconditions have the following syntax (the deposits \u03c7 in a contract precondition G must be distinct):Definition 1 (Contract precondition).The precondition A: v \u03c7 requires A to own vB in a deposit \u03c7, and to spend it for stipulating the contract.", [["vB", "PROTEIN", 334, 336], ["the deposits", "PROBLEM", 193, 205]]], ["We omit to define the syntax and semantics of static expressions, since they are standard.", [["the syntax", "TEST", 18, 28]]], ["We assume that a closed static expression evaluates to a 32-bit value.", [["a closed static expression", "TEST", 15, 41]]], ["Contracts are terms with the syntax inE have the correct number of arguments;(iii) the names a in a p are distinct, and they include those occurring in p; (iv) in a prefix v \u2192 C , the sequences v and C have the same length.", [["v \u2192 C", "GENE_OR_GENE_PRODUCT", 172, 177], ["inE", "DNA", 36, 39], ["the sequences v", "TEST", 180, 195]]], ["To restrict who can execute a branch and when, one can use the decoration A : D, requiring to wait for A's authorization, and the decoration E : D, requiring to wait until the time specified by the static expression E. The action * :The actionE allows the participants involved in the contract to renegotiate it.", [["participants", "SPECIES", 256, 268], ["A's authorization", "TREATMENT", 103, 120], ["branch", "OBSERVATION_MODIFIER", 30, 36]]], ["Intuitively, if (\u03b1) = {G}C , then the contract continues as C { E /\u03b1 } if all the participants give their authorization, and satisfy the precondition G.Definition 3 (Contract advertisement).", [["(\u03b1) = {G}C", "CHEMICAL", 16, 26], ["{G}C", "SIMPLE_CHEMICAL", 22, 26], ["participants", "SPECIES", 82, 94]]], ["A contract advertisement is a term {G}C such that: (i) each secret name in C occurs inThe second condition is used to guarantee that the contract is stipulated only if all the involved participants give their authorizations.", [["{G}C", "CHEMICAL", 35, 39], ["participants", "SPECIES", 185, 197]]], ["5 how to relax it, by allowing renegotiations to exclude some participants, or to include new ones, which were not among those who originally stipulated the contract.Definition 3 (Contract advertisement).", [["participants", "SPECIES", 62, 74]]], ["A contract advertisement is a term {G}C such that: (i) each secret name in C occurs inWe now extend the reduction semantics of BitML [11] , by focussing on the new renegotiation primitive.", [["{G}C", "CHEMICAL", 35, 39]]], ["Because of space limitations, here we just provide the underlying intuition, relegating the full formalisation to [9] .", [["space limitations", "PROBLEM", 11, 28], ["space", "OBSERVATION", 11, 16]]], ["Configurations have the following syntax:We illustrate configurations and their semantics through a series of examples.Deposits.A deposit A, v x can be subject to several operations, like e.g. split into two smaller deposits, join with another deposit, transfer to another participant, or destroy.", [["Deposits", "PROBLEM", 119, 127], ["several operations", "TREATMENT", 163, 181], ["two smaller deposits", "PROBLEM", 204, 224], ["deposit", "OBSERVATION", 130, 137], ["several", "OBSERVATION_MODIFIER", 163, 170], ["operations", "OBSERVATION", 171, 181], ["smaller", "OBSERVATION_MODIFIER", 208, 215], ["deposits", "OBSERVATION", 216, 224]]], ["In all cases A must authorise the operation.", [["the operation", "TREATMENT", 30, 43]]], ["For instance, to authorize the join of two deposits, A can perform the following step:Deposits.After A also provides the dual authorization to spend y, anyone can actually join the deposits:Deposits.Advertisement.", [["deposits", "OBSERVATION", 43, 51], ["Deposits", "OBSERVATION", 190, 198]]], ["Any participant can broadcast a new contract advertisement {G}C , provided that all the deposits mentioned in G exist in the current configuration, and that the names of the secrets declared in G are fresh.Stipulation.To stipulate an advertised contract {G}C , all the participants mentioned in it must fulfill the preconditions, and authorise the stipulation.", [["{G}C", "CHEMICAL", 59, 63], ["{G}C", "CHEMICAL", 254, 258], ["G}C", "SIMPLE_CHEMICAL", 60, 63], ["G}C", "SIMPLE_CHEMICAL", 255, 258], ["participant", "SPECIES", 4, 15], ["participants", "SPECIES", 269, 281], ["all the deposits", "PROBLEM", 80, 96], ["deposits", "OBSERVATION", 88, 96]]], ["For instance, let G = A: 1 x | B: 1 y | A : a, and let C be an arbitrary contract involving only A and B. The stipulation starts from a configuration containing the advertisement and the participants' deposits:Stipulation.At this point the participants must commit to their secrets (in this case, only A has a secret).", [["let C", "GENE_OR_GENE_PRODUCT", 51, 56], ["participants", "ORGANISM", 240, 252], ["participants", "SPECIES", 187, 199], ["participants", "SPECIES", 240, 252], ["a", "TEST", 44, 45], ["let C", "TEST", 51, 56], ["an arbitrary contract", "TEST", 60, 81]]], ["This is rendered as a sequence of steps:Stipulation.represent ending the commitment phase (these steps might seem redundant, but they are useful to obtain a step-by-step correspondence between BitML executions and Bitcoin executions).Stipulation.After that, A and B must perform an additional sequence of steps to authorize the transfer of their deposits x, y to the contract: At this point all the needed authorizations have been given, so the advertisement can be turned into an active contract.", [["authorizations", "TREATMENT", 406, 420], ["commitment phase", "OBSERVATION_MODIFIER", 73, 89]]], ["This step consumes the deposits and all the authorizations, and creates an active contract, with a fresh name z:Stipulation.a, and C is an arbitrary contract involving only A and B, and possibly containing the integer variable \u03b1 in static expressions.", [["\u03b1", "PROTEIN", 227, 228], ["the deposits", "PROBLEM", 19, 31], ["deposits", "OBSERVATION", 23, 31], ["active", "OBSERVATION_MODIFIER", 75, 81]]], ["Unlike in the case of contract stipulation above, deposits names are unknown before renegotiation, so we use the deposit variables d, e to refer to them.Stipulation.Consider a configuration * :Stipulation.where C contains the branches alternative to the renegotiation.", [["branches", "ANATOMY_MODIFIER", 226, 234]]], ["A possible execution of the action * :Stipulation.k starts as follows: * :Stipulation.where the advertisement {G } x C is obtained by transforming {G}C as follows: (i) variables d, e are renamed into fresh ones d , e , and similarly the secret name a into a ,(ii) the static expressions in C are evaluated, assuming \u03b1 = k, and replaced with their results.The superscript x in the advertisement is used to record that, when the renegotiation is concluded, the contract x must be reduced.Stipulation.In the subsequent steps participants choose the actual deposit names, and A commits to her secret.", [["{G}C", "CHEMICAL", 147, 151], ["G } x C", "SIMPLE_CHEMICAL", 111, 118], ["{G}C", "SIMPLE_CHEMICAL", 147, 151], ["participants", "SPECIES", 522, 534]]], ["These choices are performed as follows:Stipulation.At this point, participants must authorise spending their deposits and the balance of the contract at x.", [["participants", "SPECIES", 66, 78]]], ["This is done through a series of steps:Stipulation.Finally, the new contract is stipulated.", [["new", "OBSERVATION_MODIFIER", 64, 67]]], ["This closes the old contract, and transfers its balance to the newly generated one, with a fresh name x :Stipulation.Note that the branches in C are discarded only in the last step above, where we complete the renegotiation.", [["branches", "OBSERVATION_MODIFIER", 131, 139]]], ["Before this step, it would have been possible to take one of the branches in C , aborting the renegotiation.Withdraw.", [["branches", "ANATOMY_MODIFIER", 65, 73]]], ["ExecutingAfter the execution, the alternative branch C is discarded, and a fresh deposit of vB for A is created.", [["vB", "PROTEIN", 92, 94], ["branch", "OBSERVATION_MODIFIER", 46, 52]]], ["Note that the active contract x is terminated.Withdraw.", [["active", "OBSERVATION_MODIFIER", 14, 20]]], ["The primitive divides the contract balance in n parts, each one controlled by its own contract.", [["primitive", "OBSERVATION_MODIFIER", 4, 13], ["contract balance", "OBSERVATION", 26, 42]]], ["ExecutingAfter this step, the new spawned contracts C 1 and C 2 are executed concurrently.Withdraw.", [["C 2", "GENE_OR_GENE_PRODUCT", 60, 63]]], ["For instance, if \u0393 = A : a#N | B : b#N :Withdraw.", [["Withdraw", "PROBLEM", 40, 48]]], ["ExecutingThe terms A : a#N and B : b#N represent the fact that the secrets a and b have been revealed.", [["N", "PROBLEM", 37, 38]]], ["Crucially, only the participant who performed the commitment can add the corresponding term to the configuration.Authorizations.A branch decorated by A : \u00b7 \u00b7 \u00b7 can be taken only if the participant A has provided her authorization.", [["\u00b7 \u00b7 \u00b7", "SIMPLE_CHEMICAL", 154, 159], ["participant", "SPECIES", 20, 31], ["branch", "ANATOMY_MODIFIER", 130, 136]]], ["For instance:Authorizations.The leftmost configuration contains the term A[x A : B], which represents A's authorization to take the branch B. This enables the step to be taken.", [["A's authorization", "TREATMENT", 102, 119], ["leftmost", "OBSERVATION_MODIFIER", 32, 40], ["configuration", "OBSERVATION_MODIFIER", 41, 54]]], ["A branch decorated with d can be taken only if time d has passed.", [["branch", "ANATOMY_MODIFIER", 2, 8]]], ["For instance:Time Constraints.For the branches not guarded by , we lift transitions from untimed to timed configurations: namely, for an untimed transition \u0393 \u2212 \u2192 \u0393 , we also have the timed transition \u0393 | t \u2212 \u2192 \u0393 | t.", [["branches", "ANATOMY_MODIFIER", 38, 46]]], ["This reflects the assumption that participants can always meet deadlines, if they want to.Executing BitML on BitcoinTo execute a BitML contract, participants first compile it to a set of Bitcoin transactions, and then append these transactions to the blockchain, each following their own strategy.", [["participants", "SPECIES", 34, 46], ["participants", "SPECIES", 145, 157]]], ["Participants' strategies can involve other actions besides appending transactions, like e.g. broadcasting signatures on given transactions (which corresponds, in BitML, to add an authorization to the configuration), revealing secrets, and waiting some time (see Definition 16 in [11] ).", [["Participants", "SPECIES", 0, 12]]], ["The coherence between the BitML semantics and the execution on Bitcoin is guaranteed by a step-by-step correspondence between the transitions of the BitML semantics and the actions performed by participants on the Bitcoin network.Executing BitML on BitcoinIn this section we illustrate the compiler and the execution protocol through a couple of examples, focussing on the new renegotiation primitive.", [["Bitcoin network", "MULTI-TISSUE_STRUCTURE", 214, 229], ["BitML", "DNA", 26, 31], ["participants", "SPECIES", 194, 206], ["the execution protocol", "TREATMENT", 303, 325]]], ["The needed background on Bitcoin will be introduced along with these examples.", [["Bitcoin", "SIMPLE_CHEMICAL", 25, 32], ["Bitcoin", "TREATMENT", 25, 32]]], ["We relegate the formal definition of the compilation rules to [9] .Executing BitML on BitcoinZero-Coupon Bond.", [["BitcoinZero", "TREATMENT", 86, 97]]], ["Recall the ZCB contract from Sect.", [["ZCB", "PROTEIN", 11, 14]]], ["We represent these transactions as follows, using the notation in [7] : Tx 1 in : \u00b7 \u00b7 \u00b7 wit : \u00b7 \u00b7 \u00b7 out : (\u03bbx.versig K(A) (x), 1B) Tx 2 in : \u00b7 \u00b7 \u00b7 wit : \u00b7 \u00b7 \u00b7 out : (\u03bbx.versig K(B) (x), 2B)Executing BitML on BitcoinThe transaction T x1 is a record with three fields (T x2 is similar).", [["\u00b7 \u00b7 \u00b7", "SIMPLE_CHEMICAL", 82, 87], ["Tx", "TEST", 72, 74], ["K", "TEST", 117, 118], ["1B", "TEST", 127, 129], ["Tx", "TEST", 131, 133], ["\u00b7", "TEST", 145, 146], ["\u03bbx.versig", "TEST", 166, 175], ["K", "TEST", 176, 177], ["B", "TEST", 178, 179], ["2B", "TEST", 186, 188], ["Executing BitML", "TEST", 189, 204]]], ["The field out is a pair, whose first element is a boolean predicate (with parameter x), and the second element, 1B, is the amount that a subsequent transaction satisfying the predicate can redeem from T x1 .", [["T x1", "GENE_OR_GENE_PRODUCT", 201, 205], ["T x1", "CELL_TYPE", 201, 205]]], ["Here, the predicate versig K(A) (x) is true when x is a signature of A on the redeeming transaction (i.e., one having T x1 as in).", [["K", "CHEMICAL", 27, 28], ["T x1", "GENE_OR_GENE_PRODUCT", 118, 122], ["T x1", "PROTEIN", 118, 122]]], ["The contract ZCB is compiled into the transactions in Fig. 2 .", [["ZCB", "PROTEIN", 13, 16]]], ["The first one that can be appended to the blockchain is T init .", [["T init", "GENE_OR_GENE_PRODUCT", 56, 62]]], ["This requires a few conditions to be met: (i) T x1 and T x2 are unspent on the blockchain, i.e. no other transactions spend them; (ii) the amount specified in the out field of T init does not exceed the sum of the amounts in T x1 and T x2 ;(iii) the predicates in the out fields of T x1 and T x2 are true, after replacing the formal parameters with the signatures sig K(A) and sig K(B) , contained in the wit field of T init .The contract ZCB becomes stipulated once T init is on the blockchain.Executing BitML on BitcoinAfter that, the action can be performed by either A or B, by redeeming T init with T split .", [["T x2", "GENE_OR_GENE_PRODUCT", 55, 59], ["T x1", "GENE_OR_GENE_PRODUCT", 282, 286], ["T x2", "GENE_OR_GENE_PRODUCT", 291, 295], ["T init", "GENE_OR_GENE_PRODUCT", 418, 424], ["ZCB", "GENE_OR_GENE_PRODUCT", 439, 442], ["T init", "GENE_OR_GENE_PRODUCT", 592, 598], ["T init", "PROTEIN", 418, 424], ["ZCB", "PROTEIN", 439, 442], ["sig K", "TEST", 377, 382]]], ["This transaction uses K(ZCB , {A, B}), a set of two key pairs, each one owned by each participant.", [["K", "CHEMICAL", 22, 23], ["K", "TEST", 22, 23], ["ZCB", "TEST", 24, 27]]], ["These keys are only used in this step, to ensure that no transaction but T split can redeem T init .Executing BitML on BitcoinThe transaction T split creates two unspent outputs (indexed by 0 and 1), corresponding to the two parallel components of the , each with its own balance.", [["T init", "GENE_OR_GENE_PRODUCT", 92, 98]]], ["The output at index 0 can only be redeemed by T B (note that T B 's in field refers to the output 0 of T split ), transferring 1B to B. No other redemption is possible, since such output requires a signature with a specific key set, i.e. K( B, {A, B}), which is not used for any other purpose.", [["T B", "GENE_OR_GENE_PRODUCT", 46, 49], ["T B", "GENE_OR_GENE_PRODUCT", 61, 64], ["T B", "PROTEIN", 46, 49], ["T B", "PROTEIN", 61, 64], ["The output at index", "TEST", 0, 19], ["the output", "TEST", 87, 97], ["such output", "PROBLEM", 175, 186], ["a specific key set", "TEST", 213, 231], ["K", "TEST", 238, 239], ["output", "OBSERVATION_MODIFIER", 4, 10]]], ["Further, the output of T B can be redeemed with B's key, without A's one.", [["T B", "GENE_OR_GENE_PRODUCT", 23, 26], ["T B", "PROTEIN", 23, 26]]], ["Similarly, the output 1 of T split can be redeemed by T A , which in turns transfers 2B to A. The absLock field in T A ensures that this may only happen after time 2030.Executing BitML on BitcoinThe stipulation protocol followed by participants requires that all the signatures needed to append the transactions in Fig. 2 are exchanged before T init is appended.", [["T", "GENE_OR_GENE_PRODUCT", 27, 28], ["T A", "GENE_OR_GENE_PRODUCT", 54, 57], ["T A", "CANCER", 115, 118], ["BitML", "PROTEIN", 179, 184], ["participants", "SPECIES", 232, 244], ["the output", "TEST", 11, 21], ["Bitcoin", "TREATMENT", 188, 195], ["The stipulation protocol", "TREATMENT", 195, 219], ["output", "OBSERVATION_MODIFIER", 15, 21]]], ["This is obtained by exchanging the signatures of T init after all the other signatures.", [["T init", "GENE_OR_GENE_PRODUCT", 49, 55]]], ["This ensures that, once the execution of ZCB starts, any honest participant can make it proceed, by appending a transaction that correspond to any of the enabled BitML actions.Executing BitML on BitcoinIn general, to guarantee that such liveness property holds, the contract must be suitably crafted, using the D + t : D pattern discussed in Sect.", [["ZCB", "GENE_OR_GENE_PRODUCT", 41, 44], ["BitML", "GENE_OR_GENE_PRODUCT", 162, 167], ["ZCB", "PROTEIN", 41, 44], ["BitML", "PROTEIN", 162, 167], ["BitML", "PROTEIN", 186, 191], ["ZCB", "TREATMENT", 41, 44], ["Bitcoin", "TREATMENT", 195, 202]]], ["Compiling ZCB2 yields the transactions:, which asks 2B from B as a precondition.", [["ZCB2", "CHEMICAL", 10, 14], ["ZCB2", "GENE_OR_GENE_PRODUCT", 10, 14], ["B", "GENE_OR_GENE_PRODUCT", 60, 61], ["ZCB2", "PROTEIN", 10, 14]]], ["In BitML, this corresponds to choosing the deposit name y for the deposit variable The renegotiation succeeds once T init is on the blockchain.", [["T init", "GENE_OR_GENE_PRODUCT", 115, 121], ["The renegotiation", "TREATMENT", 83, 100]]], ["After that, any participant can perform the A, by appending T A to the blockchain.", [["T A", "GENE_OR_GENE_PRODUCT", 60, 63], ["participant", "SPECIES", 16, 27]]], ["Compiling ZCB2 yields the transactions:; -at renegotiation time, the participants broadcast the identifiers of their new deposits, and the commitments of their new secrets.", [["ZCB2", "GENE_OR_GENE_PRODUCT", 10, 14], ["ZCB2", "DNA", 10, 14], ["participants", "SPECIES", 69, 81], ["their new deposits", "PROBLEM", 111, 129], ["new", "OBSERVATION_MODIFIER", 117, 120], ["deposits", "OBSERVATION", 121, 129]]], ["Finally, the new contract is compiled as usual, with the exception that the new initial transaction has an extra input, which transfers the balance of the caller contract to the callee (in the ZCB2 example, this extra input is (T split , 1) within T init ).Zero-Coupon Bond with Renegotiation.", [["T init", "GENE_OR_GENE_PRODUCT", 248, 254], ["Renegotiation", "TREATMENT", 279, 292], ["new", "OBSERVATION_MODIFIER", 13, 16]]], ["Compiling ZCB2 yields the transactions:Computational Soundness.", [["ZCB2", "SIMPLE_CHEMICAL", 10, 14], ["ZCB2", "DNA", 10, 14]]], ["The main result of [11] is computational soundness, which ensures that each execution trace at the Bitcoin level has a corresponding one in the semantics of BitML.", [["BitML", "GENE_OR_GENE_PRODUCT", 157, 162], ["Bitcoin", "PROTEIN", 99, 106], ["BitML", "PROTEIN", 157, 162], ["main", "OBSERVATION_MODIFIER", 4, 8], ["trace", "OBSERVATION_MODIFIER", 86, 91]]], ["This was achieved by formalizing the semantics of Bitcoin using a computational model, where participants can exchange bitstrings as messages, and append transactions to the blockchain.", [["participants", "SPECIES", 93, 105]]], ["Then, a coherence relation was defined to relate symbolic runs to computational ones, essentially matching symbolic moves with their implementation in Bitcoin.Zero-Coupon Bond with Renegotiation.", [["Bitcoin", "TREATMENT", 151, 158]]], ["Compiling ZCB2 yields the transactions:Our extension of BitML with renegotiation still enjoys computational soundness.", [["ZCB2", "GENE_OR_GENE_PRODUCT", 10, 14], ["ZCB2", "DNA", 10, 14], ["BitML", "DNA", 56, 61]]], ["The argument is similar, and requires extending the coherence relation to the new primitive.", [["similar", "OBSERVATION_MODIFIER", 16, 23], ["new", "OBSERVATION_MODIFIER", 78, 81], ["primitive", "OBSERVATION", 82, 91]]], ["In particular, the reduction:Zero-Coupon Bond with Renegotiation.", [["reduction", "OBSERVATION_MODIFIER", 19, 28]]], ["Compiling ZCB2 yields the transactions:corresponds, in Bitcoin, to A broadcasting a message which contains the hashes of her secrets and the transaction identifiers that she wishes to use as deposits.Zero-Coupon Bond with Renegotiation.", [["ZCB2", "DNA", 10, 14]]], ["Compiling ZCB2 yields the transactions:Instead, the reduction:Zero-Coupon Bond with Renegotiation.", [["ZCB2", "GENE_OR_GENE_PRODUCT", 10, 14], ["ZCB2", "PROTEIN", 10, 14], ["reduction", "OBSERVATION_MODIFIER", 52, 61]]], ["Compiling ZCB2 yields the transactions:corresponds to A signing all the transactions obtained by compiling the new contract, and broadcasting the signatures.", [["ZCB2", "GENE_OR_GENE_PRODUCT", 10, 14], ["ZCB2", "DNA", 10, 14]]], ["A participant signs T init only after receiving the signatures of the other transactions from all the other participants.Zero-Coupon Bond with Renegotiation.", [["participant", "SPECIES", 2, 13], ["participants", "SPECIES", 108, 120]]], ["Compiling ZCB2 yields the transactions:Computational soundness requires that each contract involves at least one participant, say A, who follows the Bitcoin implementation of BitML.", [["ZCB2", "GENE_OR_GENE_PRODUCT", 10, 14], ["BitML", "GENE_OR_GENE_PRODUCT", 175, 180], ["ZCB2", "DNA", 10, 14], ["BitML", "PROTEIN", 175, 180]]], ["In particular, A follows the stipulation and renegotiation protocols correctly, i.e. signing nothing but the protocol messages, and signing T init last.", [["renegotiation protocols", "TREATMENT", 45, 68]]], ["Consequently, we only consider computational runs of polynomial length (with respect to the security parameter).", [["computational runs of polynomial length", "TREATMENT", 31, 70]]], ["Compiling ZCB2 yields the transactions:Below, we provide an intuitive statement of computational soundness.", [["ZCB2", "DNA", 10, 14]]], ["Under the hypotheses above, eachBitcoin-level computational run has a corresponding coherent BitML run, with overwhelming probability.A Fair Recursive Coin Flipping GameTo illustrate recursion in our extended BitML, we introduce a simple game where two players repeatedly flip coins, and the one who wins two consecutive flips takes the pot.", [["eachBitcoin", "PROTEIN", 28, 39], ["overwhelming probability", "PROBLEM", 109, 133]]], ["The current flip winner is A if the secrets of A and B are equal, otherwise it is B. At this point, the contract can be renegotiated as A 1 or B 1 , depending on the flip winner (the parameter 1 represents the round).", [["A", "GENE_OR_GENE_PRODUCT", 47, 48], ["B", "GENE_OR_GENE_PRODUCT", 53, 54], ["B 1", "GENE_OR_GENE_PRODUCT", 143, 146]]], ["If players do not agree on the renegotiation, then the funds are split fairly, according to the current expected win.A Fair Recursive Coin Flipping GameThe contract A n requires A and B to generate fresh secrets for the n-th turn.", [["B", "GENE_OR_GENE_PRODUCT", 184, 185], ["Coin Flipping", "OBSERVATION", 134, 147]]], ["If A wins again, she can withdraw the pot, otherwise the contract can be renegotiated as B n + 1 .", [["B n + 1", "GENE_OR_GENE_PRODUCT", 89, 96]]], ["The contract B is similar.A Fair Recursive Coin Flipping GameThe following theorem states that our coin flipping game is fair.", [["B", "CELL", 13, 14], ["contract B", "OBSERVATION", 4, 14], ["similar", "OBSERVATION_MODIFIER", 18, 25]]], ["Indeed, B would be prevented from revealing his secrets (by the predicate in the b), and so A could win after the timeout.", [["B", "GENE_OR_GENE_PRODUCT", 8, 9]]], ["This ensures that, when renegotiation happens, there is still time to reveal the round secrets.", [["round", "OBSERVATION_MODIFIER", 81, 86], ["secrets", "OBSERVATION", 87, 94]]], ["When this happens, the rational player takes the Split branch, distributing the pot according to the expected payoff in the current game state, thus ensuring the fairness of the whole game.", [["branch", "OBSERVATION_MODIFIER", 55, 61]]], ["The player who won the last coin flip is expected to win pB, with p = 1 /2 \u00b7 6 + 1 /2 \u00b7 ( 1 /2 \u00b7 p + 1 /2 \u00b7 0), giving p = 4.", [["p", "TEST", 66, 67]]], ["Accordingly, the Split contracts transfer 4B to the winner of the last flip and (6 \u2212 4)B = 2B to the other player.More Expressive Renegotiation PrimitivesThe renegotiation primitive we have proposed for BitML is motivated by its simplicity, and by the possibility of compiling into standard Bitcoin transactions.", [["Bitcoin", "SIMPLE_CHEMICAL", 291, 298]]], ["The primitive * :More Expressive Renegotiation PrimitivesE allows participants to choose at run-time only the deposit variables used in the renegotiated contracts, and to commit to new secrets.", [["participants", "SPECIES", 66, 78]]], ["A possible extension is to allow participants to choose at run-time arbitrary values for the renegotiation parameters E.More Expressive Renegotiation PrimitivesFor instance, consider a mortgage payment, where a buyer A must pay 10B to a bank B in 10 installments.", [["participants", "SPECIES", 33, 45], ["the renegotiation parameters", "TEST", 89, 117]]], ["After A has paid the first five installments (of 1B each), the bank might propose to renegotiate the contract, varying the amount of the installment.", [["amount", "OBSERVATION_MODIFIER", 123, 129]]], ["Using the BitML renegotiation primitive presented in Sect.", [["BitML", "DNA", 10, 15], ["the BitML renegotiation", "TREATMENT", 6, 29]]], ["2, we could not model this contract, since the new amount and the number of installments are unknown at the time of the original stipulation.", [["new", "OBSERVATION_MODIFIER", 47, 50], ["amount", "OBSERVATION_MODIFIER", 51, 57], ["number", "OBSERVATION_MODIFIER", 66, 72]]], ["Note that if A does not agree with these values, the renegotiation fails.", [["these values", "TEST", 35, 47]]], ["A more refined version of the contract should take this possibility into account, by adding suitable compensation branches.", [["branches", "OBSERVATION_MODIFIER", 114, 122]]], ["Although adding the new primitive would moderately increase the complexity of the semantics and of the compiler, this extension can still be implemented on top of standard Bitcoin, preserving our computational soundness result.More Expressive Renegotiation PrimitivesRenegotiation with a Given set of Participants.", [["Participants", "SPECIES", 301, 313], ["moderately", "OBSERVATION_MODIFIER", 40, 50], ["increase", "OBSERVATION_MODIFIER", 51, 59], ["complexity", "OBSERVATION_MODIFIER", 64, 74]]], ["2, a renegotiation can be performed only if all the participants of the contract agree.", [["participants", "SPECIES", 52, 64], ["a renegotiation", "TREATMENT", 3, 18]]], ["To generalise, we could require the agreement of a given set of participants (possibly, not among those who originally stipulated the contract).More Expressive Renegotiation PrimitivesFor instance, consider an escrow service between a buyer A and a seller B for the purchase of an item worth 1B.", [["participants", "SPECIES", 64, 76]]], ["The normal case is that the buyer authorizes the transfer of 1B after receiving the item, but it may happen that a dishonest seller never sends the item, or that a dishonest buyer never authorizes the payment.", [["normal", "OBSERVATION", 4, 10]]], ["To cope with these cases, the participants can renegotiate the contract, including an escrow service M which mediates the dispute, as follows: A means that only A and M need to agree in order for the contract A to be executed, resolving the dispute.", [["participants", "SPECIES", 30, 42]]], ["Similarly to the one discussed before, also this extension can be implemented on-top of Bitcoin.", [["Bitcoin", "TREATMENT", 88, 95]]], ["The computational soundness property is preserved, under the assumption that at least one participant in any renegotiation is honest, i.e. it follows the renegotiation protocol.", [["the renegotiation protocol", "TREATMENT", 150, 176], ["preserved", "OBSERVATION", 40, 49]]], ["Crucially, if a renegotiation only involves dishonest participants, the renegotiated contract could be anything, not necessarily that prescribed in the original contract.More Expressive Renegotiation PrimitivesNon-consensual Renegotiation.", [["participants", "SPECIES", 54, 66]]], ["In the variants of * : discussed before, renegotiation requires one or more participants to agree.", [["participants", "SPECIES", 76, 88]]], ["In certain scenarios, we may want to renegotiate the contract without the participants having to agree.", [["participants", "SPECIES", 74, 86]]], ["For simplicity, we assume the defining equations of this primitive of the form (\u03b1) = {v}C , where v represents the amount of B added to the contract, by anyone.More Expressive Renegotiation PrimitivesWe exemplify the new primitive to design a two-players game which starts with a bet of 1B from A, and a bet of 2B from B. Then, starting from A, players take turns adding 2B each to the pot.", [["B", "PROTEIN", 125, 126]]], ["Even though the sender of these 2B is not specified in the contract, it is implicit in the game mechanism: for instance, when A n calls B n + 1 , only B is incentivized to add 2B, since not doing so will make A win.More Expressive Renegotiation PrimitivesImplementing the primitive on top of Bitcoin seems unfeasible: even if it were possible to use complex off-chain multiparty computation protocols [16] , doing so might be impractical.", [["B", "GENE_OR_GENE_PRODUCT", 151, 152], ["complex off-chain multiparty computation protocols", "TREATMENT", 350, 400], ["primitive", "OBSERVATION_MODIFIER", 272, 281]]], ["Rather, we would like to extend Bitcoin as much as needed for the new primitive.", [["Bitcoin", "TREATMENT", 32, 39]]], ["In our implementation of BitML, we compile contracts to sets of transactions and make participants sign them.", [["participants", "SPECIES", 86, 98]]], ["A way to cope with this is to extend Bitcoin with malleable signatures which only cover the part of the transaction not affected by the parameter n in B n .", [["malleable signatures", "PROBLEM", 50, 70]]], ["To overcome this problem, we could add a new opcode to allow the output script of B n to access the parameter in the redeeming transaction, so to verify that it is indeed n + 1 as intended.", [["a new opcode", "TREATMENT", 39, 51]]], ["The same goal could be achieved by adapting the techniques used in [24, 25] to realize covenants.ConclusionsWe have investigated linguistic primitives to renegotiate BitML contracts, and their implementation on standard Bitcoin.", [["BitML contracts", "TREATMENT", 166, 181], ["standard Bitcoin", "TREATMENT", 211, 227]]], ["The same technique can be directly applied to BitML contracts featuring renegotiation (but without recursion), since the abstraction would remain finite.", [["The same technique", "TREATMENT", 0, 18]]], ["Even if we could exploit the fact that Bitcoin uses 32-bit integers to make the state space finite, it would still be too large for verification to be practical.ConclusionsIf we assume that integers are unbounded, and that participants always accept renegotiations, the extension of BitML presented in Sect.", [["Bitcoin", "CHEMICAL", 39, 46], ["Bitcoin", "SIMPLE_CHEMICAL", 39, 46], ["BitML", "PROTEIN", 283, 288], ["participants", "SPECIES", 223, 235]]], ["2 can simulate a counter machine, so making BitML Turing-complete.", [["a counter machine", "TREATMENT", 15, 32]]], ["Alternative techniques to model checking (e.g., type-based approaches [15] ) could be used to analyse relevant contract properties.", [["Alternative techniques", "TREATMENT", 0, 22], ["model checking (e.g., type-based approaches", "TREATMENT", 26, 69]]]], "PMC7111159": [["Anatomy and physiologyAlthough lymph nodes are located throughout the lymphatic system, they are concentrated in certain areas of the body, including the head and neck.", [["lymph nodes", "ANATOMY", 31, 42], ["lymphatic system", "ANATOMY", 70, 86], ["body", "ANATOMY", 134, 138], ["head", "ANATOMY", 154, 158], ["neck", "ANATOMY", 163, 167], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 31, 42], ["lymphatic system", "MULTI-TISSUE_STRUCTURE", 70, 86], ["body", "ORGANISM_SUBDIVISION", 134, 138], ["head", "ORGANISM_SUBDIVISION", 154, 158], ["neck", "ORGAN", 163, 167], ["lymph nodes", "PROBLEM", 31, 42], ["lymph nodes", "OBSERVATION", 31, 42], ["lymphatic system", "ANATOMY", 70, 86], ["concentrated", "OBSERVATION_MODIFIER", 97, 109], ["body", "ANATOMY_MODIFIER", 134, 138], ["head", "ANATOMY", 154, 158], ["neck", "ANATOMY", 163, 167]]], ["Because infectious processes involving the oropharyngeal structures are common in children, cervical lymphadenitis is also common in this age group.Anatomy and physiologyLymphatic drainage follows well-defined patterns.", [["oropharyngeal structures", "ANATOMY", 43, 67], ["cervical lymphadenitis", "ANATOMY", 92, 114], ["lymphadenitis", "DISEASE", 101, 114], ["oropharyngeal structures", "MULTI-TISSUE_STRUCTURE", 43, 67], ["children", "ORGANISM", 82, 90], ["cervical", "ORGAN", 92, 100], ["children", "SPECIES", 82, 90], ["infectious processes involving the oropharyngeal structures", "PROBLEM", 8, 67], ["cervical lymphadenitis", "PROBLEM", 92, 114], ["physiologyLymphatic drainage", "TREATMENT", 160, 188], ["infectious", "OBSERVATION", 8, 18], ["oropharyngeal structures", "ANATOMY", 43, 67], ["common", "OBSERVATION_MODIFIER", 72, 78], ["cervical", "ANATOMY", 92, 100], ["lymphadenitis", "OBSERVATION", 101, 114], ["physiologyLymphatic", "OBSERVATION_MODIFIER", 160, 179], ["drainage", "OBSERVATION", 180, 188]]], ["As such, the location of the enlarged lymph node is a good indication of the likely site of entry of the inciting organism (Figure 1).", [["lymph node", "ANATOMY", 38, 48], ["lymph node", "MULTI-TISSUE_STRUCTURE", 38, 48], ["the enlarged lymph node", "PROBLEM", 25, 48], ["the inciting organism", "PROBLEM", 101, 122], ["enlarged", "OBSERVATION_MODIFIER", 29, 37], ["lymph node", "OBSERVATION", 38, 48], ["good", "OBSERVATION_MODIFIER", 54, 58]]], ["Involvement of superficial or deep cervical lymph nodes is also frequently indicative of the site of entry since superficial nodal enlargement usually reflects invasion through an epithelial surface (eg, buccal mucosa, skin, scalp), whereas deep nodal enlargement results from an infectious process involving more central structures (eg, middle ear, posterior pharynx).Anatomy and physiologyLymph nodes contain T- and B-lymphocytes as well as antigen-presenting macrophages (dendritic cells).", [["superficial", "ANATOMY", 15, 26], ["cervical lymph nodes", "ANATOMY", 35, 55], ["superficial nodal", "ANATOMY", 113, 130], ["epithelial surface", "ANATOMY", 180, 198], ["buccal mucosa", "ANATOMY", 204, 217], ["skin", "ANATOMY", 219, 223], ["scalp", "ANATOMY", 225, 230], ["nodal", "ANATOMY", 246, 251], ["central structures", "ANATOMY", 314, 332], ["middle ear", "ANATOMY", 338, 348], ["posterior pharynx", "ANATOMY", 350, 367], ["physiologyLymph nodes", "ANATOMY", 381, 402], ["T-", "ANATOMY", 411, 413], ["B-lymphocytes", "ANATOMY", 418, 431], ["macrophages", "ANATOMY", 462, 473], ["dendritic cells", "ANATOMY", 475, 490], ["cervical lymph nodes", "MULTI-TISSUE_STRUCTURE", 35, 55], ["superficial nodal", "MULTI-TISSUE_STRUCTURE", 113, 130], ["epithelial surface", "TISSUE", 180, 198], ["buccal mucosa", "MULTI-TISSUE_STRUCTURE", 204, 217], ["skin", "ORGAN", 219, 223], ["scalp", "ORGAN", 225, 230], ["nodal", "MULTI-TISSUE_STRUCTURE", 246, 251], ["central structures", "MULTI-TISSUE_STRUCTURE", 314, 332], ["ear", "ORGAN", 345, 348], ["posterior pharynx", "ORGAN", 350, 367], ["physiologyLymph nodes", "MULTI-TISSUE_STRUCTURE", 381, 402], ["T", "GENE_OR_GENE_PRODUCT", 411, 412], ["B-lymphocytes", "CELL", 418, 431], ["antigen-presenting", "GENE_OR_GENE_PRODUCT", 443, 461], ["macrophages", "CELL", 462, 473], ["dendritic cells", "CELL", 475, 490], ["T- and B-lymphocytes", "CELL_TYPE", 411, 431], ["antigen-presenting macrophages", "CELL_TYPE", 443, 473], ["dendritic cells", "CELL_TYPE", 475, 490], ["superficial or deep cervical lymph nodes", "PROBLEM", 15, 55], ["superficial nodal enlargement", "PROBLEM", 113, 142], ["invasion", "PROBLEM", 160, 168], ["deep nodal enlargement", "PROBLEM", 241, 263], ["an infectious process", "PROBLEM", 277, 298], ["Anatomy and physiologyLymph nodes", "TEST", 369, 402], ["T", "TEST", 411, 412], ["antigen", "TEST", 443, 450], ["superficial", "ANATOMY_MODIFIER", 15, 26], ["deep", "ANATOMY_MODIFIER", 30, 34], ["cervical", "ANATOMY", 35, 43], ["lymph nodes", "OBSERVATION", 44, 55], ["entry", "OBSERVATION_MODIFIER", 101, 106], ["superficial", "ANATOMY_MODIFIER", 113, 124], ["nodal", "ANATOMY", 125, 130], ["enlargement", "OBSERVATION", 131, 142], ["invasion", "OBSERVATION", 160, 168], ["epithelial", "ANATOMY_MODIFIER", 180, 190], ["surface", "OBSERVATION_MODIFIER", 191, 198], ["buccal mucosa", "ANATOMY", 204, 217], ["skin", "ANATOMY", 219, 223], ["scalp", "ANATOMY", 225, 230], ["deep", "ANATOMY_MODIFIER", 241, 245], ["nodal", "ANATOMY", 246, 251], ["enlargement", "OBSERVATION", 252, 263], ["infectious", "OBSERVATION", 280, 290], ["central", "ANATOMY_MODIFIER", 314, 321], ["middle ear", "ANATOMY", 338, 348], ["posterior", "ANATOMY_MODIFIER", 350, 359], ["pharynx", "ANATOMY", 360, 367], ["physiologyLymph nodes", "OBSERVATION", 381, 402], ["lymphocytes", "ANATOMY", 420, 431], ["macrophages", "OBSERVATION", 462, 473], ["dendritic cells", "OBSERVATION", 475, 490]]], ["Tissue lymph enters the lymph node via one or more afferent vessels and percolates through a series of reticuloendothelial-lined channels that coalesce and drain through an efferent lymphatic vessel.", [["Tissue lymph", "ANATOMY", 0, 12], ["lymph node", "ANATOMY", 24, 34], ["afferent vessels", "ANATOMY", 51, 67], ["reticuloendothelial", "ANATOMY", 103, 122], ["efferent lymphatic vessel", "ANATOMY", 173, 198], ["Tissue lymph", "MULTI-TISSUE_STRUCTURE", 0, 12], ["lymph node", "MULTI-TISSUE_STRUCTURE", 24, 34], ["afferent vessels", "MULTI-TISSUE_STRUCTURE", 51, 67], ["reticuloendothelial", "CELL", 103, 122], ["lymphatic vessel", "MULTI-TISSUE_STRUCTURE", 182, 198], ["Tissue lymph", "TEST", 0, 12], ["reticuloendothelial-lined channels", "TREATMENT", 103, 137], ["drain", "TREATMENT", 156, 161], ["lymph", "OBSERVATION", 7, 12], ["lymph node", "OBSERVATION", 24, 34], ["one", "OBSERVATION_MODIFIER", 39, 42], ["more", "OBSERVATION_MODIFIER", 46, 50], ["afferent", "ANATOMY_MODIFIER", 51, 59], ["vessels", "ANATOMY", 60, 67], ["lined channels", "OBSERVATION", 123, 137], ["coalesce", "OBSERVATION_MODIFIER", 143, 151], ["drain", "OBSERVATION", 156, 161], ["efferent", "ANATOMY_MODIFIER", 173, 181], ["lymphatic vessel", "ANATOMY", 182, 198]]], ["Particulate matter is phagocytosed by macrophages lining the lymphatic channels.", [["macrophages", "ANATOMY", 38, 49], ["lymphatic", "ANATOMY", 61, 70], ["macrophages", "CELL", 38, 49], ["lymphatic channels", "MULTI-TISSUE_STRUCTURE", 61, 79], ["macrophages", "CELL_TYPE", 38, 49], ["phagocytosed", "OBSERVATION", 22, 34], ["macrophages", "OBSERVATION", 38, 49], ["lymphatic channels", "OBSERVATION", 61, 79]]], ["Once phagocytized, foreign proteins become bound to major histocompatibility (MHC) antigens and are presented on the surface of macrophages.", [["surface", "ANATOMY", 117, 124], ["macrophages", "ANATOMY", 128, 139], ["surface", "CELLULAR_COMPONENT", 117, 124], ["macrophages", "CELL", 128, 139], ["foreign proteins", "PROTEIN", 19, 35], ["major histocompatibility (MHC) antigens", "PROTEIN", 52, 91], ["macrophages", "CELL_TYPE", 128, 139], ["phagocytized", "PROBLEM", 5, 17], ["foreign proteins", "PROBLEM", 19, 35], ["foreign proteins", "OBSERVATION", 19, 35], ["macrophages", "OBSERVATION", 128, 139]]], ["Foreign proteins bound to MHC class II molecules on the surface of dendritic cells, in combination with other cell surface receptors and secreted cellular signals (interleukins), are required for activation of T-helper lymphocytes.", [["surface", "ANATOMY", 56, 63], ["dendritic cells", "ANATOMY", 67, 82], ["cell surface", "ANATOMY", 110, 122], ["cellular", "ANATOMY", 146, 154], ["T-helper lymphocytes", "ANATOMY", 210, 230], ["MHC class II", "GENE_OR_GENE_PRODUCT", 26, 38], ["surface", "CELLULAR_COMPONENT", 56, 63], ["dendritic cells", "CELL", 67, 82], ["cell", "CELL", 110, 114], ["cellular", "CELL", 146, 154], ["interleukins", "GENE_OR_GENE_PRODUCT", 164, 176], ["T-helper lymphocytes", "CELL", 210, 230], ["Foreign proteins", "PROTEIN", 0, 16], ["MHC class II molecules", "PROTEIN", 26, 48], ["dendritic cells", "CELL_TYPE", 67, 82], ["cell surface receptors", "PROTEIN", 110, 132], ["interleukins", "PROTEIN", 164, 176], ["T-helper lymphocytes", "CELL_TYPE", 210, 230], ["Foreign proteins bound", "PROBLEM", 0, 22], ["dendritic cells", "PROBLEM", 67, 82], ["other cell surface receptors", "PROBLEM", 104, 132], ["secreted cellular signals (interleukins)", "PROBLEM", 137, 177], ["surface", "OBSERVATION_MODIFIER", 56, 63], ["dendritic cells", "OBSERVATION", 67, 82], ["cell", "OBSERVATION", 110, 114], ["surface receptors", "OBSERVATION", 115, 132], ["secreted", "OBSERVATION_MODIFIER", 137, 145], ["cellular signals", "OBSERVATION", 146, 162]]], ["These lymphocytes can in turn activate na\u00efve B-lymphocytes.", [["lymphocytes", "ANATOMY", 6, 17], ["B-lymphocytes", "ANATOMY", 45, 58], ["lymphocytes", "CELL", 6, 17], ["B-lymphocytes", "CELL", 45, 58], ["lymphocytes", "CELL_TYPE", 6, 17], ["na\u00efve B-lymphocytes", "CELL_TYPE", 39, 58], ["These lymphocytes", "TEST", 0, 17], ["lymphocytes", "OBSERVATION", 6, 17], ["lymphocytes", "ANATOMY", 47, 58]]], ["Alternatively, memory B-lymphocytes may be directly activated by dendritic cells.", [["memory B-lymphocytes", "ANATOMY", 15, 35], ["dendritic cells", "ANATOMY", 65, 80], ["memory B-lymphocytes", "CELL", 15, 35], ["dendritic cells", "CELL", 65, 80], ["memory B-lymphocytes", "CELL_TYPE", 15, 35], ["dendritic cells", "CELL_TYPE", 65, 80], ["memory B-lymphocytes", "PROBLEM", 15, 35], ["dendritic cells", "PROBLEM", 65, 80], ["dendritic cells", "OBSERVATION", 65, 80]]], ["Once activated, B- and T-lymphocytes proliferate to create a pool of lymphocytes that have the ability to recognize and bind the inciting foreign protein.", [["B-", "ANATOMY", 16, 18], ["T-lymphocytes", "ANATOMY", 23, 36], ["lymphocytes", "ANATOMY", 69, 80], ["B", "CELL", 16, 17], ["T-lymphocytes", "CELL", 23, 36], ["lymphocytes", "CELL", 69, 80], ["B- and T-lymphocytes", "CELL_TYPE", 16, 36], ["lymphocytes", "CELL_TYPE", 69, 80], ["foreign protein", "PROTEIN", 138, 153], ["B- and T-lymphocytes proliferate", "TEST", 16, 48], ["a pool of lymphocytes", "PROBLEM", 59, 80], ["the inciting foreign protein", "PROBLEM", 125, 153], ["foreign protein", "OBSERVATION", 138, 153]]], ["In addition, activated T-lymphocytes and macrophages release cellular signals (cytokines) that induce leukocyte chemotaxis and increase vascular permeability.Anatomy and physiologyThe symptoms associated with acute cervical lymphadenitis reflect these pathophysiologic events.", [["T-lymphocytes", "ANATOMY", 23, 36], ["macrophages", "ANATOMY", 41, 52], ["cellular", "ANATOMY", 61, 69], ["leukocyte", "ANATOMY", 102, 111], ["vascular", "ANATOMY", 136, 144], ["cervical lymphadenitis", "ANATOMY", 215, 237], ["lymphadenitis", "DISEASE", 224, 237], ["T-lymphocytes", "CELL", 23, 36], ["macrophages", "CELL", 41, 52], ["cellular", "CELL", 61, 69], ["leukocyte", "CELL", 102, 111], ["vascular", "MULTI-TISSUE_STRUCTURE", 136, 144], ["activated T-lymphocytes", "CELL_TYPE", 13, 36], ["macrophages", "CELL_TYPE", 41, 52], ["cytokines", "PROTEIN", 79, 88], ["activated T-lymphocytes", "TEST", 13, 36], ["cellular signals", "TEST", 61, 77], ["leukocyte chemotaxis", "PROBLEM", 102, 122], ["increase vascular permeability", "PROBLEM", 127, 157], ["The symptoms", "PROBLEM", 180, 192], ["acute cervical lymphadenitis", "PROBLEM", 209, 237], ["these pathophysiologic events", "PROBLEM", 246, 275], ["leukocyte chemotaxis", "OBSERVATION", 102, 122], ["increase", "OBSERVATION_MODIFIER", 127, 135], ["vascular permeability", "OBSERVATION", 136, 157], ["acute", "OBSERVATION_MODIFIER", 209, 214], ["cervical", "ANATOMY", 215, 223], ["lymphadenitis", "OBSERVATION", 224, 237]]], ["Nodal enlargement occurs as a result of cellular hyperplasia, leukocyte infiltration, and tissue edema.", [["cellular", "ANATOMY", 40, 48], ["leukocyte", "ANATOMY", 62, 71], ["tissue", "ANATOMY", 90, 96], ["Nodal enlargement", "DISEASE", 0, 17], ["hyperplasia", "DISEASE", 49, 60], ["tissue edema", "DISEASE", 90, 102], ["cellular", "CELL", 40, 48], ["leukocyte", "CELL", 62, 71], ["tissue", "TISSUE", 90, 96], ["Nodal enlargement", "PROBLEM", 0, 17], ["cellular hyperplasia", "PROBLEM", 40, 60], ["leukocyte infiltration", "PROBLEM", 62, 84], ["tissue edema", "PROBLEM", 90, 102], ["enlargement", "OBSERVATION", 6, 17], ["cellular", "OBSERVATION_MODIFIER", 40, 48], ["hyperplasia", "OBSERVATION", 49, 60], ["leukocyte infiltration", "OBSERVATION", 62, 84], ["tissue", "OBSERVATION_MODIFIER", 90, 96], ["edema", "OBSERVATION", 97, 102]]], ["Vasodilation and capillary leak in response to locally released cytokines causes erythema and edema of the overlying skin, and tenderness results from distention of the nodal capsule.History and physical examination ::: EvaluationA thorough history and complete physical examination often suggests the probable cause of cervical lymphadenitis.", [["capillary", "ANATOMY", 17, 26], ["skin", "ANATOMY", 117, 121], ["nodal capsule", "ANATOMY", 169, 182], ["cervical lymphadenitis", "ANATOMY", 320, 342], ["Vasodilation", "DISEASE", 0, 12], ["erythema", "DISEASE", 81, 89], ["edema", "DISEASE", 94, 99], ["tenderness", "DISEASE", 127, 137], ["lymphadenitis", "DISEASE", 329, 342], ["capillary", "TISSUE", 17, 26], ["erythema", "PATHOLOGICAL_FORMATION", 81, 89], ["edema", "PATHOLOGICAL_FORMATION", 94, 99], ["skin", "ORGAN", 117, 121], ["nodal capsule", "CANCER", 169, 182], ["cervical lymphadenitis", "PATHOLOGICAL_FORMATION", 320, 342], ["cytokines", "PROTEIN", 64, 73], ["Vasodilation", "PROBLEM", 0, 12], ["capillary leak", "PROBLEM", 17, 31], ["locally released cytokines", "PROBLEM", 47, 73], ["erythema", "PROBLEM", 81, 89], ["edema of the overlying skin", "PROBLEM", 94, 121], ["tenderness", "PROBLEM", 127, 137], ["distention of the nodal capsule", "PROBLEM", 151, 182], ["physical examination", "TEST", 195, 215], ["complete physical examination", "TEST", 253, 282], ["cervical lymphadenitis", "PROBLEM", 320, 342], ["capillary leak", "OBSERVATION", 17, 31], ["cytokines", "OBSERVATION", 64, 73], ["erythema", "OBSERVATION", 81, 89], ["edema", "OBSERVATION", 94, 99], ["overlying", "ANATOMY_MODIFIER", 107, 116], ["skin", "ANATOMY", 117, 121], ["tenderness", "OBSERVATION", 127, 137], ["distention", "OBSERVATION", 151, 161], ["nodal", "ANATOMY", 169, 174], ["capsule", "ANATOMY_MODIFIER", 175, 182], ["probable cause of", "UNCERTAINTY", 302, 319], ["cervical", "ANATOMY", 320, 328], ["lymphadenitis", "OBSERVATION", 329, 342]]], ["Consideration of whether symptoms and presentation are acute, subacute, or chronic is often helpful in establishing a differential diagnosis.", [["symptoms", "PROBLEM", 25, 33], ["acute", "PROBLEM", 55, 60], ["acute", "OBSERVATION_MODIFIER", 55, 60], ["subacute", "OBSERVATION_MODIFIER", 62, 70], ["chronic", "OBSERVATION_MODIFIER", 75, 82]]], ["Clearly, the definitions of these categories are arbitrary, and many infectious processes are associated with symptom duration that fits into more than one category.", [["many infectious processes", "PROBLEM", 64, 89], ["symptom duration", "PROBLEM", 110, 126], ["many", "OBSERVATION_MODIFIER", 64, 68], ["infectious", "OBSERVATION", 69, 79]]], ["In general, however, acute lymphadenitis, which can be 2 weeks in duration, is due to either a viral or bacterial invasion.", [["lymphadenitis", "DISEASE", 27, 40], ["acute lymphadenitis", "PROBLEM", 21, 40], ["a viral or bacterial invasion", "PROBLEM", 93, 122], ["acute", "OBSERVATION_MODIFIER", 21, 26], ["lymphadenitis", "OBSERVATION", 27, 40], ["viral", "OBSERVATION", 95, 100], ["bacterial", "OBSERVATION_MODIFIER", 104, 113], ["invasion", "OBSERVATION", 114, 122]]], ["Chronic lymphadenopathy is more likely to be due to a neoplastic process or invasion by an opportunistic organism.", [["neoplastic", "ANATOMY", 54, 64], ["lymphadenopathy", "DISEASE", 8, 23], ["Chronic lymphadenopathy", "PROBLEM", 0, 23], ["a neoplastic process", "PROBLEM", 52, 72], ["invasion", "PROBLEM", 76, 84], ["an opportunistic organism", "PROBLEM", 88, 113], ["lymphadenopathy", "OBSERVATION", 8, 23], ["more likely to be due to", "UNCERTAINTY", 27, 51], ["neoplastic", "OBSERVATION", 54, 64], ["invasion", "OBSERVATION", 76, 84], ["opportunistic organism", "OBSERVATION", 91, 113]]], ["Subacute lymphadenitis, which is 2 and 6 weeks in duration, encompasses a much broader group of potential etiologies.", [["lymphadenitis", "DISEASE", 9, 22], ["Subacute lymphadenitis", "PROBLEM", 0, 22], ["lymphadenitis", "OBSERVATION", 9, 22]]], ["In practice, surgeons seldom are involved in the care of patients with acute lymphadenitis unless the lymph nodes become suppurative.", [["lymph nodes", "ANATOMY", 102, 113], ["lymphadenitis", "DISEASE", 77, 90], ["patients", "ORGANISM", 57, 65], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 102, 113], ["patients", "SPECIES", 57, 65], ["acute lymphadenitis", "PROBLEM", 71, 90], ["the lymph nodes", "PROBLEM", 98, 113], ["suppurative", "PROBLEM", 121, 132], ["acute", "OBSERVATION_MODIFIER", 71, 76], ["lymphadenitis", "OBSERVATION", 77, 90], ["lymph nodes", "OBSERVATION", 102, 113], ["suppurative", "OBSERVATION_MODIFIER", 121, 132]]], ["Most of these patients improve during a course of antibiotic therapy prescribed by their primary care physician.History and physical examination ::: EvaluationOther important clinical information to obtain are the location (single or multiple sites) and progress of neck swelling (increasing, stable, or decreasing) and the presence of systemic symptoms (eg, fever, malaise, anorexia, weight loss, or arthralgias).", [["neck", "ANATOMY", 266, 270], ["neck swelling", "DISEASE", 266, 279], ["fever", "DISEASE", 359, 364], ["anorexia", "DISEASE", 375, 383], ["weight loss", "DISEASE", 385, 396], ["arthralgias", "DISEASE", 401, 412], ["patients", "ORGANISM", 14, 22], ["neck", "ORGANISM_SUBDIVISION", 266, 270], ["patients", "SPECIES", 14, 22], ["antibiotic therapy", "TREATMENT", 50, 68], ["physical examination", "TEST", 124, 144], ["neck swelling", "PROBLEM", 266, 279], ["systemic symptoms (eg", "PROBLEM", 336, 357], ["fever", "PROBLEM", 359, 364], ["malaise", "PROBLEM", 366, 373], ["anorexia", "PROBLEM", 375, 383], ["weight loss", "PROBLEM", 385, 396], ["arthralgias", "PROBLEM", 401, 412], ["neck", "ANATOMY", 266, 270], ["swelling", "OBSERVATION", 271, 279], ["increasing", "OBSERVATION_MODIFIER", 281, 291], ["stable", "OBSERVATION_MODIFIER", 293, 299]]], ["More specific symptoms include skin changes and pain in the region of the nodal swelling, as well as at more distant sites.", [["skin", "ANATOMY", 31, 35], ["nodal", "ANATOMY", 74, 79], ["pain", "DISEASE", 48, 52], ["swelling", "DISEASE", 80, 88], ["skin", "ORGAN", 31, 35], ["nodal", "MULTI-TISSUE_STRUCTURE", 74, 79], ["More specific symptoms", "PROBLEM", 0, 22], ["skin changes", "PROBLEM", 31, 43], ["pain", "PROBLEM", 48, 52], ["the nodal swelling", "PROBLEM", 70, 88], ["skin", "ANATOMY", 31, 35], ["changes", "OBSERVATION", 36, 43], ["pain", "OBSERVATION", 48, 52], ["nodal", "ANATOMY", 74, 79], ["swelling", "OBSERVATION", 80, 88]]], ["A history of recent upper respiratory tract symptoms, sore throat, ear pain, toothache, insect bites, superficial lacerations or rashes, and exposure to animals may suggest possible etiologies.", [["upper respiratory tract", "ANATOMY", 20, 43], ["ear", "ANATOMY", 67, 70], ["upper respiratory tract symptoms", "DISEASE", 20, 52], ["sore throat", "DISEASE", 54, 65], ["ear pain", "DISEASE", 67, 75], ["toothache", "DISEASE", 77, 86], ["insect bites", "DISEASE", 88, 100], ["lacerations", "DISEASE", 114, 125], ["rashes", "DISEASE", 129, 135], ["upper", "ORGANISM_SUBDIVISION", 20, 25], ["respiratory tract", "ORGANISM_SUBDIVISION", 26, 43], ["throat", "ORGANISM_SUBDIVISION", 59, 65], ["ear", "ORGAN", 67, 70], ["superficial lacerations", "PATHOLOGICAL_FORMATION", 102, 125], ["recent upper respiratory tract symptoms", "PROBLEM", 13, 52], ["sore throat", "PROBLEM", 54, 65], ["ear pain", "PROBLEM", 67, 75], ["toothache", "PROBLEM", 77, 86], ["insect bites", "PROBLEM", 88, 100], ["superficial lacerations", "PROBLEM", 102, 125], ["rashes", "PROBLEM", 129, 135], ["upper", "ANATOMY_MODIFIER", 20, 25], ["respiratory tract", "ANATOMY", 26, 43], ["ear", "ANATOMY", 67, 70], ["pain", "OBSERVATION", 71, 75], ["superficial", "OBSERVATION_MODIFIER", 102, 113], ["lacerations", "OBSERVATION", 114, 125], ["rashes", "OBSERVATION", 129, 135], ["may suggest possible", "UNCERTAINTY", 161, 181]]], ["In addition, a history of recent travel, exposure to individuals that are ill, and immunization status should be sought.", [["immunization status", "TREATMENT", 83, 102]]], ["Finally, patient age is another important consideration, since lymphadenopathy in young children is overwhelmingly due to infectious etiologies, whereas adenopathy due to neoplasia increases in the adolescent age group.History and physical examination ::: EvaluationFindings on physical examination may also suggest an etiology.", [["neoplasia", "ANATOMY", 171, 180], ["lymphadenopathy", "DISEASE", 63, 78], ["adenopathy", "DISEASE", 153, 163], ["neoplasia", "DISEASE", 171, 180], ["patient", "ORGANISM", 9, 16], ["children", "ORGANISM", 88, 96], ["neoplasia", "CANCER", 171, 180], ["patient", "SPECIES", 9, 16], ["children", "SPECIES", 88, 96], ["lymphadenopathy", "PROBLEM", 63, 78], ["infectious etiologies", "PROBLEM", 122, 143], ["adenopathy", "PROBLEM", 153, 163], ["neoplasia", "PROBLEM", 171, 180], ["physical examination", "TEST", 231, 251], ["physical examination", "TEST", 278, 298], ["lymphadenopathy", "OBSERVATION", 63, 78], ["overwhelmingly due to", "UNCERTAINTY", 100, 121], ["infectious", "OBSERVATION_MODIFIER", 122, 132], ["adenopathy", "OBSERVATION", 153, 163], ["neoplasia", "OBSERVATION", 171, 180], ["may also suggest", "UNCERTAINTY", 299, 315]]], ["Cervical lymph nodes are frequently palpable in children; however, lymph nodes larger than 10 mm in diameter are considered abnormal.", [["Cervical lymph nodes", "ANATOMY", 0, 20], ["lymph nodes", "ANATOMY", 67, 78], ["Cervical lymph nodes", "MULTI-TISSUE_STRUCTURE", 0, 20], ["children", "ORGANISM", 48, 56], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 67, 78], ["children", "SPECIES", 48, 56], ["Cervical lymph nodes", "PROBLEM", 0, 20], ["lymph nodes", "PROBLEM", 67, 78], ["lymph nodes", "OBSERVATION", 9, 20], ["lymph nodes", "OBSERVATION", 67, 78], ["larger", "OBSERVATION_MODIFIER", 79, 85], ["than 10 mm", "OBSERVATION_MODIFIER", 86, 96], ["abnormal", "OBSERVATION_MODIFIER", 124, 132]]], ["As noted previously, the location of involved nodes may indicate a potential site of entry and should prompt a detailed examination of that site.", [["nodes", "ANATOMY", 46, 51], ["nodes", "MULTI-TISSUE_STRUCTURE", 46, 51], ["involved nodes", "PROBLEM", 37, 51], ["a detailed examination", "TEST", 109, 131], ["nodes", "OBSERVATION", 46, 51]]], ["Erythema, tenderness, and fluctuance suggest an acute process, most likely attributable to a bacterial invasion.", [["Erythema", "DISEASE", 0, 8], ["tenderness", "DISEASE", 10, 20], ["Erythema", "PROBLEM", 0, 8], ["tenderness", "PROBLEM", 10, 20], ["fluctuance", "PROBLEM", 26, 36], ["an acute process", "PROBLEM", 45, 61], ["a bacterial invasion", "PROBLEM", 91, 111], ["tenderness", "OBSERVATION", 10, 20], ["acute", "OBSERVATION_MODIFIER", 48, 53], ["process", "OBSERVATION", 54, 61], ["most likely attributable to", "UNCERTAINTY", 63, 90], ["bacterial", "OBSERVATION_MODIFIER", 93, 102], ["invasion", "OBSERVATION", 103, 111]]], ["Involvement of bilateral cervical lymph nodes suggests a viral origin.", [["cervical lymph nodes", "ANATOMY", 25, 45], ["cervical lymph nodes", "MULTI-TISSUE_STRUCTURE", 25, 45], ["bilateral cervical lymph nodes", "PROBLEM", 15, 45], ["bilateral", "ANATOMY_MODIFIER", 15, 24], ["cervical", "ANATOMY", 25, 33], ["lymph nodes", "OBSERVATION", 34, 45], ["viral origin", "OBSERVATION", 57, 69]]], ["The characteristics of the nodes are also important.", [["nodes", "ANATOMY", 27, 32], ["nodes", "MULTI-TISSUE_STRUCTURE", 27, 32], ["the nodes", "PROBLEM", 23, 32], ["nodes", "OBSERVATION", 27, 32]]], ["Nodes involved in neoplastic processes frequently are firm and fixed, whereas those due to infectious agents tend to be softer in consistency and often slightly mobile.", [["neoplastic", "ANATOMY", 18, 28], ["neoplastic processes", "PROBLEM", 18, 38], ["firm", "PROBLEM", 54, 58], ["infectious agents", "TREATMENT", 91, 108], ["neoplastic", "OBSERVATION_MODIFIER", 18, 28], ["firm", "OBSERVATION_MODIFIER", 54, 58], ["slightly", "OBSERVATION_MODIFIER", 152, 160], ["mobile", "OBSERVATION", 161, 167]]], ["Other physical abnormalities, including respiratory findings, skin lesions, hepatosplenomegaly, and adenopathy in other parts of the body may also suggest an etiology.History and physical examination ::: EvaluationFinally, it is important to keep in mind that not all swellings in the neck represent enlarged lymph nodes and that congenital and acquired cysts and soft tissue lesions also present as neck masses.", [["respiratory", "ANATOMY", 40, 51], ["skin lesions", "ANATOMY", 62, 74], ["body", "ANATOMY", 133, 137], ["neck", "ANATOMY", 285, 289], ["lymph nodes", "ANATOMY", 309, 320], ["cysts", "ANATOMY", 354, 359], ["soft tissue lesions", "ANATOMY", 364, 383], ["neck masses", "ANATOMY", 400, 411], ["skin lesions", "DISEASE", 62, 74], ["hepatosplenomegaly", "DISEASE", 76, 94], ["adenopathy", "DISEASE", 100, 110], ["congenital and acquired cysts", "DISEASE", 330, 359], ["skin lesions", "PATHOLOGICAL_FORMATION", 62, 74], ["body", "ORGANISM_SUBDIVISION", 133, 137], ["neck", "ORGAN", 285, 289], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 309, 320], ["cysts", "CANCER", 354, 359], ["soft tissue lesions", "CANCER", 364, 383], ["neck masses", "CANCER", 400, 411], ["Other physical abnormalities", "PROBLEM", 0, 28], ["respiratory findings", "PROBLEM", 40, 60], ["skin lesions", "PROBLEM", 62, 74], ["hepatosplenomegaly", "PROBLEM", 76, 94], ["adenopathy in other parts of the body", "PROBLEM", 100, 137], ["physical examination", "TEST", 179, 199], ["all swellings in the neck", "PROBLEM", 264, 289], ["enlarged lymph nodes", "PROBLEM", 300, 320], ["congenital and acquired cysts", "PROBLEM", 330, 359], ["soft tissue lesions", "PROBLEM", 364, 383], ["neck masses", "PROBLEM", 400, 411], ["abnormalities", "OBSERVATION", 15, 28], ["respiratory", "ANATOMY", 40, 51], ["skin", "ANATOMY", 62, 66], ["lesions", "OBSERVATION", 67, 74], ["hepatosplenomegaly", "OBSERVATION", 76, 94], ["adenopathy", "OBSERVATION", 100, 110], ["body", "ANATOMY", 133, 137], ["may also suggest", "UNCERTAINTY", 138, 154], ["etiology", "OBSERVATION", 158, 166], ["swellings", "OBSERVATION", 268, 277], ["neck", "ANATOMY", 285, 289], ["enlarged", "OBSERVATION_MODIFIER", 300, 308], ["lymph nodes", "OBSERVATION", 309, 320], ["congenital", "OBSERVATION_MODIFIER", 330, 340], ["acquired", "OBSERVATION_MODIFIER", 345, 353], ["cysts", "OBSERVATION", 354, 359], ["soft tissue", "OBSERVATION_MODIFIER", 364, 375], ["lesions", "OBSERVATION", 376, 383], ["neck", "ANATOMY", 400, 404], ["masses", "OBSERVATION", 405, 411]]], ["Often the nonnodal nature of these masses is suggested by the history or by the findings on physical examination.", [["masses", "ANATOMY", 35, 41], ["masses", "CANCER", 35, 41], ["these masses", "PROBLEM", 29, 41], ["physical examination", "TEST", 92, 112], ["masses", "OBSERVATION", 35, 41]]], ["In equivocal cases, however, diagnostic imaging almost always reveals whether a particular swelling is due to nodal enlargement or to a cyst or soft tissue mass.Laboratory evaluation ::: EvaluationLaboratory tests are seldom required as part of the workup for acute cervical lymphadenitis.", [["nodal", "ANATOMY", 110, 115], ["cyst", "ANATOMY", 136, 140], ["soft tissue mass", "ANATOMY", 144, 160], ["cervical", "ANATOMY", 266, 274], ["swelling", "DISEASE", 91, 99], ["cyst", "DISEASE", 136, 140], ["lymphadenitis", "DISEASE", 275, 288], ["nodal", "MULTI-TISSUE_STRUCTURE", 110, 115], ["cyst", "CANCER", 136, 140], ["soft tissue", "TISSUE", 144, 155], ["cervical lymphadenitis", "CANCER", 266, 288], ["diagnostic imaging", "TEST", 29, 47], ["a particular swelling", "PROBLEM", 78, 99], ["nodal enlargement", "PROBLEM", 110, 127], ["a cyst", "PROBLEM", 134, 140], ["soft tissue mass", "PROBLEM", 144, 160], ["Laboratory evaluation", "TEST", 161, 182], ["EvaluationLaboratory tests", "TEST", 187, 213], ["the workup", "TEST", 245, 255], ["acute cervical lymphadenitis", "PROBLEM", 260, 288], ["particular", "OBSERVATION_MODIFIER", 80, 90], ["swelling", "OBSERVATION", 91, 99], ["nodal", "ANATOMY", 110, 115], ["enlargement", "OBSERVATION", 116, 127], ["cyst", "OBSERVATION", 136, 140], ["soft tissue", "OBSERVATION_MODIFIER", 144, 155], ["mass", "OBSERVATION", 156, 160], ["acute", "OBSERVATION_MODIFIER", 260, 265], ["cervical", "ANATOMY", 266, 274], ["lymphadenitis", "OBSERVATION", 275, 288]]], ["Leukocyte counts and markers of inflammation (C-reactive protein and erythrocyte sedimentation rate) are usually abnormal but nonspecific.", [["Leukocyte", "ANATOMY", 0, 9], ["erythrocyte", "ANATOMY", 69, 80], ["inflammation", "DISEASE", 32, 44], ["Leukocyte", "CELL", 0, 9], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 46, 64], ["erythrocyte", "CELL", 69, 80], ["C-reactive protein", "PROTEIN", 46, 64], ["Leukocyte counts", "TEST", 0, 16], ["markers", "TEST", 21, 28], ["inflammation", "PROBLEM", 32, 44], ["C-reactive protein", "TEST", 46, 64], ["erythrocyte sedimentation rate", "TEST", 69, 99], ["inflammation", "OBSERVATION", 32, 44], ["nonspecific", "OBSERVATION_MODIFIER", 126, 137]]], ["Although a left shift (ie, increased percentage of immature white cells) on the leukocyte differential count suggests a bacterial etiology, this etiology frequently is suggested by the clinical presentation alone.", [["white cells", "ANATOMY", 60, 71], ["leukocyte", "ANATOMY", 80, 89], ["cells", "CELL", 66, 71], ["leukocyte", "CELL", 80, 89], ["immature white cells", "CELL_TYPE", 51, 71], ["a left shift", "PROBLEM", 9, 21], ["immature white cells", "PROBLEM", 51, 71], ["the leukocyte differential count", "TEST", 76, 108], ["left", "ANATOMY_MODIFIER", 11, 15], ["shift", "OBSERVATION", 16, 21], ["increased", "OBSERVATION_MODIFIER", 27, 36], ["percentage", "OBSERVATION_MODIFIER", 37, 47], ["immature", "OBSERVATION_MODIFIER", 51, 59], ["white cells", "OBSERVATION", 60, 71], ["bacterial etiology", "OBSERVATION", 120, 138]]], ["Any material that has been aspirated due to fluctuance should be sent for culture and sensitivity.", [["Any material", "PROBLEM", 0, 12], ["fluctuance", "PROBLEM", 44, 54], ["culture", "TEST", 74, 81], ["sensitivity", "TEST", 86, 97]]], ["These cultures may show an organism that is resistant to prior antibiotic therapy, but occasionally they are negative due to eradication of the infectious agent by a prior course of antibiotics.", [["cultures", "ANATOMY", 6, 14], ["These cultures", "TEST", 0, 14], ["an organism", "PROBLEM", 24, 35], ["prior antibiotic therapy", "TREATMENT", 57, 81], ["antibiotics", "TREATMENT", 182, 193], ["organism", "OBSERVATION", 27, 35], ["infectious", "OBSERVATION", 144, 154]]], ["Blood cultures should be obtained in any patient that appears toxic.", [["Blood cultures", "ANATOMY", 0, 14], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["patient", "ORGANISM", 41, 48], ["patient", "SPECIES", 41, 48], ["Blood cultures", "TEST", 0, 14], ["toxic", "PROBLEM", 62, 67], ["toxic", "OBSERVATION_MODIFIER", 62, 67]]], ["Cultures of other sites that appear to be the primary site of the infection (eg, pharynx) should also be obtained, although results from pharyngeal cultures may not correlate with organisms isolated from a nodal abscess.1", [["sites", "ANATOMY", 18, 23], ["pharynx", "ANATOMY", 81, 88], ["pharyngeal cultures", "ANATOMY", 137, 156], ["nodal abscess", "ANATOMY", 206, 219], ["infection", "DISEASE", 66, 75], ["abscess", "DISEASE", 212, 219], ["pharynx", "ORGAN", 81, 88], ["pharyngeal cultures", "CELL", 137, 156], ["nodal abscess", "PATHOLOGICAL_FORMATION", 206, 219], ["Cultures", "TEST", 0, 8], ["other sites", "PROBLEM", 12, 23], ["the infection (eg, pharynx", "PROBLEM", 62, 88], ["pharyngeal cultures", "TEST", 137, 156], ["organisms", "PROBLEM", 180, 189], ["a nodal abscess", "PROBLEM", 204, 219], ["infection", "OBSERVATION", 66, 75], ["pharynx", "ANATOMY", 81, 88], ["pharyngeal", "ANATOMY", 137, 147], ["nodal", "ANATOMY", 206, 211], ["abscess", "OBSERVATION", 212, 219]]]], "0fc61c82acd36e645f5d34ea011fde41c5a7a544": [["IntroductionThe epidemic of the newly described severe acute respiratory syndrome (SARS) in 2003 confronted the world with a life-threatening disease for which no definitive treatment protocol existed.", [["acute respiratory syndrome", "DISEASE", 55, 81], ["SARS", "DISEASE", 83, 87], ["severe acute respiratory syndrome", "PROBLEM", 48, 81], ["a life-threatening disease", "PROBLEM", 123, 149], ["definitive treatment protocol", "TREATMENT", 163, 192], ["severe", "OBSERVATION_MODIFIER", 48, 54], ["acute", "OBSERVATION_MODIFIER", 55, 60], ["respiratory syndrome", "OBSERVATION", 61, 81]]], ["When such unexpected diseases become a serious threat to public health, immediate action has to be taken, and there is no time for specific drug design and safety testing.", [["safety testing", "TEST", 156, 170]]], ["Therefore, antiviral drugs already licensed for other viral diseases and known to be safe to humans have to be taken into consideration as part of the immediate response.", [["viral diseases", "DISEASE", 54, 68], ["humans", "ORGANISM", 93, 99], ["humans", "SPECIES", 93, 99], ["humans", "SPECIES", 93, 99], ["antiviral drugs", "TREATMENT", 11, 26], ["other viral diseases", "PROBLEM", 48, 68]]], ["In this regard, the example of SARS is revealing: apart from palliative treatments such as corticosteroids, the most promising anti-SARS coronavirus (SARS-CoV) molecules to date are \"recycled\" drugs known to be effective against other viral diseases.", [["SARS", "DISEASE", 31, 35], ["viral diseases", "DISEASE", 235, 249], ["corticosteroids", "CHEMICAL", 91, 106], ["anti-SARS coronavirus", "ORGANISM", 127, 148], ["SARS-CoV", "ORGANISM", 150, 158], ["anti-SARS coronavirus (SARS-CoV) molecules", "PROTEIN", 127, 169], ["anti-SARS coronavirus", "SPECIES", 127, 148], ["SARS-CoV", "SPECIES", 150, 158], ["SARS", "PROBLEM", 31, 35], ["palliative treatments", "TREATMENT", 61, 82], ["corticosteroids", "TREATMENT", 91, 106], ["the most promising anti-SARS coronavirus", "PROBLEM", 108, 148], ["drugs", "TREATMENT", 193, 198], ["other viral diseases", "PROBLEM", 229, 249]]], ["These include interferons, ribavirin, chloroquine and HIV-1 protease inhibitors (PIs).", [["ribavirin", "CHEMICAL", 27, 36], ["chloroquine", "CHEMICAL", 38, 49], ["ribavirin", "CHEMICAL", 27, 36], ["chloroquine", "CHEMICAL", 38, 49], ["interferons", "GENE_OR_GENE_PRODUCT", 14, 25], ["ribavirin", "SIMPLE_CHEMICAL", 27, 36], ["chloroquine", "SIMPLE_CHEMICAL", 38, 49], ["HIV-1", "ORGANISM", 54, 59], ["protease inhibitors", "SIMPLE_CHEMICAL", 60, 79], ["interferons", "PROTEIN", 14, 25], ["HIV-1", "SPECIES", 54, 59], ["HIV-1", "SPECIES", 54, 59], ["interferons", "TREATMENT", 14, 25], ["ribavirin", "TREATMENT", 27, 36], ["chloroquine", "TREATMENT", 38, 49], ["HIV-1 protease inhibitors", "TREATMENT", 54, 79]]], ["The first are broad spectrum * Tel.: +39 06 30155374; mobile: +39 347 1359586; fax: +39 06 3054519.IntroductionE-mail address: asavarino@medscape.com. antiviral drugs inducing the degradation of viral RNAs.", [["+39 06 30155374", "CHEMICAL", 37, 52], ["+39 347 1359586", "CHEMICAL", 62, 77], ["viral RNAs", "RNA", 195, 205], ["antiviral drugs", "TREATMENT", 151, 166], ["viral RNAs", "PROBLEM", 195, 205], ["viral RNAs", "OBSERVATION", 195, 205]]], ["Ribavirin, often used in combination with interferons (Stroher et al., 2004) , exerts its antiviral activity directly through lethal mutagenesis of the viral genetic material (Crotty et al., 2001) and has been reported in some, but not all studies to inhibit SARS-CoV replication Chu et al., 2004; Stroher et al., 2004) .", [["Ribavirin", "CHEMICAL", 0, 9], ["Ribavirin", "CHEMICAL", 0, 9], ["Ribavirin", "SIMPLE_CHEMICAL", 0, 9], ["interferons", "PROTEIN", 42, 53], ["SARS-CoV", "SPECIES", 259, 267], ["Ribavirin", "TREATMENT", 0, 9], ["interferons", "TREATMENT", 42, 53], ["antiviral activity", "OBSERVATION", 90, 108]]], ["Chloroquine was a first choice antimalarial before the malaria parasite Plasmodium falciparum developed widespread resistance.", [["Chloroquine", "CHEMICAL", 0, 11], ["malaria", "DISEASE", 55, 62], ["Plasmodium falciparum", "DISEASE", 72, 93], ["Chloroquine", "CHEMICAL", 0, 11], ["Chloroquine", "SIMPLE_CHEMICAL", 0, 11], ["Plasmodium falciparum", "ORGANISM", 72, 93], ["Plasmodium falciparum", "SPECIES", 72, 93], ["Plasmodium falciparum", "SPECIES", 72, 93], ["Chloroquine", "TREATMENT", 0, 11], ["a first choice antimalarial", "TREATMENT", 16, 43], ["the malaria parasite Plasmodium falciparum", "PROBLEM", 51, 93], ["widespread", "OBSERVATION_MODIFIER", 104, 114], ["resistance", "OBSERVATION_MODIFIER", 115, 125]]], ["Later on, this drug found an application in rheumatic diseases and was shown to exert some anti-HIV-1 effects, likely to be due to inhibition of glycosylation of the viral envelope glycoproteins (a review on the anti-HIV-1 effects of chloroquine was published on the February 2001 issue of this journal) (Savarino et al., 2001 (Savarino et al., , 2004a .", [["rheumatic diseases", "DISEASE", 44, 62], ["chloroquine", "CHEMICAL", 234, 245], ["chloroquine", "CHEMICAL", 234, 245], ["anti-HIV-1", "GENE_OR_GENE_PRODUCT", 91, 101], ["chloroquine", "SIMPLE_CHEMICAL", 234, 245], ["viral envelope glycoproteins", "PROTEIN", 166, 194], ["rheumatic diseases", "PROBLEM", 44, 62], ["glycosylation", "TREATMENT", 145, 158], ["the viral envelope glycoproteins", "PROBLEM", 162, 194], ["the anti-HIV", "TREATMENT", 208, 220], ["chloroquine", "TREATMENT", 234, 245], ["rheumatic diseases", "OBSERVATION", 44, 62]]], ["Chloroquine's capacity to interfere with viral particle maturation opens potential applications in other diseases caused by enveloped viruses.", [["Chloroquine", "CHEMICAL", 0, 11], ["Chloroquine", "CHEMICAL", 0, 11], ["Chloroquine", "SIMPLE_CHEMICAL", 0, 11], ["Chloroquine's capacity", "TREATMENT", 0, 22], ["viral particle maturation", "TREATMENT", 41, 66], ["other diseases", "PROBLEM", 99, 113], ["enveloped", "OBSERVATION_MODIFIER", 124, 133], ["viruses", "OBSERVATION", 134, 141]]], ["Following our suggestion that chloroquine might be effective against SARS-CoV (Savarino et al., 2003) , Keyaerts et al. (2004) showed that the drug is an effective inhibitor of SARS-CoV replication in vitro.", [["chloroquine", "CHEMICAL", 30, 41], ["SARS-CoV", "DISEASE", 69, 77], ["chloroquine", "CHEMICAL", 30, 41], ["chloroquine", "SIMPLE_CHEMICAL", 30, 41], ["SARS-CoV", "ORGANISM", 69, 77], ["SARS-CoV", "ORGANISM", 177, 185], ["SARS-CoV", "SPECIES", 69, 77], ["SARS-CoV", "SPECIES", 177, 185], ["chloroquine", "TREATMENT", 30, 41], ["SARS", "PROBLEM", 69, 73], ["SARS", "PROBLEM", 177, 181], ["CoV replication in vitro", "TREATMENT", 182, 206]]], ["PIs are effective treatments for HIV-1/AIDS, and their effects on other viral diseases will be the central topic of this paper.", [["HIV-1/AIDS", "DISEASE", 33, 43], ["viral diseases", "DISEASE", 72, 86], ["HIV-1", "ORGANISM", 33, 38], ["HIV-1", "SPECIES", 33, 38], ["HIV-1", "SPECIES", 33, 38], ["PIs", "TREATMENT", 0, 3], ["effective treatments", "TREATMENT", 8, 28], ["HIV", "PROBLEM", 33, 36], ["AIDS", "PROBLEM", 39, 43], ["other viral diseases", "PROBLEM", 66, 86], ["effective", "OBSERVATION_MODIFIER", 8, 17]]], ["I will first review what is known on the effects of these drugs on SARS.", [["SARS", "DISEASE", 67, 71], ["these drugs", "TREATMENT", 52, 63]]], ["Then, I will discuss the grounds for considering these drugs in the context of avian influenza.Potential anti-SARS effects of HIV-1 protease inhibitors: clinical and laboratory findingsThe anti-HIV-1 activity of PIs is based on inhibition of the HIV-1 aspartic protease, responsible for the cleavage of the Gag/Pol polypeptide containing the main viral enzymes and the structural viral core proteins.", [["influenza", "DISEASE", 85, 94], ["PIs", "CHEMICAL", 212, 215], ["avian influenza", "ORGANISM", 79, 94], ["HIV-1", "ORGANISM", 126, 131], ["anti-HIV-1", "GENE_OR_GENE_PRODUCT", 189, 199], ["PIs", "SIMPLE_CHEMICAL", 212, 215], ["HIV-1", "ORGANISM", 246, 251], ["Gag", "GENE_OR_GENE_PRODUCT", 307, 310], ["Pol", "GENE_OR_GENE_PRODUCT", 311, 314], ["HIV-1 aspartic protease", "PROTEIN", 246, 269], ["Gag", "PROTEIN", 307, 310], ["Pol polypeptide", "PROTEIN", 311, 326], ["viral enzymes", "PROTEIN", 347, 360], ["structural viral core proteins", "PROTEIN", 369, 399], ["HIV-1", "SPECIES", 126, 131], ["HIV-1", "SPECIES", 246, 251], ["HIV-1", "SPECIES", 126, 131], ["HIV-1", "SPECIES", 246, 251], ["these drugs", "TREATMENT", 49, 60], ["avian influenza", "PROBLEM", 79, 94], ["HIV-1 protease inhibitors", "TREATMENT", 126, 151], ["laboratory findings", "TEST", 166, 185], ["The anti-HIV", "TREATMENT", 185, 197], ["PIs", "TREATMENT", 212, 215], ["the HIV", "TEST", 242, 249], ["1 aspartic protease", "TREATMENT", 250, 269], ["the Gag/Pol polypeptide", "TREATMENT", 303, 326], ["the main viral enzymes", "TEST", 338, 360], ["the structural viral core proteins", "PROBLEM", 365, 399], ["influenza", "OBSERVATION", 85, 94]]], ["Inhibition of the HIV-1 protease leads to the production of immature viral particles and inhibition of viral replication.", [["HIV-1", "ORGANISM", 18, 23], ["HIV-1 protease", "PROTEIN", 18, 32], ["HIV-1", "SPECIES", 18, 23], ["HIV-1", "SPECIES", 18, 23], ["the HIV-1 protease", "TREATMENT", 14, 32], ["immature viral particles", "PROBLEM", 60, 84], ["viral replication", "TREATMENT", 103, 120], ["immature viral particles", "OBSERVATION", 60, 84], ["viral replication", "OBSERVATION", 103, 120]]], ["Although PIs were designed to be effective inhibitors of HIV-1 replication, they showed inhibitory effects against a wide spectrum of pathogens.", [["HIV-1", "ORGANISM", 57, 62], ["HIV-1", "SPECIES", 57, 62], ["HIV-1", "SPECIES", 57, 62], ["PIs", "PROBLEM", 9, 12], ["HIV-1 replication", "TREATMENT", 57, 74], ["inhibitory effects", "PROBLEM", 88, 106], ["pathogens", "PROBLEM", 134, 143], ["pathogens", "OBSERVATION", 134, 143]]], ["Indeed, inhibitory effects of PIs were shown on Candida albicans (Cassone et al., 1999) and, more recently, on P. falciparum (Savarino et al., 2004a) .", [["P. falciparum", "DISEASE", 111, 124], ["Candida albicans", "ORGANISM", 48, 64], ["P. falciparum", "ORGANISM", 111, 124], ["Candida albicans", "SPECIES", 48, 64], ["P. falciparum", "SPECIES", 111, 124], ["Candida albicans", "SPECIES", 48, 64], ["P. falciparum", "SPECIES", 111, 124], ["PIs", "TREATMENT", 30, 33]]], ["These activities seem to be due to inhibition of some non-retroviral aspartic proteases, such as the C. albicans secretory aspartic proteases (Saps) and P. falciparum plasmepsins, as the three-dimensional (3D) architecture of these microbial proteases resembles that of the HIV-1 protease (Tacconelli et al., 2004; Savarino et al., in press) .Potential anti-SARS effects of HIV-1 protease inhibitors: clinical and laboratory findingsThat the anti-HIV-1 drug Kaletra (a combination of the PIs ritonavir and lopinavir) was found to be of some benefit for individuals with SARS was rather surprising , as the SARS-CoV genome encodes for no aspartic proteases.", [["Kaletra", "CHEMICAL", 458, 465], ["PIs ritonavir", "CHEMICAL", 488, 501], ["lopinavir", "CHEMICAL", 506, 515], ["SARS", "DISEASE", 570, 574], ["SARS", "DISEASE", 606, 610], ["ritonavir", "CHEMICAL", 492, 501], ["lopinavir", "CHEMICAL", 506, 515], ["C. albicans", "ORGANISM", 101, 112], ["secretory aspartic proteases", "GENE_OR_GENE_PRODUCT", 113, 141], ["Saps", "GENE_OR_GENE_PRODUCT", 143, 147], ["P. falciparum", "ORGANISM", 153, 166], ["plasmepsins", "GENE_OR_GENE_PRODUCT", 167, 178], ["HIV-1", "ORGANISM", 274, 279], ["HIV-1", "ORGANISM", 374, 379], ["anti-HIV-1", "ORGANISM", 442, 452], ["Kaletra", "SIMPLE_CHEMICAL", 458, 465], ["ritonavir", "SIMPLE_CHEMICAL", 492, 501], ["lopinavir", "SIMPLE_CHEMICAL", 506, 515], ["SARS-CoV", "ORGANISM", 606, 614], ["non-retroviral aspartic proteases", "PROTEIN", 54, 87], ["C. albicans secretory aspartic proteases", "PROTEIN", 101, 141], ["Saps", "PROTEIN", 143, 147], ["microbial proteases", "PROTEIN", 232, 251], ["SARS-CoV genome", "DNA", 606, 621], ["aspartic proteases", "PROTEIN", 637, 655], ["C. albicans", "SPECIES", 101, 112], ["P. falciparum", "SPECIES", 153, 166], ["HIV-1", "SPECIES", 274, 279], ["HIV-1", "SPECIES", 374, 379], ["C. albicans", "SPECIES", 101, 112], ["P. falciparum", "SPECIES", 153, 166], ["HIV-1", "SPECIES", 274, 279], ["HIV-1", "SPECIES", 374, 379], ["SARS-CoV", "SPECIES", 606, 614], ["some non-retroviral aspartic proteases", "PROBLEM", 49, 87], ["the C. albicans secretory aspartic proteases", "PROBLEM", 97, 141], ["P. falciparum plasmepsins", "TREATMENT", 153, 178], ["these microbial proteases", "TEST", 226, 251], ["the HIV", "TEST", 270, 277], ["HIV-1 protease inhibitors", "TREATMENT", 374, 399], ["laboratory findings", "TEST", 414, 433], ["the anti-HIV-1 drug Kaletra", "TREATMENT", 438, 465], ["the PIs ritonavir", "TREATMENT", 484, 501], ["lopinavir", "TREATMENT", 506, 515], ["SARS", "PROBLEM", 570, 574], ["the SARS", "PROBLEM", 602, 610], ["aspartic proteases", "PROBLEM", 637, 655]]], ["Despite the lack of double-blind placebocontrolled clinical trials, the clinical experience of physicians involved in the care of people with SARS during the great epidemic of 2003 strongly suggests that lopinavir/ritonavir should be taken into consideration in the clinical management of this disease .", [["SARS", "DISEASE", 142, 146], ["lopinavir/ritonavir", "CHEMICAL", 204, 223], ["lopinavir", "CHEMICAL", 204, 213], ["ritonavir", "CHEMICAL", 214, 223], ["people", "ORGANISM", 130, 136], ["lopinavir", "SIMPLE_CHEMICAL", 204, 213], ["ritonavir", "SIMPLE_CHEMICAL", 214, 223], ["people", "SPECIES", 130, 136], ["SARS", "PROBLEM", 142, 146], ["lopinavir", "TREATMENT", 204, 213], ["ritonavir", "TREATMENT", 214, 223], ["this disease", "PROBLEM", 289, 301]]], ["A retrospective matched cohort study of Chan et al. (2003) found that the addition of lopinavir/ritonavir to standard initial treatment protocols was associated with a reduction in the overall death rate (2.3%) and intubation rate (0%), when compared with a matched cohort who received standard treatment (15.6% and 11.0%, respectively, P < 0.05), and with a lower necessity of methylprednisolone at high doses.", [["lopinavir/ritonavir", "CHEMICAL", 86, 105], ["death", "DISEASE", 193, 198], ["methylprednisolone", "CHEMICAL", 378, 396], ["lopinavir", "CHEMICAL", 86, 95], ["ritonavir", "CHEMICAL", 96, 105], ["methylprednisolone", "CHEMICAL", 378, 396], ["lopinavir", "SIMPLE_CHEMICAL", 86, 95], ["ritonavir", "SIMPLE_CHEMICAL", 96, 105], ["methylprednisolone", "SIMPLE_CHEMICAL", 378, 396], ["A retrospective matched cohort study", "TEST", 0, 36], ["lopinavir", "TREATMENT", 86, 95], ["ritonavir", "TREATMENT", 96, 105], ["standard initial treatment protocols", "TREATMENT", 109, 145], ["a reduction", "PROBLEM", 166, 177], ["the overall death rate", "PROBLEM", 181, 203], ["intubation rate", "TEST", 215, 230], ["standard treatment", "TREATMENT", 286, 304], ["methylprednisolone", "TREATMENT", 378, 396], ["reduction", "OBSERVATION_MODIFIER", 168, 177]]], ["In another study, Chu et al. (2004) evaluated the effects of Kaletra in association with ribavirin.", [["Kaletra", "CHEMICAL", 61, 68], ["ribavirin", "CHEMICAL", 89, 98], ["ribavirin", "CHEMICAL", 89, 98], ["Kaletra", "SIMPLE_CHEMICAL", 61, 68], ["ribavirin", "SIMPLE_CHEMICAL", 89, 98], ["Kaletra", "TREATMENT", 61, 68], ["ribavirin", "TREATMENT", 89, 98]]], ["The adverse clinical outcome (acute respiratory distress syndrome or death) was significantly lower in the treatment group than in the historical controls treated with ribavirin alone (2.4% versus 28.8%, P < 0.001) at day 21 after the onset of symptoms.", [["respiratory", "ANATOMY", 36, 47], ["acute respiratory distress syndrome", "DISEASE", 30, 65], ["death", "DISEASE", 69, 74], ["ribavirin", "CHEMICAL", 168, 177], ["ribavirin", "CHEMICAL", 168, 177], ["ribavirin", "SIMPLE_CHEMICAL", 168, 177], ["The adverse clinical outcome", "PROBLEM", 0, 28], ["acute respiratory distress syndrome", "PROBLEM", 30, 65], ["death", "PROBLEM", 69, 74], ["ribavirin", "TREATMENT", 168, 177], ["symptoms", "PROBLEM", 244, 252], ["acute", "OBSERVATION_MODIFIER", 30, 35], ["respiratory distress", "OBSERVATION", 36, 56], ["lower", "OBSERVATION_MODIFIER", 94, 99]]], ["Both studies conclude that a randomised trial would be needed to validate these results, but the possibility of using lopinavir/ritonavir as a SARS treatment is an option if SARS were to return.", [["lopinavir/ritonavir", "CHEMICAL", 118, 137], ["SARS", "DISEASE", 143, 147], ["SARS", "DISEASE", 174, 178], ["lopinavir", "CHEMICAL", 118, 127], ["ritonavir", "CHEMICAL", 128, 137], ["lopinavir", "SIMPLE_CHEMICAL", 118, 127], ["ritonavir", "SIMPLE_CHEMICAL", 128, 137], ["Both studies", "TEST", 0, 12], ["a randomised trial", "TREATMENT", 27, 45], ["lopinavir", "TREATMENT", 118, 127], ["ritonavir", "TREATMENT", 128, 137], ["a SARS treatment", "TREATMENT", 141, 157], ["SARS", "PROBLEM", 174, 178]]], ["Other considerations on the potential anti-SARS benefits of anti-HIV-1 substances were made in an interesting paper by Chen and Cao (2004) .", [["anti-HIV-1 substances", "TREATMENT", 60, 81]]], ["These authors observed that none of 19 people with HIV-1/AIDS, hospitalised together with 95 individuals with SARS on the same hospital floor, contracted SARS Chen and Cao, 2004) .", [["HIV-1/AIDS", "DISEASE", 51, 61], ["SARS", "DISEASE", 110, 114], ["SARS", "DISEASE", 154, 158], ["people", "ORGANISM", 39, 45], ["HIV-1", "ORGANISM", 51, 56], ["people", "SPECIES", 39, 45], ["HIV", "SPECIES", 51, 54], ["HIV-1", "SPECIES", 51, 56], ["SARS", "PROBLEM", 110, 114]]], ["However, only 11 of these subjects were under antiretroviral regimens, and only 2 were receiving a protease inhibitor (indinavir), the remaining being under different combinations of reverse transcriptase inhibitors .", [["indinavir", "CHEMICAL", 119, 128], ["indinavir", "CHEMICAL", 119, 128], ["indinavir", "SIMPLE_CHEMICAL", 119, 128], ["reverse transcriptase", "PROTEIN", 183, 204], ["antiretroviral regimens", "TREATMENT", 46, 69], ["a protease inhibitor", "TREATMENT", 97, 117], ["indinavir", "TREATMENT", 119, 128], ["reverse transcriptase inhibitors", "TREATMENT", 183, 215]]], ["Attributing this observation to casualty is difficult: according to the report of Chen and Cao, the individuals with HIV-1/AIDS indeed had close contacts with those with SARS, and 6 of 28 medical workers who served on the same floor contracted SARS.", [["HIV-1/AIDS", "DISEASE", 117, 127], ["SARS", "DISEASE", 170, 174], ["SARS", "DISEASE", 244, 248], ["individuals", "ORGANISM", 100, 111], ["HIV-1", "ORGANISM", 117, 122], ["floor", "ORGANISM_SUBDIVISION", 227, 232], ["HIV", "SPECIES", 117, 120], ["HIV-1", "SPECIES", 117, 122], ["HIV", "PROBLEM", 117, 120], ["AIDS", "PROBLEM", 123, 127]]], ["It is possible that these effects are due to viral interference and/or to non-specific antiviral factors induced by HIV-1; however, the report of Chen and Cao also raised the hypothesis that anti-SARS effects might be an unexpected property of antiretroviral drugs in general and not only a property of PIs.Potential anti-SARS effects of HIV-1 protease inhibitors: clinical and laboratory findingsThe clinical effects of antiretroviral drugs on SARS were initially attributed to non-specific anti-inflammatory effects, but later on, in vitro studies showed that members of the PI class could indeed exert direct antiviral effects against SARS-CoV.", [["SARS", "DISEASE", 445, 449], ["SARS-CoV", "DISEASE", 638, 646], ["HIV-1", "ORGANISM", 116, 121], ["HIV-1", "ORGANISM", 338, 343], ["PI class", "GENE_OR_GENE_PRODUCT", 577, 585], ["SARS-CoV", "ORGANISM", 638, 646], ["antiviral factors", "PROTEIN", 87, 104], ["HIV-1", "SPECIES", 116, 121], ["HIV-1", "SPECIES", 338, 343], ["HIV-1", "SPECIES", 116, 121], ["HIV-1", "SPECIES", 338, 343], ["SARS-CoV", "SPECIES", 638, 646], ["viral interference", "PROBLEM", 45, 63], ["non-specific antiviral factors", "PROBLEM", 74, 104], ["antiretroviral drugs", "TREATMENT", 244, 264], ["PIs", "PROBLEM", 303, 306], ["HIV-1 protease inhibitors", "TREATMENT", 338, 363], ["laboratory findings", "TEST", 378, 397], ["antiretroviral drugs", "TREATMENT", 421, 441], ["SARS", "PROBLEM", 445, 449], ["non-specific anti-inflammatory effects", "PROBLEM", 479, 517], ["vitro studies", "TEST", 536, 549], ["SARS", "PROBLEM", 638, 642], ["antiviral", "OBSERVATION", 612, 621]]], ["Yamamoto et al. (2004) showed that the protease inhibitor nelfinavir (10 M), but not ritonavir, significantly and efficiently inhibited viral antigen expression (measured by immunofluorescence), the production of virions (measured by real-time RT-PCR) and the cytopathic effect (measured by the methyl tetrazolium assay) in Vero E6 cells infected with SARS-CoV at a multiplicity of infection of 0.01.", [["virions", "ANATOMY", 213, 220], ["Vero E6 cells", "ANATOMY", 324, 337], ["nelfinavir", "CHEMICAL", 58, 68], ["ritonavir", "CHEMICAL", 85, 94], ["methyl tetrazolium", "CHEMICAL", 295, 313], ["SARS", "DISEASE", 352, 356], ["infection", "DISEASE", 382, 391], ["nelfinavir", "CHEMICAL", 58, 68], ["ritonavir", "CHEMICAL", 85, 94], ["methyl tetrazolium", "CHEMICAL", 295, 313], ["nelfinavir", "SIMPLE_CHEMICAL", 58, 68], ["ritonavir", "SIMPLE_CHEMICAL", 85, 94], ["methyl tetrazolium", "SIMPLE_CHEMICAL", 295, 313], ["Vero E6 cells", "CELL", 324, 337], ["SARS-CoV", "ORGANISM", 352, 360], ["Vero E6 cells", "CELL_LINE", 324, 337], ["Vero E6", "SPECIES", 324, 331], ["SARS-CoV", "SPECIES", 352, 360], ["the protease inhibitor nelfinavir", "TREATMENT", 35, 68], ["ritonavir", "TREATMENT", 85, 94], ["viral antigen expression", "PROBLEM", 136, 160], ["immunofluorescence", "TEST", 174, 192], ["the production of virions", "PROBLEM", 195, 220], ["PCR", "TEST", 247, 250], ["the cytopathic effect", "PROBLEM", 256, 277], ["the methyl tetrazolium assay", "TEST", 291, 319], ["Vero E6 cells", "PROBLEM", 324, 337], ["SARS", "PROBLEM", 352, 356], ["CoV", "PROBLEM", 357, 360], ["infection", "PROBLEM", 382, 391], ["cytopathic", "OBSERVATION_MODIFIER", 260, 270], ["infection", "OBSERVATION", 382, 391]]], ["Moreover, time-of-addition experiments showed that nelfinavir inhibited SARS-CoV replication at a post-entry step (Yamamoto et al., 2004) .", [["nelfinavir", "CHEMICAL", 51, 61], ["nelfinavir", "CHEMICAL", 51, 61], ["nelfinavir", "SIMPLE_CHEMICAL", 51, 61], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 72, 80], ["SARS-CoV", "SPECIES", 72, 80], ["nelfinavir", "TREATMENT", 51, 61]]], ["Chu et al. (2004) showed that lopinavir (6.4 M) inhibited the cytopathic effect of SARS-CoV (measured by plaque-reduction assay) in foetal rhesus kidney-4 (fRHK-4) cells.", [["plaque", "ANATOMY", 105, 111], ["kidney-4 (fRHK-4) cells", "ANATOMY", 146, 169], ["lopinavir", "CHEMICAL", 30, 39], ["SARS", "DISEASE", 83, 87], ["lopinavir", "CHEMICAL", 30, 39], ["lopinavir", "SIMPLE_CHEMICAL", 30, 39], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 83, 91], ["rhesus", "ORGANISM", 139, 145], ["kidney-4", "CELL", 146, 154], ["fRHK-4) cells", "CELL", 156, 169], ["foetal rhesus kidney-4 (fRHK-4) cells", "CELL_LINE", 132, 169], ["SARS-CoV", "SPECIES", 83, 91], ["lopinavir", "TREATMENT", 30, 39], ["the cytopathic effect", "PROBLEM", 58, 79], ["SARS", "PROBLEM", 83, 87], ["CoV", "PROBLEM", 88, 91], ["plaque", "TEST", 105, 111], ["reduction assay", "TEST", 112, 127], ["foetal rhesus kidney", "TEST", 132, 152], ["fRHK", "TEST", 156, 160], ["cytopathic", "OBSERVATION_MODIFIER", 62, 72], ["kidney", "ANATOMY", 146, 152]]], ["Of note, the effects of lopinavir were synergistic to those of ribavirin .", [["lopinavir", "CHEMICAL", 24, 33], ["ribavirin", "CHEMICAL", 63, 72], ["lopinavir", "CHEMICAL", 24, 33], ["ribavirin", "CHEMICAL", 63, 72], ["lopinavir", "SIMPLE_CHEMICAL", 24, 33], ["ribavirin", "SIMPLE_CHEMICAL", 63, 72], ["lopinavir", "TREATMENT", 24, 33], ["ribavirin", "TREATMENT", 63, 72]]], ["Therefore, Chu and coworkers attribute to this antiviral synergism the clinical benefits observed in individuals with SARS and treated with ribavirin plus Kaletra. screened the effects of different antiviral compounds against 10 clinical isolates of SARS-CoV.", [["SARS", "DISEASE", 118, 122], ["ribavirin", "CHEMICAL", 140, 149], ["Kaletra", "CHEMICAL", 155, 162], ["SARS-CoV", "DISEASE", 250, 258], ["ribavirin", "CHEMICAL", 140, 149], ["ribavirin", "SIMPLE_CHEMICAL", 140, 149], ["SARS-CoV", "ORGANISM", 250, 258], ["SARS-CoV", "SPECIES", 250, 258], ["this antiviral synergism", "PROBLEM", 42, 66], ["SARS", "PROBLEM", 118, 122], ["ribavirin", "TREATMENT", 140, 149], ["Kaletra", "TREATMENT", 155, 162], ["different antiviral compounds", "TREATMENT", 188, 217], ["SARS", "PROBLEM", 250, 254], ["CoV", "PROBLEM", 255, 258]]], ["These compounds included the nucleosidic reverse transcriptase inhibitors (NRTIs) zidovudine and stavudine, the non-nucleosidic reverse transcriptase inhibitor (NNRTI) nevirapine, and the PIs ritonavir and lopinavir.", [["NRTIs", "CHEMICAL", 75, 80], ["zidovudine", "CHEMICAL", 82, 92], ["stavudine", "CHEMICAL", 97, 106], ["nevirapine", "CHEMICAL", 168, 178], ["PIs ritonavir", "CHEMICAL", 188, 201], ["lopinavir", "CHEMICAL", 206, 215], ["zidovudine", "CHEMICAL", 82, 92], ["stavudine", "CHEMICAL", 97, 106], ["nevirapine", "CHEMICAL", 168, 178], ["ritonavir", "CHEMICAL", 192, 201], ["lopinavir", "CHEMICAL", 206, 215], ["nucleosidic reverse transcriptase", "GENE_OR_GENE_PRODUCT", 29, 62], ["zidovudine", "SIMPLE_CHEMICAL", 82, 92], ["stavudine", "SIMPLE_CHEMICAL", 97, 106], ["non-nucleosidic reverse transcriptase", "GENE_OR_GENE_PRODUCT", 112, 149], ["nevirapine", "SIMPLE_CHEMICAL", 168, 178], ["ritonavir", "SIMPLE_CHEMICAL", 192, 201], ["lopinavir", "SIMPLE_CHEMICAL", 206, 215], ["nucleosidic reverse transcriptase", "PROTEIN", 29, 62], ["the nucleosidic reverse transcriptase inhibitors", "TREATMENT", 25, 73], ["NRTIs", "TREATMENT", 75, 80], ["zidovudine", "TREATMENT", 82, 92], ["stavudine", "TREATMENT", 97, 106], ["the non-nucleosidic reverse transcriptase inhibitor", "TREATMENT", 108, 159], ["NNRTI", "TREATMENT", 161, 166], ["nevirapine", "TREATMENT", 168, 178], ["the PIs ritonavir", "TREATMENT", 184, 201], ["lopinavir", "TREATMENT", 206, 215]]], ["Again, only lopinavir resulted to exert detectable effects against SARS-CoV.", [["lopinavir", "CHEMICAL", 12, 21], ["SARS-CoV", "DISEASE", 67, 75], ["lopinavir", "CHEMICAL", 12, 21], ["lopinavir", "SIMPLE_CHEMICAL", 12, 21], ["SARS-CoV", "ORGANISM", 67, 75], ["SARS-CoV", "SPECIES", 67, 75], ["lopinavir", "TREATMENT", 12, 21], ["SARS", "PROBLEM", 67, 71]]], ["The EC 50 of lopinavir ranged from 1.6 to 6.4 M at 48 h post-infection and from 6.4 to 12.8 M at 72 h post-infection in the fRHK-4 cell line .", [["EC", "ANATOMY", 4, 6], ["fRHK-4 cell line", "ANATOMY", 124, 140], ["lopinavir", "CHEMICAL", 13, 22], ["infection", "DISEASE", 61, 70], ["infection", "DISEASE", 107, 116], ["lopinavir", "CHEMICAL", 13, 22], ["EC", "CELL", 4, 6], ["lopinavir", "SIMPLE_CHEMICAL", 13, 22], ["fRHK-4 cell line", "CELL", 124, 140], ["fRHK-4 cell line", "CELL_LINE", 124, 140], ["The EC", "TEST", 0, 6], ["lopinavir", "TEST", 13, 22], ["infection", "PROBLEM", 61, 70], ["infection", "PROBLEM", 107, 116], ["the fRHK", "TEST", 120, 128], ["infection", "OBSERVATION", 61, 70], ["infection", "OBSERVATION", 107, 116], ["cell line", "OBSERVATION", 131, 140]]], ["However, they warn that the antiviral effects are variable and cell line dependent.", [["cell line", "ANATOMY", 63, 72], ["cell line", "CELL", 63, 72], ["the antiviral effects", "PROBLEM", 24, 45], ["cell line dependent", "PROBLEM", 63, 82], ["antiviral effects", "OBSERVATION", 28, 45], ["cell line", "OBSERVATION", 63, 72], ["dependent", "OBSERVATION_MODIFIER", 73, 82]]], ["For example, the EC 50 of lopinavir against the prototype SARS-CoV strain 39849 ranged from 3.2 to 6.4 M in fRHK-4 cells and from 6.4 to 12.8 M in Vero cells .", [["EC", "ANATOMY", 17, 19], ["fRHK-4 cells", "ANATOMY", 108, 120], ["Vero cells", "ANATOMY", 147, 157], ["lopinavir", "CHEMICAL", 26, 35], ["SARS", "DISEASE", 58, 62], ["lopinavir", "CHEMICAL", 26, 35], ["EC", "CELL", 17, 19], ["lopinavir", "SIMPLE_CHEMICAL", 26, 35], ["SARS-CoV strain 39849", "ORGANISM", 58, 79], ["fRHK-4 cells", "CELL", 108, 120], ["Vero cells", "CELL", 147, 157], ["fRHK-4 cells", "CELL_LINE", 108, 120], ["Vero cells", "CELL_LINE", 147, 157], ["SARS-CoV strain 39849", "SPECIES", 58, 79], ["lopinavir", "TREATMENT", 26, 35], ["the prototype SARS", "TEST", 44, 62], ["CoV strain", "TEST", 63, 73], ["fRHK", "TEST", 108, 112], ["cells", "TEST", 115, 120], ["Vero cells", "OBSERVATION", 147, 157]]], ["Therefore, it is likely that the antiviral effects of some anti-SARS compounds reported in the literature have been exaggerated or underestimated depending on the assay and cell line used by the different groups.", [["cell line", "ANATOMY", 173, 182], ["cell line", "CELL", 173, 182], ["cell line", "CELL_LINE", 173, 182], ["some anti-SARS compounds", "PROBLEM", 54, 78], ["cell line", "TREATMENT", 173, 182], ["is likely", "UNCERTAINTY", 14, 23], ["antiviral", "OBSERVATION", 33, 42]]], ["In this regard, the example of ribavirin is interesting: some report that it is an inhibitor SARS-CoV replication, others report that it exerts its antiviral effects only at concentrations too high to be reached in vivo Chu et al., 2004; Stroher et al., 2004) .The SARS coronavirus main protease: grounds for the potential anti-SARS effects of HIV-1 protease inhibitorsAs a member of the Coronaviridae family, SARS-CoV encodes for three different proteases, one of which, the 3C-like protease (3CL pro ), or main coronavirus protease Sun et al., 2003; Yang et al., 2003) , is likely to be a target for PIs (Jenwitheesuk and Samudrala, 2003a,b) .", [["ribavirin", "CHEMICAL", 31, 40], ["SARS", "DISEASE", 410, 414], ["ribavirin", "CHEMICAL", 31, 40], ["ribavirin", "SIMPLE_CHEMICAL", 31, 40], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 93, 101], ["HIV-1 protease", "GENE_OR_GENE_PRODUCT", 344, 358], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 388, 401], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 410, 418], ["3CL pro", "GENE_OR_GENE_PRODUCT", 494, 501], ["SARS coronavirus main protease", "PROTEIN", 265, 295], ["Coronaviridae family", "PROTEIN", 388, 408], ["SARS-CoV", "PROTEIN", 410, 418], ["proteases", "PROTEIN", 447, 456], ["3C", "PROTEIN", 476, 478], ["protease", "PROTEIN", 484, 492], ["3CL pro", "PROTEIN", 494, 501], ["coronavirus", "SPECIES", 270, 281], ["HIV-1", "SPECIES", 344, 349], ["SARS-CoV", "SPECIES", 93, 101], ["SARS coronavirus", "SPECIES", 265, 281], ["HIV-1", "SPECIES", 344, 349], ["SARS-CoV", "SPECIES", 410, 418], ["ribavirin", "TREATMENT", 31, 40], ["an inhibitor SARS", "PROBLEM", 80, 97], ["the potential anti-SARS effects", "TREATMENT", 309, 340], ["HIV-1 protease inhibitors", "TREATMENT", 344, 369], ["three different proteases", "TREATMENT", 431, 456], ["the 3C-like protease (3CL pro )", "TREATMENT", 472, 503], ["PIs", "TEST", 602, 605], ["Samudrala", "TREATMENT", 624, 633], ["ribavirin", "OBSERVATION", 31, 40]]], ["Preliminary data of Yamamoto et al. (2004) indicate that 3CL pro can be inhibited, though only partially, by lopinavir, which is a derivative of ritonavir.", [["lopinavir", "CHEMICAL", 109, 118], ["ritonavir", "CHEMICAL", 145, 154], ["lopinavir", "CHEMICAL", 109, 118], ["ritonavir", "CHEMICAL", 145, 154], ["3CL pro", "GENE_OR_GENE_PRODUCT", 57, 64], ["lopinavir", "SIMPLE_CHEMICAL", 109, 118], ["ritonavir", "SIMPLE_CHEMICAL", 145, 154], ["lopinavir", "TREATMENT", 109, 118], ["a derivative of ritonavir", "TREATMENT", 129, 154]]], ["This is apparently surprising, because 3CL pro is a cysteine protease rather than an aspartic protease.", [["cysteine", "CHEMICAL", 52, 60], ["3CL pro", "GENE_OR_GENE_PRODUCT", 39, 46], ["3CL pro", "PROTEIN", 39, 46], ["cysteine protease", "PROTEIN", 52, 69], ["aspartic protease", "PROTEIN", 85, 102], ["a cysteine protease", "TREATMENT", 50, 69], ["an aspartic protease", "TREATMENT", 82, 102]]], ["In the active site of SARS-CoV 3CL pro , Cys 145 and a His 41 form a \"catalytic dyad\" (Anand et al., 2003) .", [["SARS", "DISEASE", 22, 26], ["Cys 145", "CHEMICAL", 41, 48], ["Cys", "CHEMICAL", 41, 44], ["His", "CHEMICAL", 55, 58], ["Cys 145", "AMINO_ACID", 41, 48], ["SARS-CoV", "SPECIES", 22, 30], ["Cys", "TEST", 41, 44], ["SARS", "OBSERVATION", 22, 26]]], ["Cysteine proteases usually display a catalytic triad consisting of serine, histidine and aspartate; however, the 3D structure of SARS-CoV 3CL pro shows no aspartate residue in the vicinity of Cys 145 and His 41 .", [["Cysteine", "CHEMICAL", 0, 8], ["histidine", "CHEMICAL", 75, 84], ["aspartate", "CHEMICAL", 89, 98], ["SARS", "DISEASE", 129, 133], ["aspartate", "CHEMICAL", 155, 164], ["Cysteine", "CHEMICAL", 0, 8], ["serine", "CHEMICAL", 67, 73], ["histidine", "CHEMICAL", 75, 84], ["aspartate", "CHEMICAL", 89, 98], ["aspartate", "CHEMICAL", 155, 164], ["Cys", "CHEMICAL", 192, 195], ["His", "CHEMICAL", 204, 207], ["Cysteine", "AMINO_ACID", 0, 8], ["serine", "AMINO_ACID", 67, 73], ["histidine", "AMINO_ACID", 75, 84], ["aspartate", "AMINO_ACID", 89, 98], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 129, 137], ["aspartate", "AMINO_ACID", 155, 164], ["Cys 145", "AMINO_ACID", 192, 199], ["Cysteine proteases", "PROTEIN", 0, 18], ["SARS-CoV 3CL pro", "PROTEIN", 129, 145], ["SARS-CoV", "SPECIES", 129, 137], ["Cysteine proteases", "PROBLEM", 0, 18], ["a catalytic triad", "PROBLEM", 35, 52], ["serine, histidine", "TREATMENT", 67, 84], ["aspartate", "TEST", 89, 98], ["SARS", "PROBLEM", 129, 133], ["CoV 3CL pro", "TEST", 134, 145], ["aspartate residue", "PROBLEM", 155, 172], ["Cys", "TEST", 192, 195], ["no", "UNCERTAINTY", 152, 154], ["aspartate residue", "OBSERVATION", 155, 172]]], ["SARS-CoV 3CL pro is a homodimer with each monomer comprising three domains (Anand et al., 2003) .", [["SARS", "DISEASE", 0, 4], ["SARS-CoV 3CL pro", "PROTEIN", 0, 16], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "PROBLEM", 0, 4], ["a homodimer", "TREATMENT", 20, 31]]], ["The first two domains show a chymotrypsinlike folding (root mean square deviation from bovine \u2423chymotrypsin: 2.6\u00c5; P < 0.05; Fig. 1 ), which is responsible for the catalytic reaction, and the third domain is \u2423-helical and plays a critical role in enzyme dimerisation (Shi et al., 2004) .", [["bovine", "ORGANISM", 87, 93], ["third domain", "PROTEIN", 192, 204], ["\u2423-helical", "PROTEIN", 208, 217], ["bovine", "SPECIES", 87, 93], ["a chymotrypsinlike folding (root mean square deviation", "PROBLEM", 27, 81], ["bovine \u2423chymotrypsin", "TEST", 87, 107], ["the catalytic reaction", "PROBLEM", 160, 182], ["chymotrypsinlike folding", "OBSERVATION", 29, 53], ["responsible for", "UNCERTAINTY", 144, 159], ["catalytic reaction", "OBSERVATION", 164, 182]]], ["The chymotrypsin-like folding of 3CL pro is intriguing because the overall sequence identity between the two proteins is quite low (\u223c11%).", [["chymotrypsin", "GENE_OR_GENE_PRODUCT", 4, 16], ["chymotrypsin", "PROTEIN", 4, 16], ["3CL pro", "PROTEIN", 33, 40], ["The chymotrypsin", "TREATMENT", 0, 16], ["the two proteins", "TEST", 101, 117], ["low", "OBSERVATION_MODIFIER", 127, 130]]], ["As chymotrypsin and other proteins with similar 3D folding are serine proteases, it raised the hypothesis that 3CL pro was originally a chymotrypsin-like serine protease that later evolved in a cysteine protease (Shan et al., 2004) .", [["serine", "CHEMICAL", 63, 69], ["serine", "CHEMICAL", 154, 160], ["cysteine", "CHEMICAL", 194, 202], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 3, 15], ["serine", "AMINO_ACID", 63, 69], ["3CL pro", "GENE_OR_GENE_PRODUCT", 111, 118], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 136, 148], ["chymotrypsin", "PROTEIN", 3, 15], ["serine proteases", "PROTEIN", 63, 79], ["3CL pro", "PROTEIN", 111, 118], ["chymotrypsin-like serine protease", "PROTEIN", 136, 169], ["cysteine protease", "PROTEIN", 194, 211], ["chymotrypsin and other proteins", "TREATMENT", 3, 34], ["serine proteases", "PROBLEM", 63, 79], ["a chymotrypsin-like serine protease", "PROBLEM", 134, 169], ["a cysteine protease", "TREATMENT", 192, 211]]], ["That a chymotrypsin-fold protease may be a target for PIs is supported by in vitro experiments of independent groups, showing that PIs also inhibit chymotrypsin-like components of the mammalian proteasome (Piccinini et al., 2002; Schmidtke et al., 1999) .The SARS coronavirus main protease: grounds for the potential anti-SARS effects of HIV-1 protease inhibitorsThe limited experimental evidence available for an inhibitory effect of PIs on 3CL pro is supported by computational simulations revealing that the catalytic site of 3CL pro allows the docking of several PIs.", [["chymotrypsin", "GENE_OR_GENE_PRODUCT", 7, 19], ["PIs", "SIMPLE_CHEMICAL", 131, 134], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 148, 160], ["HIV-1 protease", "GENE_OR_GENE_PRODUCT", 338, 352], ["chymotrypsin-fold protease", "PROTEIN", 7, 33], ["chymotrypsin", "PROTEIN", 148, 160], ["mammalian proteasome", "PROTEIN", 184, 204], ["SARS coronavirus main protease", "PROTEIN", 259, 289], ["catalytic site", "PROTEIN", 511, 525], ["3CL pro", "PROTEIN", 529, 536], ["coronavirus", "SPECIES", 264, 275], ["HIV-1", "SPECIES", 338, 343], ["SARS coronavirus", "SPECIES", 259, 275], ["HIV-1", "SPECIES", 338, 343], ["a chymotrypsin-fold protease", "TREATMENT", 5, 33], ["PIs", "PROBLEM", 54, 57], ["chymotrypsin", "PROBLEM", 148, 160], ["the mammalian proteasome", "TREATMENT", 180, 204], ["the potential anti-SARS effects", "TREATMENT", 303, 334], ["HIV-1 protease inhibitors", "TREATMENT", 338, 363], ["computational simulations", "TEST", 466, 491], ["the catalytic site", "PROBLEM", 507, 525], ["several PIs", "PROBLEM", 559, 570]]], ["The in silico simulation that I have adopted, i.e., the genetic algorithm GOLD, uses ligand/protein docking techniques which have been used to successfully predict the susceptibility of P. falciparum to PIs (Savarino et al., 2004a (Savarino et al., , 2005 .", [["P. falciparum", "DISEASE", 186, 199], ["P. falciparum", "ORGANISM", 186, 199], ["P. falciparum", "SPECIES", 186, 199], ["P. falciparum", "SPECIES", 186, 199], ["ligand/protein docking techniques", "TREATMENT", 85, 118]]], ["As shown in Fig. 2 , clinically used anti-HIV-1 PIs only partially fill the binding cavity of 3CL pro , but the GOLD fitness scores obtained (ritonavir = 62.77; saquinavir = 48.07; indinavir = 48.93) indicate stable ligand/protein interactions.", [["ritonavir", "CHEMICAL", 142, 151], ["saquinavir", "CHEMICAL", 161, 171], ["indinavir", "CHEMICAL", 181, 190], ["ritonavir", "CHEMICAL", 142, 151], ["saquinavir", "CHEMICAL", 161, 171], ["indinavir", "CHEMICAL", 181, 190], ["ritonavir", "SIMPLE_CHEMICAL", 142, 151], ["saquinavir", "SIMPLE_CHEMICAL", 161, 171], ["3CL pro", "PROTEIN", 94, 101], ["anti-HIV-1 PIs", "TREATMENT", 37, 51], ["the GOLD fitness scores", "TEST", 108, 131], ["ritonavir", "TEST", 142, 151], ["saquinavir", "TEST", 161, 171], ["indinavir", "TEST", 181, 190], ["stable", "OBSERVATION_MODIFIER", 209, 215], ["protein interactions", "OBSERVATION", 223, 243]]], ["Only ritonavir, however, was found to display significant hydrogen bonding with 3CL pro (data not shown).", [["ritonavir", "CHEMICAL", 5, 14], ["ritonavir", "CHEMICAL", 5, 14], ["hydrogen", "CHEMICAL", 58, 66], ["ritonavir", "SIMPLE_CHEMICAL", 5, 14], ["hydrogen", "SIMPLE_CHEMICAL", 58, 66], ["ritonavir", "TREATMENT", 5, 14], ["significant hydrogen bonding", "PROBLEM", 46, 74], ["3CL pro (data", "TEST", 80, 93], ["hydrogen bonding", "OBSERVATION", 58, 74]]], ["These observations are in line with previous calculations of inde-pendent groups using 3CL pro s of SARS-CoV and transmissible gastroenteritis virus (TGEV) (Jenwitheesuk and Samudrala, 2003a; Zhang and Yap, 2004) .", [["transmissible gastroenteritis", "DISEASE", 113, 142], ["SARS-CoV", "ORGANISM", 100, 108], ["transmissible gastroenteritis virus", "ORGANISM", 113, 148], ["TGEV", "ORGANISM", 150, 154], ["transmissible gastroenteritis virus", "SPECIES", 113, 148], ["SARS-CoV", "SPECIES", 100, 108], ["transmissible gastroenteritis virus", "SPECIES", 113, 148], ["TGEV", "SPECIES", 150, 154], ["previous calculations of inde-pendent groups", "TREATMENT", 36, 80], ["SARS", "PROBLEM", 100, 104], ["CoV", "PROBLEM", 105, 108], ["transmissible gastroenteritis virus", "PROBLEM", 113, 148]]], ["Among the various compounds that they tested, Zhang and Yap (2004) indicated ritonavir as the compound with the highest binding affinity (K i = 5.6 \u00d7 10 \u221225 M).", [["ritonavir", "CHEMICAL", 77, 86], ["ritonavir", "CHEMICAL", 77, 86], ["ritonavir", "SIMPLE_CHEMICAL", 77, 86], ["ritonavir", "TREATMENT", 77, 86], ["the highest binding affinity", "PROBLEM", 108, 136], ["K i", "TEST", 138, 141]]], ["These authors attribute to the other Kaletra component, lopinavir, a K i of 8.7 \u00d7 10 \u221220 M (Zhang and Yap, 2004) .", [["lopinavir", "CHEMICAL", 56, 65], ["K", "CHEMICAL", 69, 70], ["lopinavir", "CHEMICAL", 56, 65], ["lopinavir", "SIMPLE_CHEMICAL", 56, 65], ["the other Kaletra component", "PROBLEM", 27, 54], ["lopinavir", "TREATMENT", 56, 65], ["a K i", "TEST", 67, 72]]], ["Instead, Jenwitheesuk and Samudrala (2003b) attribute to ritonavir a K i of \u223c10 \u22127 M. My calculations attribute to ritonavir a K i of \u223c10 \u22125 M. The reason for these discrepancies are due to the different methods adopted.", [["ritonavir", "CHEMICAL", 57, 66], ["K", "CHEMICAL", 69, 70], ["ritonavir", "CHEMICAL", 115, 124], ["K", "CHEMICAL", 127, 128], ["ritonavir", "CHEMICAL", 57, 66], ["ritonavir", "CHEMICAL", 115, 124], ["ritonavir", "SIMPLE_CHEMICAL", 57, 66], ["ritonavir", "SIMPLE_CHEMICAL", 115, 124], ["ritonavir", "TREATMENT", 57, 66], ["ritonavir", "TREATMENT", 115, 124], ["these discrepancies", "PROBLEM", 159, 178]]], ["Instead, I estimated the theoretical binding affinity of PIs to 3CL pro based on a correlation between docking fitness and experimental data embedded in the GOLD program.", [["3CL pro", "PROTEIN", 64, 71]]], ["This dataset compares the GOLD fitness scores obtained for a panel of potential \u2423-chymotrypsin inhibitors to their experimentally determined K i 's.", [["K", "CHEMICAL", 141, 142], ["\u2423-chymotrypsin", "GENE_OR_GENE_PRODUCT", 80, 94], ["a panel", "TEST", 59, 66], ["potential \u2423-chymotrypsin inhibitors", "TREATMENT", 70, 105]]], ["It may be argued that the SARS-CoV 3CL pro is a protein with chymotrypsin folding but not \u2423-chymotrypsin itself.", [["SARS", "DISEASE", 26, 30], ["SARS-CoV", "ORGANISM", 26, 34], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 61, 73], ["\u2423-chymotrypsin", "SIMPLE_CHEMICAL", 90, 104], ["SARS-CoV 3CL pro", "PROTEIN", 26, 42], ["chymotrypsin", "PROTEIN", 61, 73], ["\u2423-chymotrypsin", "PROTEIN", 90, 104], ["SARS-CoV", "SPECIES", 26, 34], ["the SARS", "PROBLEM", 22, 30], ["chymotrypsin folding", "TREATMENT", 61, 81]]], ["In any event, the K i that I estimated is more realistic than those previously reported, given that PIs, at 10 M, have been determined to inhibit the 3C-like protease only partially (Yamamoto et al., 2004) .The SARS coronavirus main protease: grounds for the potential anti-SARS effects of HIV-1 protease inhibitorsAlthough experiments providing a causal link between 3CL pro inhibition and impairment of SARS-CoV replication are still lacking, 3CL pro is indicated by most groups as the main target for PIs in SARS-CoV, as virological, biochemical and bioinformatic data seem to agree in this regard.", [["SARS", "DISEASE", 405, 409], ["SARS", "DISEASE", 511, 515], ["K i", "GENE_OR_GENE_PRODUCT", 18, 21], ["HIV-1 protease", "GENE_OR_GENE_PRODUCT", 290, 304], ["3CL", "GENE_OR_GENE_PRODUCT", 368, 371], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 405, 413], ["3CL pro", "GENE_OR_GENE_PRODUCT", 445, 452], ["SARS-CoV", "ORGANISM", 511, 519], ["protease", "PROTEIN", 158, 166], ["SARS coronavirus main protease", "PROTEIN", 211, 241], ["3CL pro", "PROTEIN", 445, 452], ["coronavirus", "SPECIES", 216, 227], ["HIV-1", "SPECIES", 290, 295], ["SARS coronavirus", "SPECIES", 211, 227], ["HIV-1", "SPECIES", 290, 295], ["SARS-CoV", "SPECIES", 405, 413], ["SARS-CoV", "SPECIES", 511, 519], ["the potential anti-SARS effects", "TREATMENT", 255, 286], ["HIV-1 protease inhibitors", "TREATMENT", 290, 315], ["3CL pro inhibition", "TREATMENT", 368, 386], ["SARS", "PROBLEM", 405, 409], ["CoV replication", "TREATMENT", 410, 425], ["PIs in SARS", "PROBLEM", 504, 515], ["bioinformatic data", "TEST", 553, 571], ["more realistic", "OBSERVATION_MODIFIER", 42, 56]]], ["The fact that, experimentally, lopinavir and ritonavir only partially inhibit 3CL pro does not exclude a possible causal link between 3CL pro and SARS-CoV inhibition.", [["lopinavir", "CHEMICAL", 31, 40], ["ritonavir", "CHEMICAL", 45, 54], ["lopinavir", "CHEMICAL", 31, 40], ["ritonavir", "CHEMICAL", 45, 54], ["lopinavir", "SIMPLE_CHEMICAL", 31, 40], ["ritonavir", "SIMPLE_CHEMICAL", 45, 54], ["3CL pro", "GENE_OR_GENE_PRODUCT", 134, 141], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 146, 154], ["3CL pro", "PROTEIN", 78, 85], ["lopinavir", "TREATMENT", 31, 40], ["ritonavir", "TREATMENT", 45, 54], ["SARS", "PROBLEM", 146, 150], ["CoV inhibition", "TREATMENT", 151, 165]]], ["Indeed, the extent of 3CL pro inhibition necessary for exerting antiviral effects is still not known.", [["3CL pro", "GENE_OR_GENE_PRODUCT", 22, 29], ["3CL pro inhibition", "TREATMENT", 22, 40], ["exerting antiviral effects", "PROBLEM", 55, 81], ["antiviral", "OBSERVATION", 64, 73]]], ["However, it cannot be excluded that inhibition of any other of the post-entry steps of the viral life cycle may contribute to the anti-SARS-CoV effects of PIs.The SARS coronavirus main protease: grounds for the potential anti-SARS effects of HIV-1 protease inhibitorsThe possibility that PIs may dock to the active site of 3CL pro is intriguing as it extends the potential effects of these drugs beyond those organisms possessing aspartic proteases resembling the HIV-1 protease.Expanding the applications of HIV-1 protease inhibitors: theoretical effects on influenza A virusesAnother target for PIs might be a putative protease component of the RNA-directed RNA polymerase (RdRp) of the type A influenza virus.", [["influenza A viruses", "DISEASE", 559, 578], ["anti-SARS-CoV", "GENE_OR_GENE_PRODUCT", 130, 143], ["HIV-1 protease", "GENE_OR_GENE_PRODUCT", 242, 256], ["3CL pro", "GENE_OR_GENE_PRODUCT", 323, 330], ["HIV-1 protease", "GENE_OR_GENE_PRODUCT", 464, 478], ["HIV-1", "ORGANISM", 509, 514], ["influenza A viruses", "ORGANISM", 559, 578], ["RNA-directed RNA polymerase", "GENE_OR_GENE_PRODUCT", 647, 674], ["type A influenza virus", "ORGANISM", 689, 711], ["SARS coronavirus main protease", "PROTEIN", 163, 193], ["3CL pro", "PROTEIN", 323, 330], ["aspartic proteases", "PROTEIN", 430, 448], ["HIV-1 protease", "PROTEIN", 464, 478], ["protease component", "PROTEIN", 621, 639], ["RNA-directed RNA polymerase", "PROTEIN", 647, 674], ["RdRp", "PROTEIN", 676, 680], ["coronavirus", "SPECIES", 168, 179], ["HIV-1", "SPECIES", 242, 247], ["HIV-1", "SPECIES", 464, 469], ["HIV-1", "SPECIES", 509, 514], ["A influenza virus", "SPECIES", 694, 711], ["SARS coronavirus", "SPECIES", 163, 179], ["HIV-1", "SPECIES", 242, 247], ["HIV-1", "SPECIES", 464, 469], ["HIV-1", "SPECIES", 509, 514], ["influenza A viruses", "SPECIES", 559, 578], ["type A influenza virus", "SPECIES", 689, 711], ["the viral life cycle", "TREATMENT", 87, 107], ["PIs", "PROBLEM", 155, 158], ["the potential anti-SARS effects", "TREATMENT", 207, 238], ["HIV-1 protease inhibitors", "TREATMENT", 242, 267], ["PIs", "PROBLEM", 288, 291], ["3CL pro", "PROBLEM", 323, 330], ["these drugs", "TREATMENT", 384, 395], ["aspartic proteases", "PROBLEM", 430, 448], ["HIV-1 protease inhibitors", "TREATMENT", 509, 534], ["theoretical effects", "PROBLEM", 536, 555], ["influenza A viruses", "PROBLEM", 559, 578], ["PIs", "PROBLEM", 597, 600], ["a putative protease component", "TREATMENT", 610, 639], ["the RNA", "PROBLEM", 643, 650], ["directed RNA polymerase", "PROBLEM", 651, 674], ["the type A influenza virus", "PROBLEM", 685, 711], ["cannot be excluded", "UNCERTAINTY", 12, 30], ["influenza virus", "OBSERVATION", 696, 711]]], ["Orthomyxoviridae had long been believed not to encode for any proteases, until the observations of Hara et al. (2001a,b) suggested that a chymotrypsin-like protease might be hidden in the carboxy-terminal region of the PA subunit of RdRp (Hara et al., 2001a,b) .", [["Orthomyxoviridae", "CHEMICAL", 0, 16], ["carboxy", "CHEMICAL", 188, 195], ["Orthomyxoviridae", "GENE_OR_GENE_PRODUCT", 0, 16], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 138, 150], ["PA", "GENE_OR_GENE_PRODUCT", 219, 221], ["proteases", "PROTEIN", 62, 71], ["chymotrypsin-like protease", "PROTEIN", 138, 164], ["carboxy-terminal region", "PROTEIN", 188, 211], ["PA subunit", "PROTEIN", 219, 229], ["RdRp", "PROTEIN", 233, 237], ["Orthomyxoviridae", "TREATMENT", 0, 16], ["any proteases", "PROBLEM", 58, 71], ["a chymotrypsin-like protease", "TREATMENT", 136, 164]]], ["Their conclusion is based on the observed capacity of PA to cleave chymotrypsin-specific substrates and on its amidolytic activity, which is a peculiar feature of chymotrypsins (Hara et al., 2001a) .", [["PA", "GENE_OR_GENE_PRODUCT", 54, 56], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 67, 79], ["chymotrypsins", "SIMPLE_CHEMICAL", 163, 176], ["chymotrypsin", "PROTEIN", 67, 79], ["its amidolytic activity", "PROBLEM", 107, 130]]], ["Hara et al. (2001a) showed by mutational analysis that PA could be a serine protease with a Ser 624 in the active site.", [["Ser 624", "CHEMICAL", 92, 99], ["serine", "CHEMICAL", 69, 75], ["Ser", "CHEMICAL", 92, 95], ["PA", "GENE_OR_GENE_PRODUCT", 55, 57], ["Ser 624", "AMINO_ACID", 92, 99], ["serine protease", "PROTEIN", 69, 84], ["Ser 624", "PROTEIN", 92, 99], ["mutational analysis", "TEST", 30, 49], ["a serine protease", "TREATMENT", 67, 84]]], ["Abolition of this putative chymotrypsin-like protease activity of PA by substitution of the catalytic Ser 624 residue with Ala significantly decreased the yield of viral progeny (Toyoda et al., 2003) .", [["Ser 624", "CHEMICAL", 102, 109], ["Ala", "CHEMICAL", 123, 126], ["Ser", "CHEMICAL", 102, 105], ["Ala", "CHEMICAL", 123, 126], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 27, 39], ["PA", "GENE_OR_GENE_PRODUCT", 66, 68], ["Ser 624 residue", "AMINO_ACID", 102, 117], ["Ala", "AMINO_ACID", 123, 126], ["chymotrypsin", "PROTEIN", 27, 39], ["protease", "PROTEIN", 45, 53], ["this putative chymotrypsin", "TREATMENT", 13, 39], ["protease activity of PA", "TREATMENT", 45, 68]]], ["Hara et al. (2001a) identified the other active residues of the catalytic triad as His 510 and Asp 547 because of their level of conservation in the PAs of type A influenza viruses.", [["Asp 547", "CHEMICAL", 95, 102], ["influenza viruses", "DISEASE", 163, 180], ["His", "CHEMICAL", 83, 86], ["Asp", "CHEMICAL", 95, 98], ["Asp 547", "AMINO_ACID", 95, 102], ["type A influenza viruses", "ORGANISM", 156, 180], ["catalytic triad", "PROTEIN", 64, 79], ["type A influenza viruses", "SPECIES", 156, 180], ["Asp", "TEST", 95, 98], ["type A influenza viruses", "PROBLEM", 156, 180], ["influenza viruses", "OBSERVATION", 163, 180]]], ["However, a survey of public sequence databases has shown that Asp 547 is not conserved in all PAs of influenza A viruses.", [["Asp 547", "CHEMICAL", 62, 69], ["influenza A viruses", "DISEASE", 101, 120], ["Asp", "CHEMICAL", 62, 65], ["Asp 547", "AMINO_ACID", 62, 69], ["influenza A viruses", "ORGANISM", 101, 120], ["influenza A viruses", "SPECIES", 101, 120], ["public sequence databases", "TEST", 21, 46], ["Asp", "TEST", 62, 65], ["influenza A viruses", "PROBLEM", 101, 120], ["influenza", "OBSERVATION", 101, 110], ["viruses", "OBSERVATION", 113, 120]]], ["Theoretically, this observation does not contradict the Fig. 2 .", [["this observation", "TEST", 15, 31]]], ["Docking of the HIV-1 protease inhibitor (PI) saquinavir to the active site of the severe acute respiratory syndrome coronavirus (SARS-CoV) main protease.", [["saquinavir", "CHEMICAL", 45, 55], ["acute respiratory syndrome coronavirus", "DISEASE", 89, 127], ["saquinavir", "CHEMICAL", 45, 55], ["HIV-1", "GENE_OR_GENE_PRODUCT", 15, 20], ["PI", "SIMPLE_CHEMICAL", 41, 43], ["saquinavir", "SIMPLE_CHEMICAL", 45, 55], ["protease", "PROTEIN", 144, 152], ["HIV-1", "SPECIES", 15, 20], ["HIV-1", "SPECIES", 15, 20], ["severe acute respiratory syndrome coronavirus", "SPECIES", 82, 127], ["SARS-CoV", "SPECIES", 129, 137], ["the HIV-1 protease inhibitor", "TREATMENT", 11, 39], ["saquinavir", "TREATMENT", 45, 55], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 78, 127], ["main protease", "TREATMENT", 139, 152], ["active site", "OBSERVATION_MODIFIER", 63, 74], ["severe", "OBSERVATION_MODIFIER", 82, 88], ["acute", "OBSERVATION_MODIFIER", 89, 94], ["respiratory syndrome coronavirus", "OBSERVATION", 95, 127]]], ["The molecular surface corresponding to the catalytic His 41 and Cys 145 residues is shown in blue and red, respectively.", [["surface", "ANATOMY", 14, 21], ["His", "CHEMICAL", 53, 56], ["Cys", "CHEMICAL", 64, 67], ["surface", "CELLULAR_COMPONENT", 14, 21], ["Cys", "AMINO_ACID", 64, 67], ["catalytic His 41", "PROTEIN", 43, 59], ["the catalytic His", "TEST", 39, 56], ["Cys 145 residues", "TEST", 64, 80], ["surface", "OBSERVATION_MODIFIER", 14, 21]]], ["(For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) theory of Hara et al. because chymotrypsin-like proteases can be functionally active proteases without the aspartate residue.", [["aspartate", "CHEMICAL", 238, 247], ["aspartate", "CHEMICAL", 238, 247], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 161, 173], ["aspartate", "SIMPLE_CHEMICAL", 238, 247], ["chymotrypsin-like proteases", "PROTEIN", 161, 188], ["proteases", "PROTEIN", 216, 225], ["chymotrypsin-like proteases", "PROBLEM", 161, 188], ["functionally active proteases", "PROBLEM", 196, 225], ["the aspartate residue", "PROBLEM", 234, 255], ["active", "OBSERVATION", 209, 215]]], ["One example for this is the above-described catalytic dyad of 3CL pro .", [["catalytic dyad", "PROTEIN", 44, 58], ["3CL pro", "PROTEIN", 62, 69]]], ["Alternatively, other Lewis bases in the vicinity of His 510 might replace the Asp residue as a third component of the triad.Expanding the applications of HIV-1 protease inhibitors: theoretical effects on influenza A virusesIn line with the observations of Hara et al., the carboxyterminal region of PA, believed to be responsible for its chymotrypsin-like activity, in my analysis showed a significant though moderate similarity with \u2423-chymotrypsin (\u223c21% identity), according to CLUSTALW calculations (http://npsa-pbil.ibcp.fr/cgi-bin/npsa automat.pl? page=npsa clustalw.html), and His 510 and Ser 624 might correspond to His 57 and Ser 195 of chymotrypsin (Hara et al., 2001a) .", [["His 510", "CHEMICAL", 52, 59], ["Asp", "CHEMICAL", 78, 81], ["influenza A viruses", "DISEASE", 204, 223], ["\u2423-chymotrypsin", "CHEMICAL", 434, 448], ["Lewis bases", "CHEMICAL", 21, 32], ["His 510", "CHEMICAL", 52, 59], ["Asp", "CHEMICAL", 78, 81], ["\u2423-chymotrypsin", "CHEMICAL", 434, 448], ["His", "CHEMICAL", 582, 585], ["Ser", "CHEMICAL", 594, 597], ["His", "CHEMICAL", 622, 625], ["Ser", "CHEMICAL", 633, 636], ["HIV-1", "ORGANISM", 154, 159], ["influenza A viruses", "ORGANISM", 204, 223], ["PA", "GENE_OR_GENE_PRODUCT", 299, 301], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 338, 350], ["\u2423-chymotrypsin", "SIMPLE_CHEMICAL", 434, 448], ["html", "GENE_OR_GENE_PRODUCT", 571, 575], ["His 510", "GENE_OR_GENE_PRODUCT", 582, 589], ["Ser 624", "AMINO_ACID", 594, 601], ["Ser 195", "AMINO_ACID", 633, 640], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 644, 656], ["carboxyterminal region", "PROTEIN", 273, 295], ["chymotrypsin", "PROTEIN", 338, 350], ["\u2423-chymotrypsin", "PROTEIN", 434, 448], ["html", "PROTEIN", 571, 575], ["chymotrypsin", "PROTEIN", 644, 656], ["HIV-1", "SPECIES", 154, 159], ["influenza A viruses", "SPECIES", 204, 223], ["HIV-1", "SPECIES", 154, 159], ["influenza A viruses", "SPECIES", 204, 223], ["the Asp residue", "PROBLEM", 74, 89], ["HIV-1 protease inhibitors", "TREATMENT", 154, 179], ["theoretical effects", "PROBLEM", 181, 200], ["influenza A viruses", "PROBLEM", 204, 223], ["its chymotrypsin", "PROBLEM", 334, 350], ["my analysis", "TEST", 369, 380], ["Lewis", "ANATOMY_MODIFIER", 21, 26], ["bases", "ANATOMY_MODIFIER", 27, 32]]], ["According to my calculations, the second most similar protein to the carboxy-terminal region of PA was, among the proteins analysed, SARS-CoV 3CL pro .", [["carboxy", "CHEMICAL", 69, 76], ["PA", "GENE_OR_GENE_PRODUCT", 96, 98], ["carboxy-terminal region", "PROTEIN", 69, 92], ["SARS-CoV 3CL pro", "PROTEIN", 133, 149], ["SARS-CoV", "SPECIES", 133, 141], ["the proteins", "TEST", 110, 122]]], ["As shown in Fig. 3 , PA shares 43% sequence similarity and 19.1% identity with 3CL pro .", [["PA", "GENE_OR_GENE_PRODUCT", 21, 23], ["3CL pro", "PROTEIN", 79, 86], ["sequence similarity", "TEST", 35, 54], ["3CL pro", "TREATMENT", 79, 86]]], ["This level of similarity is one of the highest of those found with the other chymotrypsin-like proteases analysed (data not shown).Expanding the applications of HIV-1 protease inhibitors: theoretical effects on influenza A virusesThe sequence similarity between PA and 3CL pro raises the hypothesis that PI molecules might bind PA similarly to 3CL pro .", [["influenza A viruses", "DISEASE", 211, 230], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 77, 89], ["HIV-1", "ORGANISM", 161, 166], ["influenza A viruses", "ORGANISM", 211, 230], ["PA", "GENE_OR_GENE_PRODUCT", 262, 264], ["PI molecules", "GENE_OR_GENE_PRODUCT", 304, 316], ["PA", "GENE_OR_GENE_PRODUCT", 328, 330], ["chymotrypsin-like proteases", "PROTEIN", 77, 104], ["3CL pro", "PROTEIN", 269, 276], ["PI molecules", "PROTEIN", 304, 316], ["3CL pro", "PROTEIN", 344, 351], ["HIV-1", "SPECIES", 161, 166], ["influenza A viruses", "SPECIES", 211, 230], ["HIV-1", "SPECIES", 161, 166], ["influenza A viruses", "SPECIES", 211, 230], ["the other chymotrypsin", "PROBLEM", 67, 89], ["HIV-1 protease inhibitors", "TREATMENT", 161, 186], ["theoretical effects", "PROBLEM", 188, 207], ["influenza A viruses", "PROBLEM", 211, 230], ["PA and 3CL pro", "TREATMENT", 262, 276], ["PI molecules", "TREATMENT", 304, 316]]], ["Although substitution of the putative catalytic Ser 624 residue of the protease activity of PA was differently reported to affect viral replication (Fodor et al., 2002; Toyoda et al., 2003) , the log reduction of viral replication in mice intranasally infected with a virus expressing a Ser 624 > Ala PA mutant lacking protease activity (9.3 \u00d7 10 3 PFU in mutant virus-infected mice versus 4.0 \u00d7 10 4 PFU in controls) observed by Toyoda et al. (2003) suggests that this protein merits attention as a target for pharmacological interventions.", [["Ser", "CHEMICAL", 48, 51], ["Ser", "CHEMICAL", 287, 290], ["Ala", "CHEMICAL", 297, 300], ["Ser 624", "AMINO_ACID", 48, 55], ["PA", "GENE_OR_GENE_PRODUCT", 92, 94], ["mice", "ORGANISM", 234, 238], ["PA", "GENE_OR_GENE_PRODUCT", 301, 303], ["mutant virus", "ORGANISM", 356, 368], ["mice", "ORGANISM", 378, 382], ["protease", "PROTEIN", 71, 79], ["Ser 624 > Ala PA mutant", "PROTEIN", 287, 310], ["protease", "PROTEIN", 319, 327], ["mice", "SPECIES", 234, 238], ["mice", "SPECIES", 378, 382], ["mice", "SPECIES", 234, 238], ["mice", "SPECIES", 378, 382], ["the protease activity of PA", "TREATMENT", 67, 94], ["the log reduction", "TREATMENT", 192, 209], ["viral replication", "TREATMENT", 213, 230], ["a virus", "PROBLEM", 266, 273], ["Ala PA", "TEST", 297, 303], ["protease activity", "TEST", 319, 336], ["mutant virus", "PROBLEM", 356, 368], ["pharmacological interventions", "TREATMENT", 511, 540], ["viral replication", "OBSERVATION", 213, 230]]], ["Similar mutants constructed by Fodor et al. in a previous study (2002) had displayed no reduced replicative capacity in cell cultures.", [["cell cultures", "ANATOMY", 120, 133], ["cell cultures", "CELL", 120, 133], ["cell cultures", "CELL_LINE", 120, 133], ["a previous study", "TEST", 47, 63], ["reduced replicative capacity", "PROBLEM", 88, 116], ["cell cultures", "TEST", 120, 133], ["no", "UNCERTAINTY", 85, 87], ["reduced", "OBSERVATION_MODIFIER", 88, 95], ["replicative capacity", "OBSERVATION", 96, 116], ["cell cultures", "OBSERVATION", 120, 133]]], ["These different results are likely to be attributed to the fact that Toyoda et al. conducted their tests in a mouse model whereas Fodor and coworkers monitored viral replication in a cell line model.", [["cell line", "ANATOMY", 183, 192], ["mouse", "ORGANISM", 110, 115], ["cell line", "CELL", 183, 192], ["mouse", "SPECIES", 110, 115], ["mouse", "SPECIES", 110, 115], ["their tests", "TEST", 93, 104], ["viral replication", "TREATMENT", 160, 177], ["a cell line model", "TREATMENT", 181, 198], ["likely to be attributed to", "UNCERTAINTY", 28, 54], ["cell line", "OBSERVATION", 183, 192]]], ["A cell line may deviate from in vivo conditions in any of a number of molecular characteristics The different results between in vitro and in vivo models are reminiscent of the results on SARS-CoV 3CL pro inhibition described in the previous sections of this paper and reflect the need of further research.", [["cell line", "ANATOMY", 2, 11], ["cell line", "CELL", 2, 11], ["cell line", "CELL_LINE", 2, 11], ["SARS-CoV", "SPECIES", 188, 196], ["A cell line", "TREATMENT", 0, 11], ["CoV 3CL pro inhibition", "TREATMENT", 193, 215], ["cell line", "OBSERVATION", 2, 11]]], ["Moreover, Fodor et al. report in the same paper that the His 510 > Ala substitution in PA produces replication-defective viruses.", [["Ala", "CHEMICAL", 67, 70], ["His", "CHEMICAL", 57, 60], ["Ala", "CHEMICAL", 67, 70], ["Ala", "AMINO_ACID", 67, 70], ["PA", "GENE_OR_GENE_PRODUCT", 87, 89], ["Ala substitution in PA", "TREATMENT", 67, 89], ["defective viruses", "PROBLEM", 111, 128], ["defective viruses", "OBSERVATION", 111, 128]]], ["Of note, His 510 is a putative catalytic residue of the possible chymotrypsin activity.", [["His", "CHEMICAL", 9, 12], ["His 510", "GENE_OR_GENE_PRODUCT", 9, 16], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 65, 77], ["chymotrypsin", "PROTEIN", 65, 77], ["chymotrypsin activity", "PROBLEM", 65, 86], ["possible", "UNCERTAINTY", 56, 64], ["chymotrypsin activity", "OBSERVATION", 65, 86]]], ["These authors attribute their observation to an impaired capacity of the mutated RdRp to transcribe the viral RNA (vRNA) into mRNA because of a defect in the endonucleolytic activity required to exert this function.", [["RdRp", "GENE_OR_GENE_PRODUCT", 81, 85], ["mutated RdRp", "PROTEIN", 73, 85], ["viral RNA", "RNA", 104, 113], ["vRNA", "RNA", 115, 119], ["mRNA", "RNA", 126, 130], ["an impaired capacity", "PROBLEM", 45, 65], ["the mutated RdRp", "PROBLEM", 69, 85], ["the viral RNA (vRNA) into mRNA", "PROBLEM", 100, 130], ["a defect", "PROBLEM", 142, 150], ["the endonucleolytic activity", "PROBLEM", 154, 182], ["viral RNA", "OBSERVATION", 104, 113], ["defect", "OBSERVATION", 144, 150], ["endonucleolytic activity", "OBSERVATION", 158, 182]]], ["Indeed, all three RdRp subunits (PB1, PB2 and PA) are required for efficient synthesis of RNA transcripts.", [["PB1", "GENE_OR_GENE_PRODUCT", 33, 36], ["PB2", "GENE_OR_GENE_PRODUCT", 38, 41], ["PA", "GENE_OR_GENE_PRODUCT", 46, 48], ["RdRp subunits", "PROTEIN", 18, 31], ["PB1", "PROTEIN", 33, 36], ["PB2", "PROTEIN", 38, 41], ["PA", "PROTEIN", 46, 48], ["RNA transcripts", "RNA", 90, 105], ["all three RdRp subunits", "TREATMENT", 8, 31], ["PB1, PB2 and PA)", "TREATMENT", 33, 49], ["efficient synthesis of RNA transcripts", "TREATMENT", 67, 105], ["RNA transcripts", "OBSERVATION", 90, 105]]], ["PB1 interacts both with PB2 and PA, and a low resolution structural model of the influenza ribonucleoprotein particle generated by electron microscopy suggests a rather compact structure for the polymerase complex (Mart\u00edn-Benito et al., 2001) .", [["PB1", "GENE_OR_GENE_PRODUCT", 0, 3], ["PB2", "GENE_OR_GENE_PRODUCT", 24, 27], ["PA", "GENE_OR_GENE_PRODUCT", 32, 34], ["PB1", "DNA", 0, 3], ["PB2", "PROTEIN", 24, 27], ["polymerase complex", "PROTEIN", 195, 213], ["PB2", "TEST", 24, 27], ["PA", "TEST", 32, 34], ["a low resolution structural model of the influenza ribonucleoprotein particle", "PROBLEM", 40, 117], ["electron microscopy", "TEST", 131, 150], ["the polymerase complex", "PROBLEM", 191, 213]]], ["The observations of Toyoda and Fodor are not necessarily mutually exclusive.", [["Toyoda", "TREATMENT", 20, 26], ["Fodor", "TREATMENT", 31, 36]]], ["Indeed, His 510 does not seem to be directly involved in the endonucleolytic reaction (Fodor et al., 2002) .Expanding the applications of HIV-1 protease inhibitors: theoretical effects on influenza A virusesIn any event, if the reduction of viral replication observed in vivo by Toyoda and coworkers should become achievable in humans treated with PA inhibitors, it might contribute to attenuate the life-threatening manifestations of avian influenza.", [["His 510", "CHEMICAL", 8, 15], ["influenza A viruses", "DISEASE", 188, 207], ["avian influenza", "DISEASE", 435, 450], ["His 510", "CHEMICAL", 8, 15], ["HIV-1", "ORGANISM", 138, 143], ["influenza A viruses", "ORGANISM", 188, 207], ["humans", "ORGANISM", 328, 334], ["PA", "GENE_OR_GENE_PRODUCT", 348, 350], ["avian influenza", "ORGANISM", 435, 450], ["HIV-1", "SPECIES", 138, 143], ["influenza A viruses", "SPECIES", 188, 207], ["humans", "SPECIES", 328, 334], ["HIV-1", "SPECIES", 138, 143], ["influenza A viruses", "SPECIES", 188, 207], ["humans", "SPECIES", 328, 334], ["the endonucleolytic reaction", "PROBLEM", 57, 85], ["HIV-1 protease inhibitors", "TREATMENT", 138, 163], ["theoretical effects", "PROBLEM", 165, 184], ["influenza A viruses", "PROBLEM", 188, 207], ["viral replication", "TREATMENT", 241, 258], ["PA inhibitors", "TREATMENT", 348, 361], ["avian influenza", "PROBLEM", 435, 450], ["viral replication", "OBSERVATION", 241, 258]]], ["Alternatively, PA inhibitors might be used in combination strategies in order to impair the viral life cycle at multiple steps.Expanding the applications of HIV-1 protease inhibitors: theoretical effects on influenza A virusesThe 3D structure of RdRp has not been crystallographically solved yet, and such studies will be necessary to develop specific inhibitors.", [["influenza A viruses", "DISEASE", 207, 226], ["PA", "GENE_OR_GENE_PRODUCT", 15, 17], ["HIV-1", "ORGANISM", 157, 162], ["influenza A viruses", "ORGANISM", 207, 226], ["RdRp", "ORGANISM", 246, 250], ["RdRp", "PROTEIN", 246, 250], ["HIV-1", "SPECIES", 157, 162], ["HIV-1", "SPECIES", 157, 162], ["influenza A viruses", "SPECIES", 207, 226], ["PA inhibitors", "TREATMENT", 15, 28], ["HIV-1 protease inhibitors", "TREATMENT", 157, 182], ["theoretical effects", "PROBLEM", 184, 203], ["influenza A viruses", "PROBLEM", 207, 226], ["RdRp", "PROBLEM", 246, 250], ["such studies", "TEST", 301, 313], ["specific inhibitors", "TREATMENT", 343, 362]]], ["As the availability of an Xray structure of PA is likely to take a long time, I have modelled the chymotrypsin-like component of the PA of a H5N1 chicken influenza virus isolate (NCBI accession number: AAV48550) based on the X-ray solved structure of bovine \u2423-chymotrypsin (Protein Data Bank accession number: 1OXG).", [["influenza virus", "DISEASE", 154, 169], ["PA", "GENE_OR_GENE_PRODUCT", 44, 46], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 98, 110], ["PA", "GENE_OR_GENE_PRODUCT", 133, 135], ["H5N1", "ORGANISM", 141, 145], ["chicken influenza virus", "ORGANISM", 146, 169], ["bovine", "ORGANISM", 251, 257], ["\u2423-chymotrypsin", "SIMPLE_CHEMICAL", 258, 272], ["chymotrypsin", "PROTEIN", 98, 110], ["bovine \u2423-chymotrypsin", "PROTEIN", 251, 272], ["Protein Data Bank accession number: 1OXG", "PROTEIN", 274, 314], ["H5N1 chicken influenza virus", "SPECIES", 141, 169], ["bovine", "SPECIES", 251, 257], ["H5N1 chicken influenza virus", "SPECIES", 141, 169], ["an Xray structure", "TEST", 23, 40], ["the chymotrypsin", "TREATMENT", 94, 110], ["a H5N1 chicken influenza virus isolate", "TREATMENT", 139, 177]]], ["Although it is usually difficult to predict protein folding based on the 3D structure of homologues with less than 50% of sequence identity, the approach of homology modelling is validated in this case by experimental observations showing that chymotrypsin-like proteases show an extremely conserved 3D folding, even when homology in the primary structure is quite low.", [["chymotrypsin-like proteases", "GENE_OR_GENE_PRODUCT", 244, 271], ["chymotrypsin-like proteases", "PROTEIN", 244, 271], ["protein folding", "PROBLEM", 44, 59], ["experimental observations", "TEST", 205, 230], ["chymotrypsin-like proteases", "PROBLEM", 244, 271], ["low", "OBSERVATION_MODIFIER", 365, 368]]], ["The 3D architecture of SARS-CoV 3CL pro described in Fig. 1 constitutes such an example.", [["SARS", "DISEASE", 23, 27], ["SARS-CoV 3CL pro", "PROTEIN", 23, 39], ["SARS-CoV", "SPECIES", 23, 31], ["SARS", "PROBLEM", 23, 27], ["CoV 3CL pro", "TREATMENT", 28, 39], ["SARS", "OBSERVATION", 23, 27]]], ["Despite its chymotrypsin structure, 3CL pro shares only 10.5% sequence identity with \u2423-chymotrypsin (Fig. 1) , which is lower than that shared between \u2423-chymotrypsin and PA.", [["chymotrypsin", "GENE_OR_GENE_PRODUCT", 12, 24], ["\u2423-chymotrypsin", "SIMPLE_CHEMICAL", 85, 99], ["\u2423-chymotrypsin", "GENE_OR_GENE_PRODUCT", 151, 165], ["PA", "GENE_OR_GENE_PRODUCT", 170, 172], ["chymotrypsin", "PROTEIN", 12, 24], ["3CL pro", "PROTEIN", 36, 43], ["\u2423-chymotrypsin", "PROTEIN", 85, 99], ["\u2423-chymotrypsin", "PROTEIN", 151, 165], ["its chymotrypsin structure", "PROBLEM", 8, 34]]], ["This extremely conserved 3D folding is probably forced by evolution in order to maintain the activities of chymotrypsin-like enzymes.", [["chymotrypsin-like enzymes", "GENE_OR_GENE_PRODUCT", 107, 132], ["chymotrypsin-like enzymes", "PROTEIN", 107, 132], ["chymotrypsin", "TEST", 107, 119], ["enzymes", "TEST", 125, 132], ["probably", "UNCERTAINTY", 39, 47], ["forced", "OBSERVATION_MODIFIER", 48, 54]]], ["It is moreover worth to be noted that PA sequences may vary a lot even among influenza A viruses.", [["influenza A viruses", "DISEASE", 77, 96], ["PA", "GENE_OR_GENE_PRODUCT", 38, 40], ["influenza A viruses", "ORGANISM", 77, 96], ["influenza A viruses", "SPECIES", 77, 96], ["PA sequences", "TEST", 38, 50], ["influenza A viruses", "PROBLEM", 77, 96], ["viruses", "OBSERVATION", 89, 96]]], ["However, according to my estimations, their level of sequence similarity with \u2423-chymotrypsin resulted to be similar, independently of the viral variants analysed (data not shown).", [["\u2423-chymotrypsin", "CHEMICAL", 78, 92], ["\u2423-chymotrypsin", "GENE_OR_GENE_PRODUCT", 78, 92], ["\u2423-chymotrypsin", "PROTEIN", 78, 92], ["the viral variants", "PROBLEM", 134, 152], ["viral variants", "OBSERVATION", 138, 152]]], ["Since above-mentioned research of Fodor et al. and Tayada and coworkers both suggest that the carboxy-terminal region of PA plays a role in viral replication, it is expected to maintain some conserved 3D architecture.", [["carboxy", "CHEMICAL", 94, 101], ["PA", "GENE_OR_GENE_PRODUCT", 121, 123], ["carboxy-terminal region", "PROTEIN", 94, 117], ["PA", "PROTEIN", 121, 123], ["viral replication", "TREATMENT", 140, 157], ["viral replication", "OBSERVATION", 140, 157]]], ["Therefore, it is possible to hypothesise that there are positions that allow mutations and positions which do not, or at least, are compatible with some kinds of mutations only.", [["mutations", "PROBLEM", 162, 171], ["compatible with", "UNCERTAINTY", 132, 147], ["mutations", "OBSERVATION", 162, 171]]], ["As the types of mutations allowed often depend on mutations occurring in other positions, this is a very complex matter, not resolvable by simple sequence alignments.", [["mutations", "PROBLEM", 16, 25], ["mutations", "PROBLEM", 50, 59], ["a very complex matter", "PROBLEM", 98, 119]]], ["A specific algorithm will be necessary to clarify this point, and this could be an interesting aim for future research.Expanding the applications of HIV-1 protease inhibitors: theoretical effects on influenza A virusesComputational simulations of the docking of three wellknown PIs (ritonavir, saquinavir and indinavir) to PA indicate ritonavir as the compound with the highest GOLD fitness score (i.e., 64.67), slightly higher that obtained with SARS-CoV 3CL pro , and estimated to correspond to a K i of \u223c10 \u22125 M, well within the steady-state concentrations reachable in vivo at a dosage used in the treatment for HIV-1/AIDS.", [["ritonavir", "CHEMICAL", 283, 292], ["saquinavir", "CHEMICAL", 294, 304], ["indinavir", "CHEMICAL", 309, 318], ["ritonavir", "CHEMICAL", 335, 344], ["HIV-1/AIDS", "DISEASE", 616, 626], ["ritonavir", "CHEMICAL", 283, 292], ["saquinavir", "CHEMICAL", 294, 304], ["indinavir", "CHEMICAL", 309, 318], ["ritonavir", "CHEMICAL", 335, 344], ["HIV-1", "ORGANISM", 149, 154], ["ritonavir", "SIMPLE_CHEMICAL", 283, 292], ["saquinavir", "SIMPLE_CHEMICAL", 294, 304], ["indinavir", "SIMPLE_CHEMICAL", 309, 318], ["PA", "GENE_OR_GENE_PRODUCT", 323, 325], ["ritonavir", "SIMPLE_CHEMICAL", 335, 344], ["HIV-1", "ORGANISM", 616, 621], ["HIV-1", "SPECIES", 149, 154], ["HIV-1", "SPECIES", 616, 621], ["HIV-1", "SPECIES", 149, 154], ["SARS-CoV", "SPECIES", 447, 455], ["HIV-1", "SPECIES", 616, 621], ["A specific algorithm", "TEST", 0, 20], ["HIV-1 protease inhibitors", "TREATMENT", 149, 174], ["theoretical effects", "PROBLEM", 176, 195], ["influenza", "PROBLEM", 199, 208], ["three wellknown PIs", "TREATMENT", 262, 281], ["ritonavir", "TREATMENT", 283, 292], ["saquinavir", "TREATMENT", 294, 304], ["indinavir", "TREATMENT", 309, 318], ["ritonavir", "TREATMENT", 335, 344], ["a K i", "TEST", 497, 502], ["the treatment", "TREATMENT", 598, 611], ["HIV", "PROBLEM", 616, 619], ["AIDS", "PROBLEM", 622, 626]]], ["Similar results have been obtained by evaluating the docking of ritonavir to a PA structure calculated by the software ROSETTA, which predicts the 3D structure ab initio based on protein sequence (http://www.bioinfo.rpi. edu/\u223cbystrc/hmmstr/server.php).", [["ritonavir", "CHEMICAL", 64, 73], ["ritonavir", "CHEMICAL", 64, 73], ["ritonavir", "SIMPLE_CHEMICAL", 64, 73], ["PA", "GENE_OR_GENE_PRODUCT", 79, 81], ["\u223cbystrc", "PROTEIN", 225, 232], ["hmmstr", "PROTEIN", 233, 239], ["edu/\u223cbystrc/hmmstr/server.php", "SPECIES", 221, 250], ["ritonavir", "TREATMENT", 64, 73], ["protein sequence", "TEST", 179, 195]]], ["Fig. 4 shows the theoretical docking of ritonavir inside the binding cavity of PA.", [["ritonavir", "CHEMICAL", 40, 49], ["ritonavir", "CHEMICAL", 40, 49], ["ritonavir", "SIMPLE_CHEMICAL", 40, 49], ["PA", "GENE_OR_GENE_PRODUCT", 79, 81], ["ritonavir", "TREATMENT", 40, 49]]], ["According to this model, significant hydrogen bonding might occur with both the putatively catalytic His 510 and Ser 624 .", [["Ser 624", "CHEMICAL", 113, 120], ["hydrogen", "CHEMICAL", 37, 45], ["His", "CHEMICAL", 101, 104], ["Ser", "CHEMICAL", 113, 116], ["hydrogen", "SIMPLE_CHEMICAL", 37, 45], ["Ser 624", "AMINO_ACID", 113, 120], ["catalytic His 510", "PROTEIN", 91, 108], ["Ser 624", "PROTEIN", 113, 120], ["significant hydrogen bonding", "PROBLEM", 25, 53], ["significant", "OBSERVATION_MODIFIER", 25, 36], ["hydrogen bonding", "OBSERVATION", 37, 53]]], ["Therefore, if the above reviewed observations of both Toyoda et al. and Fodor et al. are correct, it is possible to speculate that PIs might inhibit either the proteolytic or the endonucleolytic function of PA.", [["PA", "GENE_OR_GENE_PRODUCT", 207, 209], ["PIs", "PROBLEM", 131, 134], ["the proteolytic", "PROBLEM", 156, 171]]], ["Theoretical docking of an HIV-1 protease inhibitor (ritonavir) to the active site of the chymotrypsin-like protease domains of the PA subunit of the RNA-dependent RNA polymerase of an H5N1 avian influenza virus.", [["ritonavir", "CHEMICAL", 52, 61], ["influenza virus", "DISEASE", 195, 210], ["ritonavir", "CHEMICAL", 52, 61], ["HIV-1 protease", "GENE_OR_GENE_PRODUCT", 26, 40], ["ritonavir", "SIMPLE_CHEMICAL", 52, 61], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 89, 101], ["PA", "GENE_OR_GENE_PRODUCT", 131, 133], ["H5N1 avian influenza virus", "ORGANISM", 184, 210], ["chymotrypsin-like protease domains", "PROTEIN", 89, 123], ["PA subunit", "PROTEIN", 131, 141], ["RNA-dependent RNA polymerase", "PROTEIN", 149, 177], ["HIV-1", "SPECIES", 26, 31], ["H5N1 avian influenza virus", "SPECIES", 184, 210], ["HIV-1", "SPECIES", 26, 31], ["H5N1 avian influenza virus", "SPECIES", 184, 210], ["an HIV-1 protease inhibitor", "TREATMENT", 23, 50], ["ritonavir", "TREATMENT", 52, 61], ["the chymotrypsin", "TREATMENT", 85, 101], ["protease domains", "TREATMENT", 107, 123], ["the PA subunit", "TREATMENT", 127, 141], ["dependent RNA polymerase", "PROBLEM", 153, 177], ["an H5N1 avian influenza virus", "PROBLEM", 181, 210]]], ["The three-dimensional structure of the COOH-terminal portion of PA was obtained by homology molecular modelling using the software tool SWISS MODEL (available at www.expasy.org).", [["COOH", "CHEMICAL", 39, 43], ["PA", "GENE_OR_GENE_PRODUCT", 64, 66], ["COOH-terminal portion", "PROTEIN", 39, 60], ["COOH", "OBSERVATION", 39, 43]]], ["The model was then adjusted manually so as to match the distances between the catalytic amino acids determined by X-ray in bovine \u2423-chymotrypsin (Protein Data Bank accession number: 1OXG).", [["amino acids", "CHEMICAL", 88, 99], ["amino acids", "CHEMICAL", 88, 99], ["amino acids", "AMINO_ACID", 88, 99], ["bovine", "ORGANISM", 123, 129], ["\u2423-chymotrypsin", "SIMPLE_CHEMICAL", 130, 144], ["catalytic amino acids", "PROTEIN", 78, 99], ["bovine \u2423-chymotrypsin", "PROTEIN", 123, 144], ["Protein Data Bank accession number: 1OXG", "PROTEIN", 146, 186], ["bovine", "SPECIES", 123, 129], ["the catalytic amino acids", "TREATMENT", 74, 99], ["X-ray", "TEST", 114, 119]]], ["The molecular surface corresponding to His 510 , Asp 547 and Ser 624 is shown in blue, yellow and violet, respectively.", [["surface", "ANATOMY", 14, 21], ["Asp 547", "CHEMICAL", 49, 56], ["Ser 624", "CHEMICAL", 61, 68], ["His", "CHEMICAL", 39, 42], ["Asp", "CHEMICAL", 49, 52], ["Ser", "CHEMICAL", 61, 64], ["violet", "CHEMICAL", 98, 104], ["surface", "CELLULAR_COMPONENT", 14, 21], ["Asp 547", "AMINO_ACID", 49, 56], ["Ser 624", "AMINO_ACID", 61, 68], ["violet", "SIMPLE_CHEMICAL", 98, 104], ["Asp", "TEST", 49, 52], ["surface", "OBSERVATION_MODIFIER", 14, 21]]], ["(For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Concluding remarksThe results so far obtained suggest that PIs should be taken into consideration for further study in the context of SARS and, maybe, influenza, including avian influenza viruses.", [["SARS", "DISEASE", 264, 268], ["influenza", "DISEASE", 281, 290], ["avian influenza viruses", "DISEASE", 302, 325], ["avian influenza viruses", "ORGANISM", 302, 325], ["avian influenza", "SPECIES", 302, 317], ["PIs", "TREATMENT", 189, 192], ["further study", "TEST", 232, 245], ["SARS", "PROBLEM", 264, 268], ["influenza", "PROBLEM", 281, 290], ["avian influenza viruses", "PROBLEM", 302, 325]]], ["The evidence for an inhibitory effect of PIs against the etiologic agents of these diseases is still very preliminary in the case of SARS and only theoretical in the case of type A influenza viruses.", [["PIs", "CHEMICAL", 41, 44], ["SARS", "DISEASE", 133, 137], ["influenza viruses", "DISEASE", 181, 198], ["PIs", "SIMPLE_CHEMICAL", 41, 44], ["type A influenza viruses", "ORGANISM", 174, 198], ["type A influenza viruses", "SPECIES", 174, 198], ["PIs", "TREATMENT", 41, 44], ["these diseases", "PROBLEM", 77, 91], ["SARS", "PROBLEM", 133, 137], ["type A influenza viruses", "PROBLEM", 174, 198], ["inhibitory effect", "OBSERVATION", 20, 37], ["diseases", "OBSERVATION", 83, 91], ["influenza viruses", "OBSERVATION", 181, 198]]], ["Anyway, a demonstration of effects of PIs on chymotrypsin-like viral proteases might open new avenues to antiviral research.", [["chymotrypsin", "GENE_OR_GENE_PRODUCT", 45, 57], ["chymotrypsin", "PROTEIN", 45, 57], ["viral proteases", "PROTEIN", 63, 78], ["PIs", "PROBLEM", 38, 41], ["chymotrypsin", "TREATMENT", 45, 57], ["viral proteases", "PROBLEM", 63, 78], ["antiviral research", "TREATMENT", 105, 123]]], ["As for the potential effects of PIs on SARS, more extensive studies on the inhibitory effects of PIs on 3CL pro , as well as studies on the causal link between inhibition of 3CL pro and antiviral effects, should be necessary.", [["SARS", "DISEASE", 39, 43], ["3CL pro", "GENE_OR_GENE_PRODUCT", 104, 111], ["3CL pro", "GENE_OR_GENE_PRODUCT", 174, 181], ["3CL pro", "PROTEIN", 104, 111], ["PIs on SARS", "PROBLEM", 32, 43], ["extensive studies", "TEST", 50, 67], ["3CL pro", "TREATMENT", 104, 111], ["3CL pro", "TREATMENT", 174, 181], ["antiviral effects", "TREATMENT", 186, 203]]], ["Furthermore, from the literature analysed, the need of standardisation of the in vitro testing of anti-SARS compounds is apparent, in order to better compare the results obtained by independent groups.", [["anti-SARS", "SIMPLE_CHEMICAL", 98, 107], ["the in vitro testing", "TEST", 74, 94]]], ["Moreover, more studies evaluating the effects of PIs in combination with other anti-SARS drugs are needed.", [["PIs", "CHEMICAL", 49, 52], ["PIs", "TREATMENT", 49, 52], ["other anti-SARS drugs", "TREATMENT", 73, 94]]], ["We recently demonstrated a synergistic anti-HIV-1 effect of PIs in combination with chloroquine (Savarino et al., 2004b) .", [["PIs", "CHEMICAL", 60, 63], ["chloroquine", "CHEMICAL", 84, 95], ["chloroquine", "CHEMICAL", 84, 95], ["PIs", "SIMPLE_CHEMICAL", 60, 63], ["chloroquine", "SIMPLE_CHEMICAL", 84, 95], ["a synergistic anti-HIV", "TREATMENT", 25, 47], ["PIs", "TREATMENT", 60, 63], ["chloroquine", "TREATMENT", 84, 95], ["synergistic", "OBSERVATION_MODIFIER", 27, 38], ["anti-HIV", "OBSERVATION", 39, 47]]], ["This synergism is associated to combined inhibitory effects of chloroquine and PIs on the drug-extruding pumps P-glycoprotein and multidrug resistance associated protein 1 (MRP1), likely to result in increased drug concentrations (Savarino et al., 2004b) .", [["chloroquine", "CHEMICAL", 63, 74], ["PIs", "CHEMICAL", 79, 82], ["chloroquine", "CHEMICAL", 63, 74], ["chloroquine", "SIMPLE_CHEMICAL", 63, 74], ["PIs", "SIMPLE_CHEMICAL", 79, 82], ["multidrug resistance associated protein 1", "GENE_OR_GENE_PRODUCT", 130, 171], ["MRP1", "GENE_OR_GENE_PRODUCT", 173, 177], ["P", "PROTEIN", 111, 112], ["glycoprotein", "PROTEIN", 113, 125], ["multidrug resistance associated protein 1", "PROTEIN", 130, 171], ["MRP1", "PROTEIN", 173, 177], ["chloroquine", "TREATMENT", 63, 74], ["PIs", "TREATMENT", 79, 82], ["the drug", "TREATMENT", 86, 94], ["glycoprotein", "TREATMENT", 113, 125], ["multidrug resistance associated protein", "PROBLEM", 130, 169], ["increased drug concentrations", "PROBLEM", 200, 229], ["increased", "OBSERVATION_MODIFIER", 200, 209], ["drug concentrations", "OBSERVATION", 210, 229]]], ["As chloroquine is emerging as a new promising anti-SARS compound in vitro (Keyaerts et al., 2004) , PI/chloroquine combinations should be tested in SARS-CoV-infected cell cultures, in order to increase the potential pharmacological combinations available.", [["cell cultures", "ANATOMY", 166, 179], ["chloroquine", "CHEMICAL", 3, 14], ["PI", "CHEMICAL", 100, 102], ["chloroquine", "CHEMICAL", 103, 114], ["SARS-CoV-infected", "DISEASE", 148, 165], ["chloroquine", "CHEMICAL", 3, 14], ["chloroquine", "CHEMICAL", 103, 114], ["chloroquine", "SIMPLE_CHEMICAL", 3, 14], ["PI", "SIMPLE_CHEMICAL", 100, 102], ["chloroquine", "SIMPLE_CHEMICAL", 103, 114], ["SARS-CoV", "ORGANISM", 148, 156], ["cell cultures", "CELL", 166, 179], ["SARS-CoV-infected cell cultures", "CELL_LINE", 148, 179], ["SARS-CoV", "SPECIES", 148, 156], ["chloroquine", "TREATMENT", 3, 14], ["PI/chloroquine combinations", "TREATMENT", 100, 127], ["infected cell cultures", "TEST", 157, 179], ["infected cell", "OBSERVATION", 157, 170]]], ["Alternatively, PIs might be regarded as a lead for the design of new anticoronavirus compounds.Concluding remarksAs for other possible antiviral applications of PIs, the possible chymotrypsin-like nature of the carboxy-terminal region of the PA subunit of type A influenza virus RdRp, a property shared with enzymes known to be susceptible to PIs, as well as the theoretical possibility that PIs might successfully dock to its putative active site, should constitute a basis for immediate testing of these antiretroviral drugs against the influenza viruses in vitro.", [["influenza viruses", "DISEASE", 539, 556], ["carboxy", "CHEMICAL", 211, 218], ["anticoronavirus compounds", "SIMPLE_CHEMICAL", 69, 94], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 179, 191], ["PA", "GENE_OR_GENE_PRODUCT", 242, 244], ["type A influenza virus", "ORGANISM", 256, 278], ["RdRp", "ORGANISM", 279, 283], ["PIs", "SIMPLE_CHEMICAL", 392, 395], ["influenza viruses", "ORGANISM", 539, 556], ["chymotrypsin", "PROTEIN", 179, 191], ["carboxy-terminal region", "PROTEIN", 211, 234], ["PA subunit", "PROTEIN", 242, 252], ["enzymes", "PROTEIN", 308, 315], ["A influenza virus RdRp", "SPECIES", 261, 283], ["type A influenza virus", "SPECIES", 256, 278], ["new anticoronavirus compounds", "PROBLEM", 65, 94], ["antiviral applications", "TREATMENT", 135, 157], ["PIs", "TREATMENT", 161, 164], ["chymotrypsin", "PROBLEM", 179, 191], ["type A influenza virus RdRp", "PROBLEM", 256, 283], ["enzymes", "TEST", 308, 315], ["PIs", "TREATMENT", 343, 346], ["PIs", "PROBLEM", 392, 395], ["immediate testing", "TEST", 479, 496], ["these antiretroviral drugs", "TREATMENT", 500, 526], ["the influenza viruses", "PROBLEM", 535, 556], ["terminal", "OBSERVATION_MODIFIER", 219, 227], ["influenza virus RdRp", "OBSERVATION", 263, 283]]], ["Although in other times this research should be considered to be at an embryonic stage, the recent human cases of avian influenza in Vietnam and Cambodia should prompt the scientific community to consider this as well as any other possible pharmacological strategy to combat this disease.", [["embryonic", "ANATOMY", 71, 80], ["avian influenza", "DISEASE", 114, 129], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 71, 80], ["human", "ORGANISM", 99, 104], ["avian influenza", "ORGANISM", 114, 129], ["human", "SPECIES", 99, 104], ["avian", "SPECIES", 114, 119], ["human", "SPECIES", 99, 104], ["an embryonic stage", "PROBLEM", 68, 86], ["avian influenza", "PROBLEM", 114, 129], ["pharmacological strategy", "TREATMENT", 240, 264], ["this disease", "PROBLEM", 275, 287]]], ["The World Health Organization (WHO) has recently issued an alert on the emergence of a possible pandemic of the H5N1 subtype influenza A virus (www.who.int).", [["influenza A virus", "DISEASE", 125, 142], ["H5N1 subtype influenza A virus", "ORGANISM", 112, 142], ["H5N1 subtype influenza A virus", "SPECIES", 112, 142], ["H5N1 subtype influenza A virus", "SPECIES", 112, 142], ["the H5N1 subtype influenza A virus", "PROBLEM", 108, 142]]], ["This virus is currently causing large epidemics in poultry and has acquired the ability to transmit to humans.", [["humans", "ORGANISM", 103, 109], ["humans", "SPECIES", 103, 109], ["poultry", "SPECIES", 51, 58], ["humans", "SPECIES", 103, 109], ["This virus", "PROBLEM", 0, 10], ["large epidemics in poultry", "PROBLEM", 32, 58], ["virus", "OBSERVATION", 5, 10], ["large", "OBSERVATION_MODIFIER", 32, 37], ["epidemics", "OBSERVATION", 38, 47]]], ["As the mortality of infected people is very high (76% since January 2004), many millions of deaths may be expected in case of a global outbreak.", [["deaths", "DISEASE", 92, 98], ["people", "ORGANISM", 29, 35], ["people", "SPECIES", 29, 35], ["a global outbreak", "PROBLEM", 126, 143], ["infected", "OBSERVATION", 20, 28], ["very", "OBSERVATION_MODIFIER", 39, 43], ["high", "OBSERVATION_MODIFIER", 44, 48], ["global", "OBSERVATION_MODIFIER", 128, 134], ["outbreak", "OBSERVATION", 135, 143]]], ["For these reasons, if PIs should prove to be effective against H5N1 viruses in vitro, it may be immediately available for in vivo testing in affected individuals as an alternative to the one available group of antivirals presently available, viz. the neuraminidase inhibitors.Concluding remarksMeanwhile, the importance of studying PA should not be underestimated.", [["H5N1 viruses", "ORGANISM", 63, 75], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 251, 264], ["PA", "GENE_OR_GENE_PRODUCT", 332, 334], ["H5N1 viruses", "SPECIES", 63, 75], ["PIs", "PROBLEM", 22, 25], ["H5N1 viruses", "PROBLEM", 63, 75], ["vivo testing", "TEST", 125, 137], ["antivirals", "TREATMENT", 210, 220], ["the neuraminidase inhibitors", "TREATMENT", 247, 275], ["studying PA", "TEST", 323, 334]]], ["Further research is needed to confirm the observations of Hara and coworkers on the chymotrypsin-like activity of PA, determine its 3D architecture by crystallographic analysis, and define its role in the Orthomyxoviridae life cycle.", [["chymotrypsin", "GENE_OR_GENE_PRODUCT", 84, 96], ["PA", "GENE_OR_GENE_PRODUCT", 114, 116], ["chymotrypsin", "PROTEIN", 84, 96], ["the chymotrypsin", "TREATMENT", 80, 96], ["crystallographic analysis", "TEST", 151, 176]]], ["These researches might disclose new targets for future pharmacological interventions against influenza.", [["influenza", "DISEASE", 93, 102], ["future pharmacological interventions", "TREATMENT", 48, 84], ["influenza", "PROBLEM", 93, 102]]]], "38494ede139d068abb8086eb08a5dfdde2e87e24": [["What is the normal threshold for excretion of glucose into the urine?", [["urine", "ANATOMY", 63, 68], ["glucose", "CHEMICAL", 46, 53], ["glucose", "CHEMICAL", 46, 53], ["glucose", "SIMPLE_CHEMICAL", 46, 53], ["urine", "ORGANISM_SUBSTANCE", 63, 68], ["glucose into the urine", "TEST", 46, 68]]]], "88534ac83f589e5b7cfcb52ac0062db7b6b101ac": [["H uman metapneumovirus (HMPV) was first identified in 2001 in samples from children with respiratory tract diseases (1) .", [["samples", "ANATOMY", 62, 69], ["respiratory tract", "ANATOMY", 89, 106], ["respiratory tract diseases", "DISEASE", 89, 115], ["H uman metapneumovirus", "ORGANISM", 0, 22], ["HMPV", "ORGANISM", 24, 28], ["samples", "CANCER", 62, 69], ["children", "ORGANISM", 75, 83], ["tract", "ORGANISM_SUBDIVISION", 101, 106], ["H uman metapneumovirus", "SPECIES", 0, 22], ["children", "SPECIES", 75, 83], ["H uman metapneumovirus", "SPECIES", 0, 22], ["HMPV", "SPECIES", 24, 28], ["H uman metapneumovirus (HMPV", "PROBLEM", 0, 28], ["respiratory tract diseases", "PROBLEM", 89, 115], ["metapneumovirus", "OBSERVATION", 7, 22], ["respiratory tract", "ANATOMY", 89, 106]]], ["Subsequent studies showed that the virus is responsible worldwide for a proportion of communityacquired acute respiratory tract infections in children (2) (3) (4) , as well as other age groups (5) (6) (7) (8) (9) .", [["respiratory tract", "ANATOMY", 110, 127], ["respiratory tract infections", "DISEASE", 110, 138], ["children", "SPECIES", 142, 150], ["Subsequent studies", "TEST", 0, 18], ["the virus", "PROBLEM", 31, 40], ["communityacquired acute respiratory tract infections", "PROBLEM", 86, 138], ["virus", "OBSERVATION", 35, 40], ["acute", "OBSERVATION_MODIFIER", 104, 109], ["respiratory tract", "ANATOMY", 110, 127], ["infections", "OBSERVATION", 128, 138]]], ["Co-infection of HMPV with respiratory syncytial virus (RSV) in infants has been suggested to be a factor that influences the severity of bronchiolitis (10) .", [["HMPV", "DISEASE", 16, 20], ["respiratory syncytial virus", "DISEASE", 26, 53], ["RSV", "DISEASE", 55, 58], ["bronchiolitis", "DISEASE", 137, 150], ["HMPV", "ORGANISM", 16, 20], ["respiratory syncytial virus", "ORGANISM", 26, 53], ["RSV", "ORGANISM", 55, 58], ["infants", "ORGANISM", 63, 70], ["respiratory syncytial virus", "SPECIES", 26, 53], ["infants", "SPECIES", 63, 70], ["HMPV", "SPECIES", 16, 20], ["respiratory syncytial virus", "SPECIES", 26, 53], ["RSV", "SPECIES", 55, 58], ["Co-infection of HMPV", "PROBLEM", 0, 20], ["respiratory syncytial virus", "PROBLEM", 26, 53], ["bronchiolitis", "PROBLEM", 137, 150], ["HMPV", "OBSERVATION", 16, 20], ["respiratory syncytial virus", "OBSERVATION", 26, 53], ["bronchiolitis", "OBSERVATION", 137, 150]]]], "4907af93037fab2bb0d95b3dcff90bc4ae03f7d6": [["Four recommendations were drawn based on expert opinion and scientific knowledge, according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.", [["Evaluation", "TEST", 154, 164]]], ["The present review suggests the presence of higher levels of D-dimer in those with worse prognosis, there may be an overdiagnosis of DIC in the course of the disease and there is no evidence on the benefit of starting anticoagulant treatment based only on isolated laboratory data.", [["DIC", "DISEASE", 133, 136], ["D-dimer", "GENE_OR_GENE_PRODUCT", 61, 68], ["D-dimer", "PROTEIN", 61, 68], ["DIC", "PROBLEM", 133, 136], ["the disease", "PROBLEM", 154, 165], ["anticoagulant treatment", "TREATMENT", 218, 241], ["may be", "UNCERTAINTY", 106, 112], ["DIC", "OBSERVATION", 133, 136], ["disease", "OBSERVATION", 158, 165], ["no evidence", "UNCERTAINTY", 179, 190]]]], "PMC7170025": [["Introduction and backgroundCoronavirus (CoV) is a large family of positive-sense, single-stranded RNA viruses that belong to the Nidovirales order.", [["Coronavirus", "GENE_OR_GENE_PRODUCT", 27, 38], ["CoV", "ORGANISM", 40, 43], ["CoV", "SPECIES", 40, 43], ["backgroundCoronavirus (CoV", "PROBLEM", 17, 43], ["single-stranded RNA viruses", "PROBLEM", 82, 109], ["Coronavirus", "OBSERVATION", 27, 38]]], ["The order includes Roniviridae, Arteriviridae, and Coronaviridae families [1].", [["Roniviridae", "TREATMENT", 19, 30], ["Arteriviridae", "TREATMENT", 32, 45]]], ["The Coronaviridae family is subdivided into Torovirinae and Coronavirinae subfamilies [1].", [["Coronaviridae", "GENE_OR_GENE_PRODUCT", 4, 17], ["Coronaviridae family", "PROTEIN", 4, 24]]], ["Coronavirinae is further subclassified into alpha-, beta-, gamma-, and delta-COVs [1].", [["alpha-, beta-, gamma-, and delta-COVs", "CHEMICAL", 44, 81], ["Coronavirinae", "SIMPLE_CHEMICAL", 0, 13], ["alpha-", "GENE_OR_GENE_PRODUCT", 44, 50], ["beta-", "GENE_OR_GENE_PRODUCT", 52, 57], ["gamma-", "GENE_OR_GENE_PRODUCT", 59, 65], ["alpha-", "TEST", 44, 50]]], ["Phylogenetic clustering accounts for the classification of these subtypes of viruses.", [["Phylogenetic clustering", "PROBLEM", 0, 23], ["viruses", "PROBLEM", 77, 84], ["viruses", "OBSERVATION", 77, 84]]], ["Their viral RNA genome ranges from 26 to 32 kilobases in length [2].", [["viral RNA genome", "DNA", 6, 22], ["Their viral RNA genome ranges", "TEST", 0, 29], ["viral", "OBSERVATION", 6, 11], ["RNA genome", "OBSERVATION", 12, 22]]], ["They can be isolated from different animal species.", [["different animal species", "PROBLEM", 26, 50], ["different", "OBSERVATION_MODIFIER", 26, 35], ["animal species", "OBSERVATION", 36, 50]]], ["These include birds, livestock, and mammals such as camels, bats, masked palm civets, mice, dogs, and cats [2].", [["palm", "ORGANISM_SUBDIVISION", 73, 77], ["mice", "ORGANISM", 86, 90], ["dogs", "ORGANISM", 92, 96], ["mice", "SPECIES", 86, 90], ["dogs", "SPECIES", 92, 96], ["cats", "SPECIES", 102, 106], ["mice", "SPECIES", 86, 90]]], ["The widespread distribution and infectivity of COV make it an important pathogen.Introduction and backgroundHuman pathogenic subtypes of CoV are associated with mild clinical symptoms.", [["COV", "GENE_OR_GENE_PRODUCT", 47, 50], ["Human", "ORGANISM", 108, 113], ["CoV", "ORGANISM", 137, 140], ["Human", "SPECIES", 108, 113], ["COV", "SPECIES", 47, 50], ["infectivity of COV", "PROBLEM", 32, 50], ["an important pathogen", "PROBLEM", 59, 80], ["backgroundHuman pathogenic subtypes of CoV", "PROBLEM", 98, 140], ["mild clinical symptoms", "PROBLEM", 161, 183], ["widespread", "OBSERVATION_MODIFIER", 4, 14], ["distribution", "OBSERVATION_MODIFIER", 15, 27], ["infectivity of COV", "OBSERVATION", 32, 50], ["CoV", "OBSERVATION", 137, 140], ["mild", "OBSERVATION_MODIFIER", 161, 165]]], ["However, severe acute respiratory syndrome related coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) are the two notable exceptions.", [["acute respiratory syndrome related coronavirus (SARS-CoV)", "DISEASE", 16, 73], ["Middle East respiratory syndrome coronavirus", "DISEASE", 78, 122], ["SARS-CoV", "ORGANISM", 64, 72], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 78, 122], ["MERS-CoV", "ORGANISM", 124, 132], ["severe acute respiratory syndrome related coronavirus", "SPECIES", 9, 62], ["SARS-CoV", "SPECIES", 64, 72], ["Middle East respiratory syndrome coronavirus", "SPECIES", 78, 122], ["MERS-CoV", "SPECIES", 124, 132], ["severe acute respiratory syndrome", "PROBLEM", 9, 42], ["coronavirus (SARS-CoV)", "PROBLEM", 51, 73], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 78, 122], ["severe", "OBSERVATION_MODIFIER", 9, 15], ["acute", "OBSERVATION_MODIFIER", 16, 21], ["respiratory syndrome", "OBSERVATION", 22, 42], ["coronavirus", "OBSERVATION_MODIFIER", 51, 62], ["Middle", "ANATOMY_MODIFIER", 78, 84], ["respiratory syndrome", "OBSERVATION", 90, 110]]], ["In 2012, MERS-CoV was first detected in Saudia Arabia.", [["MERS-CoV", "ORGANISM", 9, 17], ["MERS-CoV", "SPECIES", 9, 17]]], ["It was responsible for 2,494 confirmed cases, which led to 858 fatalities [2].", [["fatalities", "DISEASE", 63, 73]]], ["In 2002, a subtype of the beta-COV rapidly spread across Guangdong, China.", [["beta-COV", "GENE_OR_GENE_PRODUCT", 26, 34], ["beta-COV", "PROTEIN", 26, 34], ["the beta-COV", "PROBLEM", 22, 34]]], ["This outbreak resulted in 8,000 infections and 774 fatalities in 37 countries [2].", [["infections", "DISEASE", 32, 42], ["fatalities", "DISEASE", 51, 61], ["infections", "OBSERVATION", 32, 42]]], ["The outbreak in 2020 has presented in the form of pneumonia of unknown etiology in Wuhan, China.", [["pneumonia", "DISEASE", 50, 59], ["pneumonia", "PROBLEM", 50, 59], ["pneumonia", "OBSERVATION", 50, 59]]], ["Deep sequencing studies and lab investigations have identified the culprit as a new strain of COV [3].", [["COV", "SPECIES", 94, 97], ["Deep sequencing studies", "TEST", 0, 23], ["lab investigations", "TEST", 28, 46], ["a new strain of COV", "PROBLEM", 78, 97]]], ["Initially, this virus was designated as 2019-nCoV.", [["this virus", "PROBLEM", 11, 21]]], ["However, the International Committee on Taxonomy of Viruses designated it as the SARS-CoV-2 virus [4].", [["SARS-CoV-2 virus", "ORGANISM", 81, 97], ["CoV-2 virus", "SPECIES", 86, 97], ["SARS-CoV-2 virus", "SPECIES", 81, 97], ["Viruses", "TREATMENT", 52, 59], ["the SARS", "TEST", 77, 85]]], ["On February 11, 2020, the World Health Organization (WHO) announced the disease caused by this novel virus as coronavirus disease-2019 (COVID-19).", [["coronavirus disease", "DISEASE", 110, 129], ["the disease", "PROBLEM", 68, 79], ["this novel virus", "PROBLEM", 90, 106], ["coronavirus disease", "PROBLEM", 110, 129], ["COVID", "TEST", 136, 141]]], ["The repeated emergence and outbreaks of CoVs indicate a public health threat.", [["CoVs", "DISEASE", 40, 44], ["CoVs", "PROBLEM", 40, 44]]], ["This suggests the possibility of animal-to-human and human-to-human transmission of newly emerging CoVs.", [["human", "ORGANISM", 43, 48], ["human", "ORGANISM", 53, 58], ["human", "ORGANISM", 62, 67], ["CoVs", "CANCER", 99, 103], ["human", "SPECIES", 43, 48], ["human", "SPECIES", 53, 58], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 43, 48], ["human", "SPECIES", 53, 58], ["human", "SPECIES", 62, 67], ["newly emerging CoVs", "PROBLEM", 84, 103], ["suggests the possibility", "UNCERTAINTY", 5, 29]]], ["The ongoing changes in ecology and climate make future emergence of such infections more likely [3].ReviewEpidemiologyReviewAs of March 3, 2020, the WHO has confirmed 87,317 cases worldwide [4].", [["infections", "DISEASE", 73, 83], ["such infections", "PROBLEM", 68, 83]]], ["Of these confirmed cases, 2,977 (3.42%) patients have succumbed to the virus [4].", [["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["cases", "TEST", 19, 24]]], ["The majority of cases and deaths have been reported in China.", [["deaths", "DISEASE", 26, 32]]], ["Of the total number of cases, 79,968 (92%) patients have been identified in China [4].", [["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["cases", "TEST", 23, 28], ["total", "OBSERVATION_MODIFIER", 7, 12]]], ["Likewise, the majority of fatalities (2,873 [96.5%]) have also been reported in China [4].", [["fatalities", "DISEASE", 26, 36], ["majority", "OBSERVATION_MODIFIER", 14, 22]]], ["Table 1 provides a comparison of the epidemiological characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2.ReviewEtiologyReviewCoVs are a large family of RNA viruses that are found diversely in animal species.", [["SARS", "DISEASE", 72, 76], ["SARS-CoV", "ORGANISM", 72, 80], ["MERS-CoV", "ORGANISM", 82, 90], ["SARS-CoV-2", "ORGANISM", 96, 106], ["ReviewEtiologyReviewCoVs", "GENE_OR_GENE_PRODUCT", 107, 131], ["SARS-CoV", "SPECIES", 72, 80], ["MERS-CoV", "SPECIES", 82, 90], ["SARS-CoV", "SPECIES", 96, 104], ["SARS", "TEST", 72, 76], ["CoV", "TEST", 77, 80], ["MERS", "TEST", 82, 86], ["CoV", "TEST", 87, 90], ["SARS", "TEST", 96, 100], ["RNA viruses", "PROBLEM", 154, 165], ["large", "OBSERVATION_MODIFIER", 138, 143]]], ["They are known to cause diseases of the respiratory, hepatic, nervous system, and gastrointestinal systems in humans [3].", [["respiratory", "ANATOMY", 40, 51], ["hepatic", "ANATOMY", 53, 60], ["nervous system", "ANATOMY", 62, 76], ["gastrointestinal systems", "ANATOMY", 82, 106], ["diseases of the respiratory, hepatic, nervous system, and gastrointestinal systems", "DISEASE", 24, 106], ["hepatic", "ANATOMICAL_SYSTEM", 53, 60], ["nervous system", "ANATOMICAL_SYSTEM", 62, 76], ["gastrointestinal", "ORGAN", 82, 98], ["humans", "ORGANISM", 110, 116], ["humans", "SPECIES", 110, 116], ["humans", "SPECIES", 110, 116], ["diseases of the respiratory, hepatic, nervous system", "PROBLEM", 24, 76], ["respiratory", "ANATOMY", 40, 51], ["hepatic", "ANATOMY", 53, 60], ["nervous system", "ANATOMY", 62, 76], ["gastrointestinal systems", "ANATOMY", 82, 106]]], ["Under the electron microscope, they impart a crown-like appearance due to the presence of envelope spike glycoproteins [4].", [["envelope spike glycoproteins", "PROTEIN", 90, 118], ["the electron microscope", "TEST", 6, 29], ["a crown-like appearance", "PROBLEM", 43, 66], ["envelope spike glycoproteins", "PROBLEM", 90, 118]]], ["CoVs belong to the Roniviridae, Arteriviridae, and Coronaviridae families [3].", [["CoVs", "GENE_OR_GENE_PRODUCT", 0, 4], ["Roniviridae", "GENE_OR_GENE_PRODUCT", 19, 30], ["CoVs", "PROTEIN", 0, 4], ["CoVs", "PROBLEM", 0, 4], ["the Roniviridae", "TREATMENT", 15, 30], ["Arteriviridae", "TREATMENT", 32, 45]]], ["The Coronaviridae family can be classified into four genera of alpha-COV, beta-COV, delta-COV, and gamma-COV [4].", [["Coronaviridae", "GENE_OR_GENE_PRODUCT", 4, 17], ["alpha-COV", "GENE_OR_GENE_PRODUCT", 63, 72], ["beta-COV", "GENE_OR_GENE_PRODUCT", 74, 82], ["delta-COV", "GENE_OR_GENE_PRODUCT", 84, 93], ["gamma-COV", "GENE_OR_GENE_PRODUCT", 99, 108], ["Coronaviridae family", "PROTEIN", 4, 24], ["alpha", "PROTEIN", 63, 68], ["COV", "PROTEIN", 69, 72], ["beta", "PROTEIN", 74, 78], ["COV", "PROTEIN", 79, 82], ["delta-COV", "PROTEIN", 84, 93], ["gamma-COV", "PROTEIN", 99, 108], ["alpha", "TEST", 63, 68], ["COV", "TEST", 69, 72], ["beta", "TEST", 74, 78], ["delta-COV", "TEST", 84, 93]]], ["Furthermore, beta-COV can be sub-divided into 5 lineages [5].", [["beta-COV", "CHEMICAL", 13, 21], ["beta-COV", "GENE_OR_GENE_PRODUCT", 13, 21], ["beta-COV", "PROTEIN", 13, 21]]], ["Gene characterization has helped identify that bats and rodents are the gene source of alpha-COV and beta-COV [4].", [["alpha-COV", "GENE_OR_GENE_PRODUCT", 87, 96], ["beta-COV", "GENE_OR_GENE_PRODUCT", 101, 109], ["alpha-COV", "PROTEIN", 87, 96], ["Gene characterization", "TEST", 0, 21], ["alpha-COV", "TEST", 87, 96]]], ["On the other hand, avian species are deemed as genetic sources of delta-COV and gamma-COV [4].ReviewCoVs are responsible for 5-10% of acute respiratory infections [3].", [["respiratory", "ANATOMY", 140, 151], ["respiratory infections", "DISEASE", 140, 162], ["delta-COV", "SIMPLE_CHEMICAL", 66, 75], ["gamma-COV", "GENE_OR_GENE_PRODUCT", 80, 89], ["ReviewCoVs", "GENE_OR_GENE_PRODUCT", 94, 104], ["gamma-COV", "PROTEIN", 80, 89], ["delta-COV", "PROBLEM", 66, 75], ["acute respiratory infections", "PROBLEM", 134, 162], ["acute", "OBSERVATION_MODIFIER", 134, 139], ["respiratory", "ANATOMY", 140, 151], ["infections", "OBSERVATION", 152, 162]]], ["Some common human CoVs include HCoV-OC43, HCoV-HKU1, HCoV-229E, and HCoV-NL63 [4].", [["human", "ORGANISM", 12, 17], ["CoVs", "GENE_OR_GENE_PRODUCT", 18, 22], ["HCoV-OC43", "GENE_OR_GENE_PRODUCT", 31, 40], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 42, 51], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 53, 62], ["HCoV", "DNA", 68, 72], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 12, 17], ["HCoV-229E", "SPECIES", 53, 62], ["Some common human CoVs", "TEST", 0, 22], ["HCoV", "TEST", 31, 35], ["OC43", "TEST", 36, 40], ["HCoV", "TEST", 42, 46], ["HKU1", "TEST", 47, 51], ["HCoV", "TEST", 53, 57], ["HCoV", "TEST", 68, 72]]], ["In the immunocompetent, these CoVs clinically present with self-limiting respiratory infections and common colds [4].", [["respiratory", "ANATOMY", 73, 84], ["respiratory infections", "DISEASE", 73, 95], ["colds", "DISEASE", 107, 112], ["CoVs", "CANCER", 30, 34], ["self-limiting respiratory infections", "PROBLEM", 59, 95], ["common colds", "PROBLEM", 100, 112], ["immunocompetent", "OBSERVATION", 7, 22], ["respiratory", "ANATOMY", 73, 84], ["infections", "OBSERVATION", 85, 95]]], ["In the elderly and immunocompromised, they can involve the lower respiratory tracts [4].", [["lower respiratory tracts", "ANATOMY", 59, 83], ["immunocompromised", "PROBLEM", 19, 36], ["immunocompromised", "OBSERVATION", 19, 36], ["lower", "ANATOMY_MODIFIER", 59, 64], ["respiratory tracts", "ANATOMY", 65, 83]]], ["Other human CoVs such as MERS-CoV, SARS-CoV, and SARS-CoV-2 present with pulmonary and extra-pulmonary features [4].ReviewSARS-CoV-2, which is responsible for the COVID-19 pandemic, is a type of beta-COV.", [["pulmonary", "ANATOMY", 73, 82], ["pulmonary and extra-pulmonary features", "DISEASE", 73, 111], ["human", "ORGANISM", 6, 11], ["CoVs", "GENE_OR_GENE_PRODUCT", 12, 16], ["MERS-CoV", "ORGANISM", 25, 33], ["SARS-CoV", "ORGANISM", 35, 43], ["SARS-CoV-2", "ORGANISM", 49, 59], ["pulmonary", "ORGAN", 73, 82], ["beta-COV", "GENE_OR_GENE_PRODUCT", 195, 203], ["beta-COV", "PROTEIN", 195, 203], ["human", "SPECIES", 6, 11], ["SARS-CoV", "SPECIES", 49, 57], ["human", "SPECIES", 6, 11], ["MERS-CoV", "SPECIES", 25, 33], ["SARS-CoV", "SPECIES", 35, 43], ["SARS-CoV", "SPECIES", 49, 57], ["Other human CoVs", "PROBLEM", 0, 16], ["SARS", "PROBLEM", 35, 39], ["SARS", "PROBLEM", 49, 53], ["CoV", "TEST", 54, 57], ["pulmonary and extra-pulmonary features", "PROBLEM", 73, 111], ["ReviewSARS", "TEST", 116, 126], ["the COVID", "TEST", 159, 168], ["pulmonary", "ANATOMY", 73, 82], ["extra-pulmonary", "ANATOMY", 87, 102]]], ["Genomic characterization studies of the new strain have indicated an 89% nucleotide match with bat SARS-like CoVZXC21 [3,6].", [["nucleotide", "CHEMICAL", 73, 83], ["nucleotide", "CHEMICAL", 73, 83], ["Genomic characterization studies", "TEST", 0, 32], ["the new strain", "PROBLEM", 36, 50], ["an 89% nucleotide match", "PROBLEM", 66, 89], ["bat SARS", "PROBLEM", 95, 103]]], ["There is also an 82% nucleotide match with the human SARS virus [6].", [["nucleotide", "CHEMICAL", 21, 31], ["SARS", "DISEASE", 53, 57], ["nucleotide", "CHEMICAL", 21, 31], ["human", "ORGANISM", 47, 52], ["SARS virus", "ORGANISM", 53, 63], ["human", "SPECIES", 47, 52], ["human SARS virus", "SPECIES", 47, 63], ["an 82% nucleotide match", "PROBLEM", 14, 37], ["the human SARS virus", "PROBLEM", 43, 63]]], ["Therefore, these findings form the basis for the new strain to be called SARS-CoV-2.", [["SARS", "DISEASE", 73, 77], ["SARS-CoV-2", "ORGANISM", 73, 83], ["SARS-CoV", "SPECIES", 73, 81], ["the new strain", "PROBLEM", 45, 59], ["CoV", "TEST", 78, 81]]], ["It has a full genomic length of 29,891 to 29,903 nucleotides.", [["nucleotides", "CHEMICAL", 49, 60], ["full", "OBSERVATION_MODIFIER", 9, 13], ["genomic", "OBSERVATION_MODIFIER", 14, 21], ["length", "OBSERVATION_MODIFIER", 22, 28]]], ["The virus is sensitive to ultraviolet light and heat [4].", [["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9]]], ["SARS-CoV-2 bind to their target cells through angiotensin-converting enzyme 2 (ACE2), which is expressed in the lungs.", [["cells", "ANATOMY", 32, 37], ["lungs", "ANATOMY", 112, 117], ["angiotensin", "CHEMICAL", 46, 57], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["cells", "CELL", 32, 37], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 46, 77], ["ACE2", "GENE_OR_GENE_PRODUCT", 79, 83], ["lungs", "ORGAN", 112, 117], ["target cells", "CELL_TYPE", 25, 37], ["angiotensin-converting enzyme 2", "PROTEIN", 46, 77], ["ACE2", "PROTEIN", 79, 83], ["SARS", "TEST", 0, 4], ["angiotensin", "TEST", 46, 57], ["lungs", "ANATOMY", 112, 117]]], ["Furthermore, these viruses can be functionally inactivated with the use of ethanol (60%), ether (75%), and chlorine-containing disinfectants.ReviewTransmissionReviewThe initial cases were presumably linked to direct exposure to infected animals (animal-to-human transmission) at a seafood market in Wuhan, China.", [["ethanol", "CHEMICAL", 75, 82], ["chlorine", "CHEMICAL", 107, 115], ["ethanol", "CHEMICAL", 75, 82], ["ether", "CHEMICAL", 90, 95], ["chlorine", "CHEMICAL", 107, 115], ["ethanol", "SIMPLE_CHEMICAL", 75, 82], ["ether", "SIMPLE_CHEMICAL", 90, 95], ["chlorine-containing disinfectants", "SIMPLE_CHEMICAL", 107, 140], ["human", "ORGANISM", 256, 261], ["human", "SPECIES", 256, 261], ["human", "SPECIES", 256, 261], ["these viruses", "PROBLEM", 13, 26], ["ethanol", "TREATMENT", 75, 82], ["chlorine", "TREATMENT", 107, 115], ["infected animals", "PROBLEM", 228, 244], ["viruses", "OBSERVATION", 19, 26]]], ["This helps further elaborate that human-to-human transmission of the virus is also possible.", [["human", "ORGANISM", 34, 39], ["human", "ORGANISM", 43, 48], ["human", "SPECIES", 34, 39], ["human", "SPECIES", 43, 48], ["human", "SPECIES", 34, 39], ["human", "SPECIES", 43, 48], ["the virus", "PROBLEM", 65, 74], ["virus", "OBSERVATION", 69, 74]]], ["Therefore, human-to-human transmission is now considered the main form of transmission.", [["human", "ORGANISM", 11, 16], ["human", "ORGANISM", 20, 25], ["human", "SPECIES", 11, 16], ["human", "SPECIES", 20, 25], ["human", "SPECIES", 11, 16], ["human", "SPECIES", 20, 25]]], ["Individuals who remain asymptomatic could also transmit the virus [4].", [["asymptomatic", "PROBLEM", 23, 35]]], ["However, the most common source of infection is symptomatic people.", [["infection", "DISEASE", 35, 44], ["people", "ORGANISM", 60, 66], ["people", "SPECIES", 60, 66], ["infection", "PROBLEM", 35, 44], ["most common", "OBSERVATION_MODIFIER", 13, 24], ["infection", "OBSERVATION", 35, 44], ["symptomatic", "OBSERVATION_MODIFIER", 48, 59]]], ["Transmission occurs from the spread of respiratory droplets through coughing or sneezing [4].", [["respiratory droplets", "ANATOMY", 39, 59], ["coughing", "DISEASE", 68, 76], ["sneezing", "DISEASE", 80, 88], ["respiratory droplets", "PROBLEM", 39, 59], ["coughing", "PROBLEM", 68, 76], ["sneezing", "PROBLEM", 80, 88], ["respiratory droplets", "OBSERVATION", 39, 59]]], ["This also indicates possible transmission in closed spaces due to elevated aerosol concentrations [4].ReviewSARS-CoV-2 has a basic reproduction number of 2.2 [4].", [["transmission in closed spaces", "PROBLEM", 29, 58], ["elevated aerosol concentrations", "PROBLEM", 66, 97], ["indicates possible", "UNCERTAINTY", 10, 28], ["elevated", "OBSERVATION_MODIFIER", 66, 74], ["aerosol concentrations", "OBSERVATION", 75, 97]]], ["This suggests that a patient can transmit the infection to two other individuals.", [["infection", "DISEASE", 46, 55], ["patient", "ORGANISM", 21, 28], ["patient", "SPECIES", 21, 28], ["the infection", "PROBLEM", 42, 55], ["infection", "OBSERVATION", 46, 55]]], ["Current data suggest that the virus has an incubation period of three to seven days [8].", [["the virus", "PROBLEM", 26, 35]]], ["Therefore, further studies are needed to address transmission dynamics and incubation times.ReviewClinical featuresReviewCOVID-19 manifests with a wide clinical spectrum ranging from asymptomatic patients to septic shock and multiorgan dysfunction [4].", [["multiorgan", "ANATOMY", 225, 235], ["septic shock", "DISEASE", 208, 220], ["multiorgan dysfunction", "DISEASE", 225, 247], ["patients", "ORGANISM", 196, 204], ["patients", "SPECIES", 196, 204], ["further studies", "TEST", 11, 26], ["ReviewClinical featuresReviewCOVID", "TEST", 92, 126], ["a wide clinical spectrum", "PROBLEM", 145, 169], ["septic shock", "PROBLEM", 208, 220], ["multiorgan dysfunction", "PROBLEM", 225, 247], ["septic shock", "OBSERVATION", 208, 220], ["multiorgan dysfunction", "OBSERVATION", 225, 247]]], ["COVID-19 is classified based on the severity of the presentation [4].", [["COVID-19", "DNA", 0, 8]]], ["The disease may be classified into mild, moderate, severe, and critical [9].", [["The disease", "PROBLEM", 0, 11], ["mild, moderate, severe", "PROBLEM", 35, 57], ["disease", "OBSERVATION", 4, 11], ["may be", "UNCERTAINTY", 12, 18], ["mild", "OBSERVATION_MODIFIER", 35, 39], ["moderate", "OBSERVATION_MODIFIER", 41, 49], ["severe", "OBSERVATION_MODIFIER", 51, 57]]], ["The most common symptoms of patients include fever (98.6%), fatigue (69.6%), dry cough, and diarrhea [9].ReviewMild DiseaseReviewPatients with mild illness may present with symptoms of an upper respiratory tract viral infection [4].", [["fever", "DISEASE", 45, 50], ["fatigue", "DISEASE", 60, 67], ["dry cough", "DISEASE", 77, 86], ["diarrhea", "DISEASE", 92, 100], ["respiratory tract viral infection", "DISEASE", 194, 227], ["patients", "ORGANISM", 28, 36], ["upper respiratory", "ORGANISM_SUBDIVISION", 188, 205], ["tract", "ORGANISM_SUBDIVISION", 206, 211], ["patients", "SPECIES", 28, 36], ["The most common symptoms", "PROBLEM", 0, 24], ["fever", "PROBLEM", 45, 50], ["fatigue", "PROBLEM", 60, 67], ["dry cough", "PROBLEM", 77, 86], ["diarrhea", "PROBLEM", 92, 100], ["Mild DiseaseReviewPatients", "PROBLEM", 111, 137], ["mild illness", "PROBLEM", 143, 155], ["symptoms", "PROBLEM", 173, 181], ["an upper respiratory tract viral infection", "PROBLEM", 185, 227], ["cough", "OBSERVATION", 81, 86], ["Mild", "OBSERVATION_MODIFIER", 111, 115], ["mild", "OBSERVATION_MODIFIER", 143, 147], ["illness", "OBSERVATION", 148, 155], ["upper", "ANATOMY_MODIFIER", 188, 193], ["respiratory tract", "ANATOMY", 194, 211], ["infection", "OBSERVATION", 218, 227]]], ["These include dry cough, mild fever, nasal congestion, sore throat, headache, muscle pain, and malaise [4].", [["nasal", "ANATOMY", 37, 42], ["muscle", "ANATOMY", 78, 84], ["dry cough", "DISEASE", 14, 23], ["fever", "DISEASE", 30, 35], ["nasal congestion", "DISEASE", 37, 53], ["sore throat", "DISEASE", 55, 66], ["headache", "DISEASE", 68, 76], ["muscle pain", "DISEASE", 78, 89], ["nasal", "ORGANISM_SUBDIVISION", 37, 42], ["muscle", "ORGAN", 78, 84], ["dry cough", "PROBLEM", 14, 23], ["mild fever", "PROBLEM", 25, 35], ["nasal congestion", "PROBLEM", 37, 53], ["sore throat", "PROBLEM", 55, 66], ["headache", "PROBLEM", 68, 76], ["muscle pain", "PROBLEM", 78, 89], ["malaise", "PROBLEM", 95, 102], ["cough", "OBSERVATION", 18, 23], ["mild", "OBSERVATION_MODIFIER", 25, 29], ["fever", "OBSERVATION", 30, 35], ["nasal", "ANATOMY", 37, 42], ["congestion", "OBSERVATION", 43, 53], ["sore throat", "ANATOMY", 55, 66], ["muscle", "ANATOMY", 78, 84]]], ["It is also characterized by the absence of serious symptoms such as dyspnea.", [["dyspnea", "DISEASE", 68, 75], ["serious symptoms", "PROBLEM", 43, 59], ["dyspnea", "PROBLEM", 68, 75]]], ["The majority (81%) of COVID-19 cases are mild in severity [4].", [["COVID", "TEST", 22, 27], ["mild in severity", "PROBLEM", 41, 57], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["mild", "OBSERVATION_MODIFIER", 41, 45]]], ["Furthermore, radiograph features are also absent in such cases [9].", [["radiograph features", "TEST", 13, 32]]], ["Patients with mild disease can quickly deteriorate into severe or critical cases.ReviewModerate DiseaseReviewThese patients present with respiratory symptoms of cough, shortness of breath, and tachypnea [4].", [["respiratory", "ANATOMY", 137, 148], ["cough", "DISEASE", 161, 166], ["shortness of breath", "DISEASE", 168, 187], ["tachypnea", "DISEASE", 193, 202], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 115, 123], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 115, 123], ["mild disease", "PROBLEM", 14, 26], ["respiratory symptoms", "PROBLEM", 137, 157], ["cough", "PROBLEM", 161, 166], ["shortness of breath", "PROBLEM", 168, 187], ["tachypnea", "PROBLEM", 193, 202], ["mild", "OBSERVATION_MODIFIER", 14, 18], ["disease", "OBSERVATION", 19, 26], ["cough", "OBSERVATION", 161, 166]]], ["However, no signs and symptoms of severe disease are present.ReviewSevere DiseaseReviewPatients with severe disease present with severe pneumonia. acute respiratory distress syndrome (ARDS), sepsis, or septic shock [4].", [["respiratory", "ANATOMY", 153, 164], ["pneumonia", "DISEASE", 136, 145], ["acute respiratory distress syndrome", "DISEASE", 147, 182], ["ARDS", "DISEASE", 184, 188], ["sepsis", "DISEASE", 191, 197], ["septic shock", "DISEASE", 202, 214], ["signs and symptoms", "PROBLEM", 12, 30], ["severe disease", "PROBLEM", 34, 48], ["severe disease", "PROBLEM", 101, 115], ["severe pneumonia", "PROBLEM", 129, 145], ["acute respiratory distress syndrome", "PROBLEM", 147, 182], ["ARDS)", "PROBLEM", 184, 189], ["sepsis", "PROBLEM", 191, 197], ["septic shock", "PROBLEM", 202, 214], ["no signs", "UNCERTAINTY", 9, 17], ["severe", "OBSERVATION_MODIFIER", 34, 40], ["disease", "OBSERVATION", 41, 48], ["severe", "OBSERVATION_MODIFIER", 101, 107], ["disease", "OBSERVATION", 108, 115], ["severe", "OBSERVATION_MODIFIER", 129, 135], ["pneumonia", "OBSERVATION", 136, 145], ["respiratory", "ANATOMY", 153, 164], ["distress", "OBSERVATION", 165, 173], ["ARDS", "OBSERVATION", 184, 188], ["sepsis", "OBSERVATION", 191, 197], ["septic shock", "OBSERVATION", 202, 214]]], ["Diagnosis is clinical, and complications can be excluded with the help of radiographic studies.", [["radiographic studies", "TEST", 74, 94]]], ["Clinical presentations include the presence of severe dyspnea, tachypnea (respiratory rate > 30/minute), respiratory distress, SpO2 \u2264 93%, PaO2/FiO2 < 300, and/or greater than 50% lung infiltrates within 24 to 48 hours [4].", [["respiratory", "ANATOMY", 74, 85], ["respiratory", "ANATOMY", 105, 116], ["lung", "ANATOMY", 180, 184], ["dyspnea", "DISEASE", 54, 61], ["tachypnea", "DISEASE", 63, 72], ["respiratory distress", "DISEASE", 105, 125], ["lung", "ORGAN", 180, 184], ["severe dyspnea", "PROBLEM", 47, 61], ["tachypnea", "PROBLEM", 63, 72], ["respiratory rate", "TEST", 74, 90], ["respiratory distress", "PROBLEM", 105, 125], ["SpO2", "TEST", 127, 131], ["PaO2", "TEST", 139, 143], ["FiO2", "TEST", 144, 148], ["50% lung infiltrates", "PROBLEM", 176, 196], ["severe", "OBSERVATION_MODIFIER", 47, 53], ["dyspnea", "OBSERVATION", 54, 61], ["tachypnea", "OBSERVATION", 63, 72], ["respiratory", "ANATOMY", 105, 116], ["distress", "OBSERVATION", 117, 125], ["greater", "OBSERVATION_MODIFIER", 163, 170], ["lung", "ANATOMY", 180, 184], ["infiltrates", "OBSERVATION", 185, 196]]], ["Even in severe forms of the disease, fever can be absent or moderate [4].ReviewIn addition, 5% of patients can develop a critical disease with features of respiratory failure, RNAaemia, cardiac injury, septic shock, or multiple organ dysfunction [4,9].", [["respiratory", "ANATOMY", 155, 166], ["cardiac", "ANATOMY", 186, 193], ["organ", "ANATOMY", 228, 233], ["fever", "DISEASE", 37, 42], ["respiratory failure", "DISEASE", 155, 174], ["RNAaemia", "DISEASE", 176, 184], ["cardiac injury", "DISEASE", 186, 200], ["septic shock", "DISEASE", 202, 214], ["organ dysfunction", "DISEASE", 228, 245], ["patients", "ORGANISM", 98, 106], ["cardiac", "ORGAN", 186, 193], ["organ", "ORGAN", 228, 233], ["patients", "SPECIES", 98, 106], ["the disease", "PROBLEM", 24, 35], ["fever", "PROBLEM", 37, 42], ["a critical disease", "PROBLEM", 119, 137], ["respiratory failure", "PROBLEM", 155, 174], ["RNAaemia", "PROBLEM", 176, 184], ["cardiac injury", "PROBLEM", 186, 200], ["septic shock", "PROBLEM", 202, 214], ["multiple organ dysfunction", "PROBLEM", 219, 245], ["severe", "OBSERVATION_MODIFIER", 8, 14], ["disease", "OBSERVATION", 28, 35], ["fever", "OBSERVATION", 37, 42], ["moderate", "OBSERVATION_MODIFIER", 60, 68], ["disease", "OBSERVATION", 130, 137], ["respiratory failure", "OBSERVATION", 155, 174], ["cardiac", "ANATOMY", 186, 193], ["injury", "OBSERVATION", 194, 200], ["septic shock", "OBSERVATION", 202, 214], ["multiple", "OBSERVATION_MODIFIER", 219, 227], ["organ", "ANATOMY", 228, 233], ["dysfunction", "OBSERVATION", 234, 245]]], ["Data from the Chinese Centers for Disease Control and Prevention (CDC) suggest that the case fatality rate for critical patients is 49% [4].", [["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128], ["Disease Control", "TREATMENT", 34, 49]]], ["Patients with preexisting comorbidities have a higher case fatality rate.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["preexisting comorbidities", "PROBLEM", 14, 39]]], ["These comorbidities include diabetes (7.3%), respiratory disease (6.5%), cardiovascular disease (10.5%), hypertension (6%), and oncological complications (5.6%) [9].", [["respiratory", "ANATOMY", 45, 56], ["cardiovascular", "ANATOMY", 73, 87], ["diabetes", "DISEASE", 28, 36], ["respiratory disease", "DISEASE", 45, 64], ["cardiovascular disease", "DISEASE", 73, 95], ["hypertension", "DISEASE", 105, 117], ["These comorbidities", "PROBLEM", 0, 19], ["diabetes", "PROBLEM", 28, 36], ["respiratory disease", "PROBLEM", 45, 64], ["cardiovascular disease", "PROBLEM", 73, 95], ["hypertension", "PROBLEM", 105, 117], ["oncological complications", "PROBLEM", 128, 153], ["diabetes", "OBSERVATION", 28, 36], ["respiratory disease", "OBSERVATION", 45, 64], ["cardiovascular", "ANATOMY", 73, 87], ["disease", "OBSERVATION", 88, 95], ["hypertension", "OBSERVATION", 105, 117]]], ["Patients without comorbidities have a lower case fatality rate (0.9%) [9].ReviewAcute Respiratory Distress SyndromeReviewThe development of ARDS indicates new-onset or worsening respiratory failure.", [["respiratory", "ANATOMY", 178, 189], ["ARDS", "DISEASE", 140, 144], ["respiratory failure", "DISEASE", 178, 197], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["comorbidities", "PROBLEM", 17, 30], ["Respiratory Distress", "PROBLEM", 86, 106], ["ARDS", "PROBLEM", 140, 144], ["worsening respiratory failure", "PROBLEM", 168, 197], ["Respiratory Distress", "OBSERVATION", 86, 106], ["ARDS", "OBSERVATION", 140, 144], ["new", "OBSERVATION_MODIFIER", 155, 158], ["onset", "OBSERVATION_MODIFIER", 159, 164], ["worsening", "OBSERVATION_MODIFIER", 168, 177], ["respiratory failure", "OBSERVATION", 178, 197]]], ["It occurs as a complication within one week of known clinical insult.", [["a complication", "PROBLEM", 13, 27], ["known clinical insult", "PROBLEM", 47, 68]]], ["The values of PaO2/FiO2 are used to distinguish ARDS based on varying degrees of hypoxia.", [["ARDS", "DISEASE", 48, 52], ["hypoxia", "DISEASE", 81, 88], ["FiO2", "CHEMICAL", 19, 23], ["The values", "TEST", 0, 10], ["PaO2", "TEST", 14, 18], ["FiO2", "TREATMENT", 19, 23], ["ARDS", "PROBLEM", 48, 52], ["hypoxia", "PROBLEM", 81, 88], ["hypoxia", "OBSERVATION", 81, 88]]], ["PaO2/FiO2 \u2264 100 mm Hg is indicative of severe ARDS [4].", [["ARDS", "DISEASE", 46, 50], ["FiO2", "CHEMICAL", 5, 9], ["Hg", "CHEMICAL", 19, 21], ["PaO2", "TEST", 0, 4], ["FiO2", "TEST", 5, 9], ["severe ARDS", "PROBLEM", 39, 50], ["indicative of", "UNCERTAINTY", 25, 38], ["severe", "OBSERVATION_MODIFIER", 39, 45], ["ARDS", "OBSERVATION", 46, 50]]], ["PaO2/FiO2 values between 100 mm Hg and 200 mm Hg are diagnostic for moderate ARDS [4].", [["ARDS", "DISEASE", 77, 81], ["Hg", "CHEMICAL", 32, 34], ["Hg", "CHEMICAL", 46, 48], ["PaO2", "TEST", 0, 4], ["FiO2 values", "TEST", 5, 16], ["Hg", "TEST", 32, 34], ["moderate ARDS", "PROBLEM", 68, 81], ["moderate", "OBSERVATION_MODIFIER", 68, 76], ["ARDS", "OBSERVATION", 77, 81]]], ["PaO2/FiO2 values between 200 mmHg and 300 mmHg support the diagnosis of mild ARDS [4].", [["ARDS", "DISEASE", 77, 81], ["PaO2", "TEST", 0, 4], ["FiO2 values", "TEST", 5, 16], ["mild ARDS", "PROBLEM", 72, 81], ["mild", "OBSERVATION_MODIFIER", 72, 76], ["ARDS", "OBSERVATION", 77, 81]]], ["Levels of AST (aspartate transaminase) and ALT (alanine transaminase) at the time of admission correlate with clinical deterioration to ARDS.", [["aspartate", "CHEMICAL", 15, 24], ["alanine", "CHEMICAL", 48, 55], ["ARDS", "DISEASE", 136, 140], ["aspartate", "CHEMICAL", 15, 24], ["alanine", "CHEMICAL", 48, 55], ["AST", "SIMPLE_CHEMICAL", 10, 13], ["aspartate transaminase", "GENE_OR_GENE_PRODUCT", 15, 37], ["ALT", "SIMPLE_CHEMICAL", 43, 46], ["alanine", "AMINO_ACID", 48, 55], ["transaminase", "GENE_OR_GENE_PRODUCT", 56, 68], ["AST", "PROTEIN", 10, 13], ["aspartate transaminase", "PROTEIN", 15, 37], ["ALT", "PROTEIN", 43, 46], ["alanine transaminase", "PROTEIN", 48, 68], ["Levels", "TEST", 0, 6], ["AST", "TEST", 10, 13], ["aspartate transaminase", "TEST", 15, 37], ["ALT", "TEST", 43, 46], ["alanine transaminase", "TEST", 48, 68], ["clinical deterioration", "PROBLEM", 110, 132], ["ARDS", "PROBLEM", 136, 140], ["ARDS", "OBSERVATION", 136, 140]]], ["Therefore, higher levels at admission result in rapid clinical deterioration to ARDS.ReviewIn addition to the clinical and ventilatory criteria, chest imaging modalities such as chest X-ray, computed tomography (CT) scan, and lung ultrasound can be used to support the diagnosis.", [["chest", "ANATOMY", 145, 150], ["lung", "ANATOMY", 226, 230], ["ARDS", "DISEASE", 80, 84], ["lung", "ORGAN", 226, 230], ["rapid clinical deterioration", "PROBLEM", 48, 76], ["ARDS", "PROBLEM", 80, 84], ["chest imaging modalities", "TEST", 145, 169], ["chest X-ray", "TEST", 178, 189], ["computed tomography (CT) scan", "TEST", 191, 220], ["lung ultrasound", "TEST", 226, 241], ["ARDS", "OBSERVATION", 80, 84], ["chest", "ANATOMY", 145, 150], ["chest", "ANATOMY", 178, 183], ["lung", "ANATOMY", 226, 230]]], ["The most frequent finding on CT scan includes ground-glass opacity (86%), consolidation (29%), crazy paving (19%), bilateral disease distribution (76%), and peripheral disease distribution (33%) [10].", [["peripheral disease", "DISEASE", 157, 175], ["CT scan", "TEST", 29, 36], ["ground-glass opacity", "PROBLEM", 46, 66], ["consolidation", "PROBLEM", 74, 87], ["crazy paving", "TEST", 95, 107], ["bilateral disease distribution", "PROBLEM", 115, 145], ["peripheral disease distribution", "PROBLEM", 157, 188], ["ground-glass opacity", "OBSERVATION", 46, 66], ["consolidation", "OBSERVATION", 74, 87], ["bilateral", "ANATOMY_MODIFIER", 115, 124], ["disease", "OBSERVATION", 125, 132], ["peripheral", "ANATOMY_MODIFIER", 157, 167], ["disease", "OBSERVATION", 168, 175]]], ["It is important to note that a chest X-ray has a lower sensitivity (59%) to detect subtle opacities.", [["opacities", "DISEASE", 90, 99], ["a chest X-ray", "TEST", 29, 42], ["subtle opacities", "PROBLEM", 83, 99], ["chest", "ANATOMY", 31, 36], ["subtle", "OBSERVATION_MODIFIER", 83, 89], ["opacities", "OBSERVATION", 90, 99]]], ["A CT scan can further detect mediastinal lymphadenopathy, nodules, cystic changes, and pleural effusion.", [["mediastinal lymphadenopathy", "ANATOMY", 29, 56], ["nodules", "ANATOMY", 58, 65], ["cystic", "ANATOMY", 67, 73], ["pleural effusion", "ANATOMY", 87, 103], ["lymphadenopathy", "DISEASE", 41, 56], ["pleural effusion", "DISEASE", 87, 103], ["nodules", "CANCER", 58, 65], ["pleural effusion", "CANCER", 87, 103], ["A CT scan", "TEST", 0, 9], ["mediastinal lymphadenopathy", "PROBLEM", 29, 56], ["nodules", "PROBLEM", 58, 65], ["cystic changes", "PROBLEM", 67, 81], ["pleural effusion", "PROBLEM", 87, 103], ["mediastinal", "ANATOMY", 29, 40], ["lymphadenopathy", "OBSERVATION", 41, 56], ["nodules", "OBSERVATION", 58, 65], ["cystic", "OBSERVATION_MODIFIER", 67, 73], ["pleural", "ANATOMY", 87, 94], ["effusion", "OBSERVATION", 95, 103]]], ["The aforementioned abnormalities might be detectable before the onset of symptoms.ReviewSepsis and Septic ShockReviewPatients with COVID-19 and sepsis are deemed the most critical of them all.", [["sepsis", "DISEASE", 144, 150], ["The aforementioned abnormalities", "PROBLEM", 0, 32], ["symptoms", "PROBLEM", 73, 81], ["Septic ShockReviewPatients", "TREATMENT", 99, 125], ["COVID", "TEST", 131, 136], ["sepsis", "PROBLEM", 144, 150], ["abnormalities", "OBSERVATION", 19, 32], ["Septic", "OBSERVATION", 99, 105], ["sepsis", "OBSERVATION", 144, 150]]], ["The accompanying multiorgan dysfunction results as a consequence of dysregulated host response to infection.", [["multiorgan", "ANATOMY", 17, 27], ["multiorgan dysfunction", "DISEASE", 17, 39], ["infection", "DISEASE", 98, 107], ["multiorgan", "ORGAN", 17, 27], ["The accompanying multiorgan dysfunction", "PROBLEM", 0, 39], ["dysregulated host response", "PROBLEM", 68, 94], ["infection", "PROBLEM", 98, 107], ["multiorgan dysfunction", "OBSERVATION", 17, 39], ["host response", "OBSERVATION", 81, 94], ["infection", "OBSERVATION", 98, 107]]], ["Signs of organ dysfunction include severe dyspnea, low oxygen saturation, reduced urine output, tachycardia, hypotension, cold extremities, skin mottling, and altered mentation [4].", [["organ", "ANATOMY", 9, 14], ["urine", "ANATOMY", 82, 87], ["skin", "ANATOMY", 140, 144], ["organ dysfunction", "DISEASE", 9, 26], ["dyspnea", "DISEASE", 42, 49], ["oxygen", "CHEMICAL", 55, 61], ["reduced urine output", "DISEASE", 74, 94], ["tachycardia", "DISEASE", 96, 107], ["hypotension", "DISEASE", 109, 120], ["cold extremities", "DISEASE", 122, 138], ["skin mottling", "DISEASE", 140, 153], ["oxygen", "CHEMICAL", 55, 61], ["organ", "ORGAN", 9, 14], ["oxygen", "SIMPLE_CHEMICAL", 55, 61], ["urine", "ORGANISM_SUBSTANCE", 82, 87], ["extremities", "ORGANISM_SUBDIVISION", 127, 138], ["skin", "ORGAN", 140, 144], ["organ dysfunction", "PROBLEM", 9, 26], ["severe dyspnea", "PROBLEM", 35, 49], ["low oxygen saturation", "PROBLEM", 51, 72], ["reduced urine output", "PROBLEM", 74, 94], ["tachycardia", "PROBLEM", 96, 107], ["hypotension", "PROBLEM", 109, 120], ["cold extremities", "PROBLEM", 122, 138], ["skin mottling", "PROBLEM", 140, 153], ["altered mentation", "PROBLEM", 159, 176], ["organ", "ANATOMY", 9, 14], ["dysfunction", "OBSERVATION", 15, 26], ["severe", "OBSERVATION_MODIFIER", 35, 41], ["dyspnea", "OBSERVATION", 42, 49], ["low", "OBSERVATION_MODIFIER", 51, 54], ["oxygen saturation", "OBSERVATION", 55, 72], ["urine output", "OBSERVATION", 82, 94], ["hypotension", "OBSERVATION", 109, 120], ["cold extremities", "ANATOMY", 122, 138], ["skin", "ANATOMY", 140, 144], ["mottling", "OBSERVATION", 145, 153]]], ["Laboratory evidence of other homeostatic dysregulation includes acidosis, high lactate, hyperbilirubinemia, thrombocytopenia, and evidence of coagulopathy [4].ReviewPatients with septic shock are persistently hypotensive despite volume resuscitation.", [["acidosis", "DISEASE", 64, 72], ["lactate", "CHEMICAL", 79, 86], ["hyperbilirubinemia", "DISEASE", 88, 106], ["thrombocytopenia", "DISEASE", 108, 124], ["coagulopathy", "DISEASE", 142, 154], ["septic shock", "DISEASE", 179, 191], ["hypotensive", "DISEASE", 209, 220], ["lactate", "CHEMICAL", 79, 86], ["lactate", "SIMPLE_CHEMICAL", 79, 86], ["other homeostatic dysregulation", "PROBLEM", 23, 54], ["acidosis", "PROBLEM", 64, 72], ["high lactate", "PROBLEM", 74, 86], ["hyperbilirubinemia", "PROBLEM", 88, 106], ["thrombocytopenia", "PROBLEM", 108, 124], ["coagulopathy", "PROBLEM", 142, 154], ["septic shock", "PROBLEM", 179, 191], ["persistently hypotensive", "PROBLEM", 196, 220], ["volume resuscitation", "TREATMENT", 229, 249], ["homeostatic dysregulation", "OBSERVATION", 29, 54], ["acidosis", "OBSERVATION", 64, 72], ["high", "OBSERVATION_MODIFIER", 74, 78], ["hyperbilirubinemia", "OBSERVATION", 88, 106], ["thrombocytopenia", "OBSERVATION", 108, 124], ["coagulopathy", "OBSERVATION", 142, 154], ["septic shock", "OBSERVATION", 179, 191], ["persistently", "OBSERVATION_MODIFIER", 196, 208], ["hypotensive", "OBSERVATION_MODIFIER", 209, 220], ["volume resuscitation", "OBSERVATION", 229, 249]]], ["They may also have an accompanying serum lactate level of >2 mmol/L.ReviewLaboratory FeaturesReviewLaboratory findings specific to COVID-19 include elevated prothrombin time, LDH (lactate dehydrogenase), D-dimer, ALT, C-reactive protein (CRP), and creatine kinase [9].", [["serum", "ANATOMY", 35, 40], ["lactate", "CHEMICAL", 41, 48], ["lactate", "CHEMICAL", 180, 187], ["creatine", "CHEMICAL", 248, 256], ["lactate", "CHEMICAL", 41, 48], ["lactate", "CHEMICAL", 180, 187], ["creatine", "CHEMICAL", 248, 256], ["serum", "ORGANISM_SUBSTANCE", 35, 40], ["lactate", "SIMPLE_CHEMICAL", 41, 48], ["prothrombin", "GENE_OR_GENE_PRODUCT", 157, 168], ["LDH", "SIMPLE_CHEMICAL", 175, 178], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 180, 201], ["D-dimer", "SIMPLE_CHEMICAL", 204, 211], ["ALT", "SIMPLE_CHEMICAL", 213, 216], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 218, 236], ["CRP", "GENE_OR_GENE_PRODUCT", 238, 241], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 248, 263], ["prothrombin", "PROTEIN", 157, 168], ["LDH", "PROTEIN", 175, 178], ["lactate dehydrogenase", "PROTEIN", 180, 201], ["D-dimer", "PROTEIN", 204, 211], ["ALT", "PROTEIN", 213, 216], ["C-reactive protein", "PROTEIN", 218, 236], ["CRP", "PROTEIN", 238, 241], ["creatine kinase", "PROTEIN", 248, 263], ["an accompanying serum lactate level", "TEST", 19, 54], ["COVID", "TEST", 131, 136], ["elevated prothrombin time", "PROBLEM", 148, 173], ["LDH", "TEST", 175, 178], ["lactate dehydrogenase", "TEST", 180, 201], ["D-dimer", "TEST", 204, 211], ["ALT", "TEST", 213, 216], ["C", "TEST", 218, 219], ["reactive protein", "TEST", 220, 236], ["CRP", "TEST", 238, 241], ["creatine kinase", "TEST", 248, 263]]], ["In the early stages of the disease, a marked reduction in CD4 and CD8 lymphocytes can also be noted [9].", [["CD4", "ANATOMY", 58, 61], ["CD8 lymphocytes", "ANATOMY", 66, 81], ["CD4", "GENE_OR_GENE_PRODUCT", 58, 61], ["CD8", "GENE_OR_GENE_PRODUCT", 66, 69], ["CD4", "PROTEIN", 58, 61], ["CD8 lymphocytes", "CELL_TYPE", 66, 81], ["the disease", "PROBLEM", 23, 34], ["a marked reduction in CD4 and CD8 lymphocytes", "PROBLEM", 36, 81], ["early stages", "OBSERVATION_MODIFIER", 7, 19], ["disease", "OBSERVATION", 27, 34], ["marked", "OBSERVATION_MODIFIER", 38, 44], ["reduction", "OBSERVATION_MODIFIER", 45, 54], ["CD4", "OBSERVATION", 58, 61], ["CD8 lymphocytes", "OBSERVATION", 66, 81]]], ["Patients in the intensive care unit have shown higher levels of interleukin (IL) 2, IL-7, IL-10, GCSF (granulocyte colony-stimulating factor), IP10 (interferon gamma-induced protein 10), MCP1 (monocyte chemotactic protein 1), MIP1A (macrophage inflammatory protein alpha), and TNF-\u03b1 (tumor necrosis factor-\u03b1) [11].", [["tumor", "DISEASE", 284, 289], ["Patients", "ORGANISM", 0, 8], ["interleukin (IL) 2", "GENE_OR_GENE_PRODUCT", 64, 82], ["IL-7", "GENE_OR_GENE_PRODUCT", 84, 88], ["IL-10", "GENE_OR_GENE_PRODUCT", 90, 95], ["GCSF", "GENE_OR_GENE_PRODUCT", 97, 101], ["granulocyte colony-stimulating factor", "GENE_OR_GENE_PRODUCT", 103, 140], ["IP10", "GENE_OR_GENE_PRODUCT", 143, 147], ["interferon gamma-induced protein 10", "GENE_OR_GENE_PRODUCT", 149, 184], ["MCP1", "GENE_OR_GENE_PRODUCT", 187, 191], ["monocyte chemotactic protein 1", "GENE_OR_GENE_PRODUCT", 193, 223], ["MIP1A", "GENE_OR_GENE_PRODUCT", 226, 231], ["macrophage inflammatory protein alpha", "GENE_OR_GENE_PRODUCT", 233, 270], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 277, 282], ["tumor necrosis factor-\u03b1", "GENE_OR_GENE_PRODUCT", 284, 307], ["interleukin (IL) 2, IL-7", "PROTEIN", 64, 88], ["IL-10", "PROTEIN", 90, 95], ["GCSF", "PROTEIN", 97, 101], ["granulocyte colony-stimulating factor", "PROTEIN", 103, 140], ["IP10", "PROTEIN", 143, 147], ["interferon gamma-induced protein 10", "PROTEIN", 149, 184], ["MCP1", "PROTEIN", 187, 191], ["monocyte chemotactic protein 1", "PROTEIN", 193, 223], ["MIP1A", "PROTEIN", 226, 231], ["macrophage inflammatory protein alpha", "PROTEIN", 233, 270], ["TNF-\u03b1", "PROTEIN", 277, 282], ["tumor necrosis factor-\u03b1", "PROTEIN", 284, 307], ["Patients", "SPECIES", 0, 8], ["interleukin (IL)", "TREATMENT", 64, 80], ["IL", "TEST", 84, 86], ["IL", "TEST", 90, 92], ["GCSF", "TEST", 97, 101], ["granulocyte colony", "TEST", 103, 121], ["IP10", "TEST", 143, 147], ["interferon gamma-induced protein", "TEST", 149, 181], ["MCP1", "TEST", 187, 191], ["monocyte chemotactic protein", "TEST", 193, 221], ["MIP1A", "TEST", 226, 231], ["macrophage inflammatory protein alpha", "TEST", 233, 270], ["TNF", "TEST", 277, 280], ["tumor necrosis factor", "TEST", 284, 305], ["TNF", "ANATOMY", 277, 280]]], ["They also displayed other abnormal findings indicative of coagulation activation, cellular immune deficiency, myocardial injury, renal injury, and hepatic injury [9].", [["cellular", "ANATOMY", 82, 90], ["myocardial", "ANATOMY", 110, 120], ["renal", "ANATOMY", 129, 134], ["hepatic", "ANATOMY", 147, 154], ["immune deficiency", "DISEASE", 91, 108], ["myocardial injury", "DISEASE", 110, 127], ["renal injury", "DISEASE", 129, 141], ["hepatic injury", "DISEASE", 147, 161], ["cellular", "CELL", 82, 90], ["myocardial", "MULTI-TISSUE_STRUCTURE", 110, 120], ["renal", "ORGAN", 129, 134], ["hepatic", "ORGAN", 147, 154], ["other abnormal findings", "PROBLEM", 20, 43], ["coagulation activation", "PROBLEM", 58, 80], ["cellular immune deficiency", "PROBLEM", 82, 108], ["myocardial injury", "PROBLEM", 110, 127], ["renal injury", "PROBLEM", 129, 141], ["hepatic injury", "PROBLEM", 147, 161], ["indicative of", "UNCERTAINTY", 44, 57], ["coagulation activation", "OBSERVATION", 58, 80], ["cellular immune deficiency", "OBSERVATION", 82, 108], ["myocardial", "ANATOMY", 110, 120], ["injury", "OBSERVATION", 121, 127], ["renal", "ANATOMY", 129, 134], ["injury", "OBSERVATION", 135, 141], ["hepatic", "ANATOMY", 147, 154], ["injury", "OBSERVATION", 155, 161]]], ["In critical patients, amylase and D-dimer levels are significantly elevated [4,11].", [["patients", "ORGANISM", 12, 20], ["amylase", "GENE_OR_GENE_PRODUCT", 22, 29], ["D-dimer", "GENE_OR_GENE_PRODUCT", 34, 41], ["amylase", "PROTEIN", 22, 29], ["patients", "SPECIES", 12, 20], ["amylase", "TEST", 22, 29], ["D-dimer levels", "TEST", 34, 48], ["significantly elevated", "PROBLEM", 53, 75], ["significantly", "OBSERVATION_MODIFIER", 53, 66], ["elevated", "OBSERVATION_MODIFIER", 67, 75]]], ["However, blood lymphocyte counts progressively decreased [4,11].", [["blood lymphocyte", "ANATOMY", 9, 25], ["blood lymphocyte", "CELL", 9, 25], ["blood lymphocyte counts", "TEST", 9, 32], ["lymphocyte counts", "OBSERVATION", 15, 32], ["progressively", "OBSERVATION_MODIFIER", 33, 46], ["decreased", "OBSERVATION_MODIFIER", 47, 56]]], ["Common to non-survivors are the elevations in ferritin, neutrophil count, D-dimer, blood urea, and creatinine levels [12].", [["neutrophil", "ANATOMY", 56, 66], ["blood", "ANATOMY", 83, 88], ["urea", "CHEMICAL", 89, 93], ["creatinine", "CHEMICAL", 99, 109], ["urea", "CHEMICAL", 89, 93], ["creatinine", "CHEMICAL", 99, 109], ["ferritin", "GENE_OR_GENE_PRODUCT", 46, 54], ["neutrophil", "CELL", 56, 66], ["D-dimer", "SIMPLE_CHEMICAL", 74, 81], ["blood", "ORGANISM_SUBSTANCE", 83, 88], ["urea", "SIMPLE_CHEMICAL", 89, 93], ["creatinine", "SIMPLE_CHEMICAL", 99, 109], ["ferritin", "PROTEIN", 46, 54], ["the elevations", "PROBLEM", 28, 42], ["ferritin", "TEST", 46, 54], ["neutrophil count", "TEST", 56, 72], ["blood urea", "TEST", 83, 93], ["creatinine levels", "TEST", 99, 116], ["non-survivors", "OBSERVATION", 10, 23], ["elevations", "OBSERVATION_MODIFIER", 32, 42], ["neutrophil count", "OBSERVATION", 56, 72]]], ["Elevations in procalcitonin levels are not a feature of COVID-19.", [["COVID-19", "CHEMICAL", 56, 64], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 14, 27], ["procalcitonin", "PROTEIN", 14, 27], ["Elevations in", "PROBLEM", 0, 13], ["procalcitonin levels", "TEST", 14, 34], ["COVID", "TEST", 56, 61]]], ["Therefore, an elevated level of procalcitonin may suggest an alternative diagnosis such as bacterial pneumonia.", [["bacterial pneumonia", "DISEASE", 91, 110], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 32, 45], ["procalcitonin", "PROTEIN", 32, 45], ["an elevated level of procalcitonin", "PROBLEM", 11, 45], ["bacterial pneumonia", "PROBLEM", 91, 110], ["elevated", "OBSERVATION", 14, 22], ["bacterial", "OBSERVATION_MODIFIER", 91, 100], ["pneumonia", "OBSERVATION", 101, 110]]], ["Levels of CRP correlate directly with disease severity and progression.ReviewDiagnosisReviewThe U.S. CDC has developed criteria for persons under investigation (PUI) [4].", [["CRP", "GENE_OR_GENE_PRODUCT", 10, 13], ["persons", "ORGANISM", 132, 139], ["CRP", "PROTEIN", 10, 13], ["persons", "SPECIES", 132, 139], ["Levels of CRP", "TEST", 0, 13], ["disease severity", "PROBLEM", 38, 54], ["progression", "PROBLEM", 59, 70], ["progression", "OBSERVATION_MODIFIER", 59, 70]]], ["If a person is deemed a PUI, immediate prevention and infection control measures are undertaken.", [["PUI", "DISEASE", 24, 27], ["infection", "DISEASE", 54, 63], ["person", "SPECIES", 5, 11], ["a PUI", "PROBLEM", 22, 27], ["infection control measures", "TREATMENT", 54, 80], ["infection", "OBSERVATION", 54, 63]]], ["Epidemiological factors are used to assess the requirement of testing.", [["Epidemiological factors", "PROBLEM", 0, 23], ["testing", "TEST", 62, 69]]], ["These include close contact with a laboratory-confirmed patient within 14 days of symptoms or travel history to an infected area within 14 days of symptom onset [4].ReviewThe WHO recommends collecting samples from both the upper and lower respiratory tracts.", [["samples", "ANATOMY", 201, 208], ["lower respiratory tracts", "ANATOMY", 233, 257], ["patient", "ORGANISM", 56, 63], ["upper", "ORGANISM_SUBDIVISION", 223, 228], ["lower respiratory", "ORGANISM_SUBDIVISION", 233, 250], ["patient", "SPECIES", 56, 63], ["symptoms", "PROBLEM", 82, 90], ["an infected area", "PROBLEM", 112, 128], ["symptom onset", "PROBLEM", 147, 160], ["collecting samples", "TEST", 190, 208], ["both", "ANATOMY_MODIFIER", 214, 218], ["upper", "ANATOMY_MODIFIER", 223, 228], ["lower", "ANATOMY_MODIFIER", 233, 238], ["respiratory tracts", "ANATOMY", 239, 257]]], ["This can be achieved through expectorated sputum, bronchoalveolar lavage, or endotracheal aspirate [4].", [["sputum", "ANATOMY", 42, 48], ["bronchoalveolar lavage", "ANATOMY", 50, 72], ["endotracheal", "ANATOMY", 77, 89], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 50, 72], ["expectorated sputum", "TEST", 29, 48], ["bronchoalveolar lavage", "TEST", 50, 72], ["endotracheal aspirate", "TEST", 77, 98], ["bronchoalveolar lavage", "OBSERVATION", 50, 72], ["endotracheal", "ANATOMY", 77, 89]]], ["These samples are then assessed for viral RNA using polymerase chain reaction (PCR).", [["samples", "ANATOMY", 6, 13], ["samples", "CANCER", 6, 13], ["viral RNA", "RNA", 36, 45], ["These samples", "TEST", 0, 13], ["viral RNA", "PROBLEM", 36, 45], ["polymerase chain reaction", "PROBLEM", 52, 77], ["PCR", "TEST", 79, 82]]], ["If a positive test result is achieved, it is recommended to repeat the test for re-verification purposes.", [["a positive test", "TEST", 3, 18], ["the test", "TEST", 67, 75], ["re-verification purposes", "TEST", 80, 104]]], ["A negative test with a strong clinical suspicion also warrants repeat testing.ReviewManagementReviewIsolation remains the most effective measure for containment of COVID-19.", [["COVID-19", "CHEMICAL", 164, 172], ["A negative test", "TEST", 0, 15], ["repeat testing", "TEST", 63, 77], ["ReviewIsolation", "TREATMENT", 94, 109], ["COVID", "TEST", 164, 169]]], ["No specific anti-viral medication or vaccine is currently available [4].", [["specific anti-viral medication", "TREATMENT", 3, 33], ["vaccine", "TREATMENT", 37, 44]]], ["Therefore, the treatment of COVID-19 includes symptomatic care and oxygen therapy.", [["COVID-19", "CHEMICAL", 28, 36], ["oxygen", "CHEMICAL", 67, 73], ["oxygen", "CHEMICAL", 67, 73], ["oxygen", "SIMPLE_CHEMICAL", 67, 73], ["COVID", "TEST", 28, 33], ["symptomatic care", "TREATMENT", 46, 62], ["oxygen therapy", "TREATMENT", 67, 81], ["oxygen therapy", "OBSERVATION", 67, 81]]], ["Patients with mild infections require early supportive management.", [["infections", "DISEASE", 19, 29], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["mild infections", "PROBLEM", 14, 29], ["early supportive management", "TREATMENT", 38, 65], ["mild", "OBSERVATION_MODIFIER", 14, 18], ["infections", "OBSERVATION", 19, 29]]], ["This can be achieved with the use of acetaminophen, external cooling, oxygen therapy, nutritional supplements, and anti-bacterial therapy [9].", [["acetaminophen", "CHEMICAL", 37, 50], ["oxygen", "CHEMICAL", 70, 76], ["acetaminophen", "CHEMICAL", 37, 50], ["oxygen", "CHEMICAL", 70, 76], ["acetaminophen", "SIMPLE_CHEMICAL", 37, 50], ["oxygen", "SIMPLE_CHEMICAL", 70, 76], ["acetaminophen", "TREATMENT", 37, 50], ["external cooling", "TREATMENT", 52, 68], ["oxygen therapy", "TREATMENT", 70, 84], ["nutritional supplements", "TREATMENT", 86, 109], ["anti-bacterial therapy", "TREATMENT", 115, 137]]], ["Critically ill patients require high flow oxygen, extracorporeal membrane oxygenation (ECMO), glucocorticoid therapy, and convalescent plasma [9].", [["extracorporeal membrane", "ANATOMY", 50, 73], ["plasma", "ANATOMY", 135, 141], ["Critically ill", "DISEASE", 0, 14], ["oxygen", "CHEMICAL", 42, 48], ["oxygen", "CHEMICAL", 42, 48], ["patients", "ORGANISM", 15, 23], ["oxygen", "SIMPLE_CHEMICAL", 42, 48], ["glucocorticoid", "SIMPLE_CHEMICAL", 94, 108], ["plasma", "ORGANISM_SUBSTANCE", 135, 141], ["patients", "SPECIES", 15, 23], ["Critically ill", "PROBLEM", 0, 14], ["high flow oxygen", "TREATMENT", 32, 48], ["extracorporeal membrane oxygenation", "TREATMENT", 50, 85], ["ECMO", "TREATMENT", 87, 91], ["glucocorticoid therapy", "TREATMENT", 94, 116], ["high flow oxygen", "OBSERVATION", 32, 48]]], ["The administration of systemic corticosteroids is not recommended to treat ARDS [4].", [["ARDS", "DISEASE", 75, 79], ["systemic corticosteroids", "TREATMENT", 22, 46], ["ARDS", "PROBLEM", 75, 79]]], ["Moreover, unnecessary administration of antibiotics should also be avoided.", [["antibiotics", "TREATMENT", 40, 51]]], ["ECMO should be considered in patients with refractory hypoxemia despite undergoing protective ventilation [4].", [["hypoxemia", "DISEASE", 54, 63], ["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["ECMO", "TREATMENT", 0, 4], ["refractory hypoxemia", "PROBLEM", 43, 63], ["protective ventilation", "TREATMENT", 83, 105], ["hypoxemia", "OBSERVATION", 54, 63]]], ["Patients with respiratory failure may require intubation, mechanical ventilation, high-flow nasal oxygen, or non-invasive ventilation [4].", [["respiratory", "ANATOMY", 14, 25], ["nasal", "ANATOMY", 92, 97], ["respiratory failure", "DISEASE", 14, 33], ["oxygen", "CHEMICAL", 98, 104], ["oxygen", "CHEMICAL", 98, 104], ["Patients", "ORGANISM", 0, 8], ["oxygen", "SIMPLE_CHEMICAL", 98, 104], ["Patients", "SPECIES", 0, 8], ["respiratory failure", "PROBLEM", 14, 33], ["intubation", "TREATMENT", 46, 56], ["mechanical ventilation", "TREATMENT", 58, 80], ["high-flow nasal oxygen", "TREATMENT", 82, 104], ["non-invasive ventilation", "TREATMENT", 109, 133], ["respiratory failure", "OBSERVATION", 14, 33], ["nasal oxygen", "OBSERVATION", 92, 104]]], ["Treatment of septic shock requires hemodynamic support with the administration of vasopressors.", [["septic shock", "DISEASE", 13, 25], ["septic shock", "PROBLEM", 13, 25], ["hemodynamic support", "TREATMENT", 35, 54], ["vasopressors", "TREATMENT", 82, 94], ["septic shock", "OBSERVATION", 13, 25], ["hemodynamic support", "OBSERVATION", 35, 54]]], ["Organ function support is necessary for patients with multiple organ dysfunction [4].ReviewTherapeutically, aerosol administration of alpha-interferon (5 million units twice daily), chloroquine phosphate, and lopinavir/ritonavir have been suggested [4].", [["Organ", "ANATOMY", 0, 5], ["organ", "ANATOMY", 63, 68], ["organ dysfunction", "DISEASE", 63, 80], ["alpha-interferon", "CHEMICAL", 134, 150], ["chloroquine phosphate", "CHEMICAL", 182, 203], ["lopinavir/ritonavir", "CHEMICAL", 209, 228], ["chloroquine phosphate", "CHEMICAL", 182, 203], ["lopinavir", "CHEMICAL", 209, 218], ["ritonavir", "CHEMICAL", 219, 228], ["patients", "ORGANISM", 40, 48], ["organ", "ORGAN", 63, 68], ["alpha-interferon", "SIMPLE_CHEMICAL", 134, 150], ["chloroquine phosphate", "SIMPLE_CHEMICAL", 182, 203], ["lopinavir", "SIMPLE_CHEMICAL", 209, 218], ["ritonavir", "SIMPLE_CHEMICAL", 219, 228], ["alpha-interferon", "PROTEIN", 134, 150], ["patients", "SPECIES", 40, 48], ["Organ function support", "TREATMENT", 0, 22], ["multiple organ dysfunction", "PROBLEM", 54, 80], ["alpha-interferon", "TREATMENT", 134, 150], ["chloroquine phosphate", "TREATMENT", 182, 203], ["lopinavir", "TREATMENT", 209, 218], ["ritonavir", "TREATMENT", 219, 228], ["organ", "ANATOMY", 63, 68], ["dysfunction", "OBSERVATION", 69, 80]]], ["Other suggested anti-virals include ribavirin and abidor [9].", [["ribavirin", "CHEMICAL", 36, 45], ["ribavirin", "CHEMICAL", 36, 45], ["abidor", "CHEMICAL", 50, 56], ["ribavirin", "SIMPLE_CHEMICAL", 36, 45], ["anti-virals", "TREATMENT", 16, 27], ["ribavirin", "TREATMENT", 36, 45], ["abidor", "TREATMENT", 50, 56]]], ["The use of three or more anti-viral drugs simultaneously is not recommended.", [["more anti-viral drugs", "TREATMENT", 20, 41]]], ["Ongoing clinical studies suggest that remdesivir (GS5734) can be used for prophylaxis and therapy [4].", [["remdesivir", "CHEMICAL", 38, 48], ["GS5734", "CHEMICAL", 50, 56], ["remdesivir", "CHEMICAL", 38, 48], ["GS5734", "CHEMICAL", 50, 56], ["remdesivir", "SIMPLE_CHEMICAL", 38, 48], ["GS5734", "SIMPLE_CHEMICAL", 50, 56], ["Ongoing clinical studies", "TEST", 0, 24], ["remdesivir (GS5734)", "TREATMENT", 38, 57], ["prophylaxis", "TREATMENT", 74, 85], ["therapy", "TREATMENT", 90, 97]]], ["Furthermore, a fusion inhibitor targeting the HR1 domain of spike protein is reported to have the potential to treat COVID-19.ReviewPreventionReviewPreventive measures must focus on optimizing infection control protocols, self-isolation, and patient isolation during the provision of clinical care.", [["infection", "DISEASE", 193, 202], ["COVID-19", "CHEMICAL", 117, 125], ["patient", "ORGANISM", 242, 249], ["HR1 domain", "PROTEIN", 46, 56], ["spike protein", "PROTEIN", 60, 73], ["patient", "SPECIES", 242, 249], ["a fusion inhibitor", "TREATMENT", 13, 31], ["spike protein", "PROBLEM", 60, 73], ["COVID", "TEST", 117, 122], ["ReviewPreventive measures", "TREATMENT", 142, 167], ["optimizing infection control protocols", "TREATMENT", 182, 220], ["self-isolation", "TREATMENT", 222, 236], ["patient isolation", "TREATMENT", 242, 259], ["clinical care", "TREATMENT", 284, 297]]], ["The WHO has advised against close contact with patients, farm animals, and wild animals [4].", [["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55]]], ["Patients and the general public must cover coughs and sneezes to help prevent aerosol transmission.", [["coughs", "DISEASE", 43, 49], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["coughs", "PROBLEM", 43, 49], ["sneezes", "TREATMENT", 54, 61]]], ["Frequent handwashing with soap and water is also required.", [["soap and water", "TREATMENT", 26, 40]]], ["As an alternative measure, hand sanitizers can also be used.", [["hand", "ANATOMY", 27, 31], ["an alternative measure", "TREATMENT", 3, 25], ["hand sanitizers", "TREATMENT", 27, 42]]], ["Immunocompromised individuals are advised to avoid public gatherings.", [["individuals", "ORGANISM", 18, 29], ["Immunocompromised individuals", "PROBLEM", 0, 29]]], ["Emergency medicine departments must apply strict hygiene measures for the control of infections.", [["infections", "DISEASE", 85, 95], ["strict hygiene measures", "TREATMENT", 42, 65], ["infections", "PROBLEM", 85, 95], ["infections", "OBSERVATION", 85, 95]]], ["Healthcare personnel must use personal protective equipment such as N95 masks, FFP3 masks, gowns, eye protection, gloves, and gowns.ConclusionsThe COVID-19 pandemic is spreading across the globe at an alarming rate.", [["eye", "ANATOMY", 98, 101], ["eye", "ORGANISM_SUBDIVISION", 98, 101], ["personal protective equipment", "TREATMENT", 30, 59], ["N95 masks", "TREATMENT", 68, 77], ["FFP3 masks", "TREATMENT", 79, 89], ["gowns", "TREATMENT", 91, 96], ["eye protection", "TREATMENT", 98, 112], ["gloves", "TREATMENT", 114, 120], ["The COVID", "TEST", 143, 152], ["pandemic", "PROBLEM", 156, 164], ["eye", "ANATOMY", 98, 101], ["pandemic", "OBSERVATION", 156, 164], ["globe", "ANATOMY", 189, 194]]], ["It has caused more infections and deaths as compared with SARS or MERS.", [["infections", "DISEASE", 19, 29], ["deaths", "DISEASE", 34, 40], ["SARS", "DISEASE", 58, 62], ["more infections", "PROBLEM", 14, 29], ["deaths", "PROBLEM", 34, 40], ["more", "OBSERVATION_MODIFIER", 14, 18], ["infections", "OBSERVATION", 19, 29]]], ["Based on R0 values, it is deemed that SARS-CoV-2 is more infectious than SARS or MERS.", [["SARS", "DISEASE", 38, 42], ["SARS", "DISEASE", 73, 77], ["SARS-CoV", "SPECIES", 38, 46], ["R0 values", "TEST", 9, 18], ["SARS", "PROBLEM", 38, 42], ["CoV", "TEST", 43, 46], ["infectious", "OBSERVATION_MODIFIER", 57, 67]]], ["Elderly and immunocompromised patients are at the greatest risk of fatality.", [["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["immunocompromised", "OBSERVATION", 12, 29], ["fatality", "OBSERVATION", 67, 75]]], ["The rapid spread of disease warrants intense surveillance and isolation protocols to prevent further transmission.", [["The rapid spread of disease", "PROBLEM", 0, 27], ["intense surveillance", "TEST", 37, 57], ["isolation protocols", "TREATMENT", 62, 81], ["rapid", "OBSERVATION_MODIFIER", 4, 9], ["spread", "OBSERVATION_MODIFIER", 10, 16], ["disease", "OBSERVATION", 20, 27]]], ["No confirmed medication or vaccine has been developed.", [["medication", "TREATMENT", 13, 23], ["vaccine", "TREATMENT", 27, 34]]], ["Current treatment strategies are aimed at symptomatic care and oxygen therapy.", [["oxygen", "CHEMICAL", 63, 69], ["oxygen", "CHEMICAL", 63, 69], ["oxygen", "SIMPLE_CHEMICAL", 63, 69], ["Current treatment strategies", "TREATMENT", 0, 28], ["symptomatic care", "TREATMENT", 42, 58], ["oxygen therapy", "TREATMENT", 63, 77], ["oxygen therapy", "OBSERVATION", 63, 77]]], ["Prophylactic vaccination is required for the future prevention of COV-related epidemic or pandemic.", [["COV", "CHEMICAL", 66, 69], ["Prophylactic vaccination", "TREATMENT", 0, 24], ["COV", "PROBLEM", 66, 69], ["epidemic", "PROBLEM", 78, 86], ["pandemic", "PROBLEM", 90, 98]]]]}